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ABSTRACT 
This thesis discloses two distinct applications of synthesized iodoarene-containing 
compounds: as hypervalent iodine (HI) organocatalysts and as biodegradable X-ray 
contrasting agents.  This thesis also details a short chapter regarding the synthesis of 
rarely accessible chemical moieties: diazacyclobutenes and 2-imidothioimidates. 
Recently, organohypervalent iodine compounds have prevailed as valuable 
synthetic reagents.  These reagents have the ability to efficiently perform transition 
metal-like transformations while possessing environmentally friendly properties.  
However, a persistent obstacle in utilizing hypervalent iodine (HI) reagents has been 
promoting synthetic reactions with high reactivities and enantioselectivities.  To this fact, 
it is necessary to further improve upon the field of hypervalent iodine chemistry, 
especially in the context of the development of new, modular, and tunable catalyst 
scaffolds.   
The first chapter of this thesis reviews the background and history of hypervalent 
iodine compounds.  The second chapter describes the progress that has been made in the 
field of catalysis, with emphasis on asymmetric organocatalysis.  The third chapter details 
the advances that were made to design, develop, and understand the reactivity of 
iodoarene-containing catalysts in hypervalent iodine(III)-mediated transformations.  
Furthermore, the third chapter provides insight on merging the fields of hypervalent 
iodine chemistry with organocatalysis and asymmetric synthesis to generate chiral 
catalysts that can be used in valuable organic transformations.  These organocatalysts 
iii 
have the potential to be broadly applicable and to impact synthetically useful 
transformations by imparting high yields and stereoselectivities. 
Synthetic materials have proven to have a key role in the medical field.  In 
particular, polymeric materials have exhibited significance as contrast imaging agents 
due to their inherent biodegradable and biocompatible profile.  The fourth chapter of this 
thesis describes the efficient synthesis, characterization, and X-ray evaluation of several 
iodoarene-containing polyesters.  
Synthetic chemists are continuously searching for novel and efficient bond-
forming methods to produce new chemical species.  The final chapter of this thesis 
describes a new strategy to generate unique chemical motifs (diazacyclobutenes and 2-
imidothioimidates) via a formal [2+2] cycloaddition between electron rich alkynes and 
azodicarbonyl reagents. 
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CHAPTER ONE 
GENERAL ASPECTS OF HYPERVALENT IODINE (HI) COMPOUNDS 
1.1 HYPERVALENCY 
In 1916, Gilbert N. Lewis disclosed a critical scientific concept known as the ‘rule 
of eight’ or as later named, the ‘octet rule’.1, 2  This rule states that central atoms are more 
stable when their valence shell is filled with eight electrons, thereby attaining a similar 
electron configuration as the noble gases.  This rule-of-thumb, heuristic device serves to 
help predict the position, as well as the bonding, of the atoms and lone pair electrons that 
make up a molecule.3  Although this concept has been fundamental in understanding 
molecular bonding, it is not directly compatible with molecules that contain atoms with 
expanded octets.4-9 
In 1969, Jeremy I. Musher coined the term ‘hypervalent’ to describe the ability of 
a central, non-metallic atom confined within a molecule to expand its valence shell 
beyond the limits of the octet rule.10, 11  Hypervalent molecules are often assembled from 
elements within groups 15-18 that can accommodate the expanded octet within its 
valence shell.12, 13  One element that has the capacity to formally break the octet rule, and 
thereby become hypervalent, is iodine.14, 15   
 2 
1.2 IODINE AS A HYPERVALENT ELEMENT  
 
Iodine, isolated in 1811 by Bernard Courtois, is a chemical element of the 
periodic table with an atomic number of 53.  Iodine-containing reagents have intrigued 
chemists due to their distinct chemical properties.  In relation to the other non-radioactive 
group 17 elements, iodine is the largest, heaviest, most electropositive, and most 
polarizable. 
Due to these unique properties, iodine is able to form stable polycoordinate, 
multivalent compounds.16-18  Generally, iodine atoms form bonds with elements within 
the second period of the periodic table.  These kinds of bonds are relatively weak.  For 
instance, a carbon-iodine bond is the weakest carbon-halogen bond, with a bond 
dissociation energy of approximately 57 kcal/mol.19  The formal electron configuration of 
iodine is [Kr]d10s2p5, with seven electrons in its valence shell.  While iodine prefers to 
have an oxidation state of –1, the electronic makeup and large atomic radius permit it to 
exist in various oxidation states ranging from –1 to +7 (Figure 1.1).18, 20, 21   





















1a 1b 1c 1d 1e
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Polyvalent compounds are classified by using Martin-Arduengo N-X-L 
nomenclature, where N represents the number of valence electrons associated with the 
central atom, X, and L signifies the number of ligands bound to the central atom (Figure 
1.2).22  It should be noted that historically, iodine compounds with a +3 oxidation state 
were referred to as iodinanes and iodine compounds with a +5 oxidation state were 
referred to as periodinanes.  However, IUPAC suggests the use of lambda notation (ln) 
when considering compounds with varying valence.  This notation specifies an atom with 
an abnormal valence state.23, 24  While iodine has a normal valence state of 1, iodine(III) 
and iodine(V) compounds contain a non-standard valence, and are respectively named as 
l3-iodanes and l5-iodanes. 
The large range of possible oxidation states allows for iodine to form up to 7 
chemical bonds.  These bonds are typically constructed through oxidations and ligand 
associations (Scheme 1.1).23  In short, the oxidative addition occurs when an iodine(I) 
compound utilizes a lone pair of electrons to attack an electrophilic species (L+), which 
thereby leaves a positive charge on the central iodine atom (Scheme 1.1, 1f).  The ligand 
association can then take place, whereby a nucleophilic reagent (L-) attacks a positively 
[N-X-L]
Number of valence electrons
Central atom
Number of ligands bound to central atom
Figure 1.2 Martin-Arduengo Nomenclature
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charged iodine, to form a 10 electron, three coordinate iodane species (Scheme 1.1, 1g).  
This process of oxidative addition (Scheme 1.1, 1f and 1h) and ligand association 
(Scheme 1.1, 1g and 1i)  allows for the formation of iodine species with various 
oxidation states.  Although iodine can adapt to several oxidation states, the most widely 
used iodine compounds rely on the +3 and +5 oxidation states.   
While the aforementioned nomenclature can help classify polyvalent iodine 
compounds, many well-known and widely used reagents are referred to by their trivial 
names.  The most noteworthy HI(III) and HI(V) compounds are derived from 
iodobenzene and can be seen in Figure 1.3.25  In 1886, German chemist Conrad 
Willgerodt combined iodobenzene and chlorine gas to produce the first multivalent 
iodine reagent: (dichloroiodo)benzene, i.e. PhICl2 (1j).26  Although the first hypervalent 
iodine (HI) molecule was discovered over a century ago, their synthetic utility was not 
exploited until the last few decades. Most notably, the commercially available 
















































Oxidative addition Ligand Association
1f 1g 1h 1i
 5 
aryliodine(III) carboxylates, such as phenyliodine diacetate (PIDA) (1k) and 
phenyliodine bis(trifluoroacetate) (PIFA) (1l), and organosulfonates, like 
[hydroxy(tosyloxy)iodo]benzene (HTIB) (1m), are commonly utilized in synthetic 
chemistry as oxidants.  The commercially available organoiodine(V) reagent known as 
Dess-Martin periodinane (DMP) (1o),  a five-membered iodine-containing heterocycle 
with acetate ligands, is frequently used to oxidize primary and secondary alcohols to 
aldehydes and ketones, respectively.27, 28  Extensive work has been completed by several 
laboratories to synthesize these, as well as analogous, hypervalent iodine reagents.12, 16-18, 
23, 29-31  While both HI(III) and HI(V) compounds are synthetically useful, the work 
described herein focuses on HI(III) compounds due to their more desirable properties.  In 













R = CH3 (PIDA) 1k



























prepare, have lower thermal stabilities, and are less soluble in many common organic 
solvents.16, 25  
1.3 HYPERVALENT IODINE(III) STRUCTURAL FEATURES 
While the traditional definition of a hypervalent state, in which an atom breaks the 
octet rule by bearing more than four pairs of electrons in its valence shell, has been 
highly debated, the conventional interpretation will be applied in this work.8, 32-42 Akiba 
considered the bonding within multivalent iodine species to rationalize the possibility of 
expanded octets.13  He reasoned that hypervalent atoms can carry more than eight 
electrons in their outermost shell by two plausible modes: (1) utilizing higher energy d-
orbitals to form hybridized dsp3 or d2sp3 orbitals or (2) utilizing orbitals other than d-
orbitals to form highly ionic orbitals.  Contemporary computational research has 
demonstrated that d-orbitals have little to no contribution in hypervalent bonds.13, 34, 37  
The most widely accepted theory to describe hypervalent bonding is the concept of a 
highly polarized bond known as a three-center, four-electron (3c-4e) bond.  The 3c-4e 
bond was independently introduced in 1951 by G.C. Pimentel and R. E. Rundle.38, 39  
This concept can be conceptualized by reviewing the structural features of hypervalent 
iodine(III) species and how it relates to molecular orbital theory. 
 7 
The most common trivalent iodine species are the aryl-l3-iodanes (ArL1L2).  As 
shown in Figure 1.4, the atoms that constitute aryl-l3-iodanes share ten valence electrons 
(decet structure) to form a distorted trigonal bipyramidal geometry with an overall T-
shape.12, 23  The central iodine atom is bound to two apically positioned ligands (L1 and 
L2), one equatorial aryl substituent (Ar), and two equatorial lone pairs of electrons.  The 
iodine and aryl group overlap orbitals to form a conventional two-center, two-electron 
(2c-2e) covalent, carbon-iodine	𝜎-bond with 5sp2 hybridization.  A highly polarized 3c-
4e bond is created from the interaction of a filled 5p orbital of iodine and half-filled 
orbitals of each ligand.  This results in three molecular orbitals: a bonding, non-bonding, 
and anti-bonding orbital (Figure 1.5).  Four valence electrons, two electrons from iodine 
and one electron from each ligand, are shared between the three atoms (iodine and two 
ligands). Consequently, this electron distribution allows for the two lower molecular 
orbitals, the bonding and non-bonding orbitals, to each be filled with two electrons, while 








Figure 1.4 Geometric structure of aryl-!3-iodanes
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The highly polarized nature of the 3c-4e bond is invoked at the highest occupied 
molecular orbital (HOMO), in this case, the non-bonding orbital, in which a node is 
situated at the central iodine position.  This allows for the development of charge 
distributions; in particular, there is an intrinsic partial positive charge on the central 
iodine atom (+1.0 charge), and a partial negative charge (-0.5 charge) on each apically 
positioned ligand.23  Ligands that can better stabilize this partial negative charge (e.g. 
halide, tosylate, carboxylate, hydroxyl) tend to reside at the apical positions around the 
positively charged central iodine, while the least electronegative ligand, the aryl group, 
occupies the equatorial position.  Furthermore, the more electropositive the central atom 
is the more energetically stable the polycoordinated, multivalent species is, hence aryl-l3-
iodanes are more stable than the related aryl-l3-chloranes and aryl-l3 bromanes.12, 18, 43, 44 















Iodine species with expanded octets can result in distinct and interesting chemical 
structures, properties, and reactivities.  With the ability to possess multiple oxidation 
states, it has been suggested that hypervalent iodine species have reactivity patterns that 
resemble transition metals.  This is apparent when considering the quintessential 
reactions involved in both transition metals and polyvalent iodine reagents: oxidative 
additions, ligand exchanges, and reductive eliminations (Scheme 1.2).23  
 The transition metals (1r) and iodine species (in this case, iodoarene 1w) undergo 
an increase in coordination number or oxidation state through an oxidative addition.  An 
exogeneous nucleophile (Nu) can then readily add to the central iodine through an 
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Scheme 1.2 Comparing reactivities of hypervalent iodine species to transition metals






associative or dissociative ligand exchange process to form the active species (Scheme 
1.2, 1t and 2c).  Subsequently, a reductive elimination, or as it is analogously called in 
hypervalent terminology, ligand coupling, allows for the new bond to form (1v and 2e), 
while also liberating the byproducts: the metal reagent (1u) or iodobenzene (2d).  
Numerous experimental and computational studies have been conducted to 
validate the mechanistic pathway for ligand exchange in hypervalent iodine species.12, 45-
49  The two pathways that have been probed are the associate pathway and the 
dissociative pathway.  The associative mechanism involves the addition of a nucleophile 
to the electropositive central iodine to give a trans 12 electron, 4 ligand (12-I-4) iodate 
(1z).12, 49-51  This trans intermediate is in equilibrium with the cis 12-I-4 iodate (2a), 
which gives a favorable structural geometry for one of the ligands (L) to depart, 
furnishing the desired 10-I-3 hypervalent iodine(III) species (2c).  Conversely, the 
dissociative pathway commences with the ejection of a ligand (L) to form a cationic 8-I-2 
iodonium species (2b).  This process typically requires a strong electrophile to assist in 
the removal of the ligand.12  This species is then subjected to a nucleophilic addition at 
the central iodine atom to afford the trivalent aryl-l3-iodane (2c).  Due to the lack of 
experimental evidence of the high energy dicoordinated (8-I-2) iodium ion (2b), in the 
dissociative pathway, the associative pathway has been the more widely accepted ligand 
exchange pathway of l3-iodanes.12, 23  
Ligand couplings involved in hypervalent species were presented by Oae to 
explain the formation of an intramolecular bond between two ligands that were bound to 
the central hypervalent atom.52, 53  As depicted in Scheme 1.3, reductive eliminations, a 
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concept widely invoked in organometallic chemistry, are when the central metal atom 
decreases in oxidation state and forms a new bond between the bound ligands.  It should 
be noted that in non-transition metal chemistry, the term ‘reductive elimination’ has also 
been used in several other fashions, for example in the synthesis of alkenes.54, 55  The 
aryl-l3-iodanaes can be subjected to a reaction known as ligand coupling (Scheme 1.3).  
There is limited experimental evidence of the ligand coupling mechanism, but it has been 
proposed that due to the configurational instability of organo-l3-iodanes, rapid 
psuedorotation occurs to generate an appropriate coupling configuration (2g).  This 
psuedorotation is followed by a favorable and concerted coupling of the ligands (Nu and 
L) to form the desired product (2i) with retention of configuration of the ligands.13, 52, 56-59 
Another detail that illustrates the similarity between hypervalent iodine 























phenomenon states that most electronegative ligands bound to the central atom tend to 
configure trans to each other in order to form stable complexes.  The mutual influence of 
the two ligands occurs when the central atom preserves the ns2 lone pair of electrons.61   
In T-shaped hypervalent iodine(III) compounds, such as the generic structure shown in 
Figure 1.4, the central iodine atom retains the 5s2 lone pair of electrons, and the I-L1 
trans bond becomes influenced by the 𝜎-donating ability of the trans configured ligand 
(L2).60  The 3c-4e bond of these hypervalent iodine(III) complexes experience a trans 
influence, which is attributed to the inductive effects of the trans positioned ligands, L1 
and L2.  This phenomenon has been studied and utilized by Ochiai to account for the 
stabilities of various HI(III) species.31, 64, 65  In metal complexes, the metal-ligand bond 
(M-X) is affected by a trans oriented ligand (L), which weakens the M-X bond.66, 67 In 
both metal and hypervalent species, the trans positioned substituents share a central atom, 
and can influence and effect each other’s bonding abilities, stabilities, and reactivities.   
While multivalent iodine reagents have comparable reactivity profiles as heavy 
metal reagents (e.g. Hg(II), Pb(IV), Cr(III), Os(VIII)), the main appeal toward utilizing 
hypervalent iodine compounds stems from their environmentally benign character.18, 23, 30, 
68  Their less-toxic nature allows hypervalent iodine species to be employed as 
sustainable alternatives to the more toxic heavy metal-based reagents, and thus 
contributes to ‘greener’ replacement methods in organic synthesis.69       
Although organic molecules bearing hypervalent iodine moieties were discovered 
over a century ago, they were not employed in synthetically useful transformations until 
the last few decades.  Due to the partial positive charge around the central iodine atom 
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(cf. Figure 1.4), hypervalent iodine(III) compounds are inherently electrophilic agents.  
The distinct 3c-4e bond involved in these species has been investigated, showing that the 
iodine to ligand (L) bonds are longer and weaker than analogous covalent bonds, giving 
important reactive characteristics to this class of compounds.  Allen et al. disclosed a 
study concerning the bond length in a hypervalent iodine(III) compound named 
diphenyliodonium chloride (Ph2ICl), and showed that the iodine to chlorine bond length 
was notably longer (3.06 Å) than the average covalent bond length (2.56 Å).70  These 
unique characteristics have contributed to l3-iodane reagents to be routinely utilized as 
versatile and selective oxidants and electrophiles.  The strong electrophilic nature of l3-
iodanes can be observed as shown in Scheme 1.4. 
 The predominant reactive property of highly electrophilic HI(III) compounds is 























Generally, the aryl-λ3-iodane (2j) is susceptible to nucleophilic attack at the positively 
charged iodine atom, which affords 2k and the newly displaced ligand 2l.  An external 
nucleophile (2m) is then added to afford the new Nu-R bond formation (2o).     
The functional group known as phenyliodonio (PhIX), highlighted in blue within 
structure 2k, is considered to be a potent nucleofuge, or leaving group that retains the 
electrons from the broken bond.  In fact, Ochiai referred to the phenyliodonio group as a 
‘hypernucleofuge’, or an exceptional hypervalent leaving group that has a better leaving 
group ability than a “super leaving group”.  The phenyliodonio group is estimated to 
possess a 1013 times greater leaving group ability than iodine and 106 times higher leaving 
ability than triflate (Figure 1.6).12, 13, 71  Furthermore, by using Hammett substituent 
constants, Mironova et al. probed the electron nature of phenyl-l3-iodanyl groups, and 































showed that they have powerful electron-withdrawing capabilities due to inductive 
effects.72   
This reaction (Scheme 1.4) proceeds due to the remarkable leaving and electron-
withdrawing ability of the hypervalent iodine group, which can be ascribed from the 
entropic favorability of having one molecule (2k) split into three: the anionic 
electrophilic ligand (2l), iodoarene (2n), and the intended product (2o).  The 
thermodynamic driving force of aryl hypervalent iodine(III) reactions is due to the 
formation of the highly stable iodoarene by-product (2n). 
Chemists have employed l3-iodanes in numerous synthetic transformations due to 
their versatility and environmentally benign character.  Many aryl-substituted l3-iodanes 
are commercially available, and are commonly used as mild and selective reagents in 
synthetic chemistry.  As described above, these species have a potent electrophilic and 
oxidative chemical character, and thus have been particularly impactful in a multitude of 
synthetic applications including: oxidations, oxidative rearrangements and 
fragmentations, cyclizations, carbon-carbon/carbon-heteroatom/heteroatom-heteroatom 
bond forming reactions, and even in total syntheses of natural products.12, 18, 23, 29, 44, 68, 73  
The second chapter of this thesis will focus on the utilization of asymmetric 
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SYNTHETIC UTILITY OF ASYMMETRIC PEPTIDE-BASED ORGANOCATALYSTS 
 
2.1 INTRODUCTION TO CATALYSIS 
Chemical synthesis is an essential method used by scientists to construct particular 
chemical compounds.  From medicines and herbicides to foods and dyes, chemical 
synthesis is a fundamental field that impacts several branches of life.  Researchers are 
constantly searching for new strategies to progress the field of synthesis, and a common 
area of exploration involves the use of new reagents to carry out reactions. 
Although metal-based reagents continue to demonstrate their importance in the 
facilitation of chemical transformations, recent efforts have been made to develop 
nontoxic, metal-free synthetic methodologies; it should be noted that while metal 
reagents may have drawbacks, they also possess many advantages, especially in the 
context of redox chemistry.  Small organic molecules, which lack a metallic component, 
have become attractive alternatives as they are considered to be “greener” alternatives to 
metal reagents.74  In comparison to metal species, metal-free organic molecules are 
typically cheaper and more environmentally friendly, with potential to attain highly 
efficient synthetic processes.   
  In 1836, the Swedish chemist J. J. Berzelius introduced the term ‘catalysis’.  
According to Berzelius75, catalysis can be conceptualized as a situation whereby: 
 “…several simple or compound bodies, soluble and insoluble, have the property of 
exercising on other bodies an action very different from chemical affinity. By means of 
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this action they produce, in these bodies, decompositions of their elements and different 
recombinations of these same elements to which they remain indifferent.” 
 
In other words, Berzelius hypothesized that chemical reactions can occur by catalytic 
contact.  During this time in history, the concept of reaction rate was unknown; instead 
scientists believed the driving force of a reaction was due to either an ‘affinity’ force, or 
as Berzelius stated, a ‘catalytic’ force.75, 76   
Catalysts are compounds used in chemical transformations that speed up reactions.  In 
short, a catalyst forms a bond with a reactant, a chemical reaction transpires to form a 
Figure 2.1 Simplified catalytic cycle
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product, and a subsequent detachment of the unconsumed catalyst from the product 
occurs (Figure 2.1).77  When the catalyst is separated from the product, it is available to 
be used again in the next reaction sequence, hence the term catalytic cycle.  To illustrate a 
general catalytic cycle, Figure 2.1 shows a catalyst interacting with compound A and 
compound B to form a complex.  When bound to the catalyst, A and B react to give a 
product, P.  The cycle is complete when the catalyst desorbs and departs from the 
product, allowing for the cycle to repeat. 
The catalyst increases a reaction’s rate by lowering the activation energy that is 
needed to get over the high energy activated complex, the transition state.  As shown in 
Figure 2.2, a reaction coordinate diagram can emphasize the differences between a 
catalyzed (red line) versus an uncatalyzed reaction (blue line).15  In a catalytic reaction, 
the energy of the substrate can be lowered when bound to a catalyst, in comparison to the 
free, uncatalyzed substrate.  Furthermore, the binding between the transition state and the 
catalyst can be strong, allowing for a lower activation energy than the uncatalyzed route 
(ΔG °‡cat < ΔG °‡uncat).  With a lower activation energy, the rate of the reaction increases.  
Therefore, catalysis is accomplished when the catalyst can stabilize the transition state at 
a greater extent than it can stabilize the ground state.  To put it another way, a catalyst 
can react with a starting material to generate a lower energy transition state (in 
comparison to the noncatalyzed reaction), and as a result, less energy is needed to 
overcome the activation energy barrier; this in turn, accelerates the rate of the reaction.  
The catalyst does not change the position of equilibrium between the reactants and 
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products, but instead lowers the energy of the rate-determining step.  Catalysis is 
therefore considered to be a kinetic, and not a thermodynamic, process.15, 78   
Nature has harnessed the power of catalysis to perform virtually all biochemical 
transformations of life through the development of a novel type of catalyst known as an 
enzyme.  Enzymes have the ability to selectively bind to the active site of a substrate, and 
this complex maintains an optimal configuration for catalysis to occur.79  Enzymes have 
many advantages, in that they are highly efficient catalysts that can exhibit exquisite 
selectivities, however they can also exhibit disadvantages; for instance, in order to be 










Transition state for 
catalyzed reaction






effective, they may require specific conditions (temperature, pH, pressure, etc.), and 
while they can provide exquisite selectivities, each enzyme has a rather limited substrate 
scope.  Consequently, leveraging enzymatic catalysis in the laboratory can be tedious, 
and it can be difficult to discover/evolve enzymes for broad applicability.  To expand the 
synthetic chemistry toolbox, scientists have worked toward the development and 
application of new catalysts. 
 
2.2 HOMOGENEOUS AND HETEROGENEOUS CATALYSTS 
Catalysts can be categorized in many ways, but based on their state of aggregation, 
the two main classes are homogeneous or heterogeneous catalysts.77  A homogeneous 
catalyst is one that operates in the same phase as the reactant(s) while a heterogeneous 
catalyst operates in a separate phase than the reactant(s).77, 80, 81  Ordinarily, for a reaction 
to occur with a heterogeneous catalyst, the reactant must first adsorb onto the surface of 
the catalyst.  On the other hand, homogeneous catalysts merely have to be added to the 
reaction mixture.  Some of the more notable homogeneous and heterogeneous catalysts 
are seen in Figure 2.3.   
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2.3 GENERAL APSECTS OF ORGANOCATALYSIS 
A pivotal advancement in the field of synthetic chemistry has been the 
implementation of organocatalysts, or small organic molecules that serve as catalysts.  
Organocatalysis has been known and described for over a century, yet this field has only 
recently emerged as a prominent concept.82, 83  As reported by MacMillan, a staggering 
statistic shows the growing interest of utilizing organic catalysts (Figure 2.4).84  From 
1968-1997, there were no review articles, and only a limited number of manuscripts 
disclosing the use of organocatalysts, however from 1998-2008, more than 1,500 
publications reported the use of organic molecules to catalyze over 130 distinct reaction  
types.   
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Organocatalysts can be considered homogeneous or heterogeneous, and each type of 
catalyst has advantages and disadvantages.85-87  The common benefits of using 
homogeneous organocatalysts hinge on their ease of modification, and that they have 
well-understood structures and predictable reaction mechanisms.88  However, a major 
drawback of homogeneous catalysis involves the difficulty in separating the catalyst from 
the intended product.  Heterogeneous catalysts can be difficult to fine-tune and typically 
have poorly-characterized reaction mechanisms, yet they can be easily separated from the 
reaction mixture.   
Figure 2.4 The amount of publications pertaining to organocatalysis from 1968-200812
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While biocatalysis78, 87, 89-91 and metal catalysis78, 92-94 continue to be valuable within 
the realm of synthesis, organocatalysis has become a complementary, and often superior 
strategy to effectively catalyze chemical transformations.15, 95-101   The energy-efficient 
nature of organocatalysis enable chemists to obtain desired products in a timely and 
practical fashion.  Organocatalysts are typically more stable to air and moisture, and are 
readily accessible and operationally simple to implement.  Furthermore, because organic 
catalysts are metal-free and are used in substoichiometric amounts without being 
consumed, they are considered to be more atom-economical and sustainable alternatives, 
with the potential to be recovered, recycled, and reused.88  It should be noted that the 
metal-free aspect of organocatalysts is particularly crucial within the pharmaceutical and 
food industries, owing to the fact that the FDA has placed strict regulations on metal 
contamination, even at trace amounts, of final products, due to possible adverse 
toxicological effects.88      
Organocatalysis has become an attractive area of research over the last decade.95, 97, 98  
Scientists have applied organocatalysts in a vast array of important synthetic 
transformations.74, 95-98  Some of the more well-known reactions that have been impacted 
by organocatalysis include: Hajos–Parrish reactions102, Knoevenagel condensations103, 104, 
esterifications105, Baylis-Hillman reactions106, Stetter reactions107, Aldol reactions108, 109, 
Diels-Alder cycloadditions110, 111, Michael reactions112, Mannich transformations113-115, 
and natural product syntheses116, 117.  While organic catalysts have been successfully 
utilized in various synthetic transformations, one of the most pivotal aspects has been 
their capacity to act as enantioselective catalysts. 
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2.4 THE IMPORTANCE OF ASYMMETRIC SYNTHESIS 
Many scientific areas depend on the chirality of organic molecules.  Depending on the 
chemical connectivity, or simply put, how atoms are arranged within a compound, can 
affect a compound’s properties and reactivity.  When enantiomers are in an achiral 
environment, they maintain the same chemical and physical properties (other than the 
direction in which they rotate plane-polarized light).  However, in chiral conditions, the 
spatial arrangement of the atoms can have drastic effects.  As an example, the difference 
in smell between oranges and lemons can be attributed to the existence of the 
enantiomeric forms of limonene: (R)-limonene and (L)-limonene (Figure 2.5).118  
Similarly, the enantiomeric forms of carvone can give discrete smells of either spearmint 
or caraway seed.  Another, more extreme example, involves the formerly prescribed drug 
named thalidomide.  In the 1960s, many West European countries advocated pregnant 
women to use thalidomide to alleviate the symptoms of morning sickness.119  Although 































some women responded well to the thalidomide medication, other women witnessed 
severe birth defects in their newborn babies.  The drug was administered as a mixture of 
enantiomers, and doctors soon realized that one of the isomers, the (S)-enantiomer of 
thalidomide, was causing birth defects. 
Since scientists have recognized the extent in which enantiomers can impact science 
and life, there has been an increase of interest in the field of enantioselective synthesis.  
One of the more elegant and eco-friendly strategies that can install chirality into a 
molecule is to apply a substoichiometric amount of a metal-free chiral catalyst; this is the 
basis of asymmetric organocatalysis.95, 97, 98, 100  Asymmetric organocatalysis can be 
broadly defined as an enantioselective process that is accelerated through the use of a 
catalytic amount of organic-based chiral reagent.  In contrast to transition metal and 
enzymatic catalysis, the key detail to recognize is that asymmetric organocatalysis 
employs small organic molecules to carry out the chemical reaction.  These chiral 
organocatalysts are typically more stable, more affordable, less toxic, and easier to 
synthesize and apply to various chemical transformations.88, 100 
 
2.5 ASYMMETRIC ORGANOCATALYSTS BASED ON ACTIVATION MODE 
In general, organocatalytic transformations can be classified based on how they 
interact with a substrate, which is referred to as their mode of action.  The 
organocatalysts react mainly as Lewis bases, Lewis acids, Brønsted bases, and Brønsted 
acids, but these can be simplified into two main modes of action: covalent and non-
covalent organocatalysts.99, 101, 120  Covalent organocatalysts involve a strong interaction 
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between a substrate and the catalyst in which a new covalent bond is formed.  The 
covalent modes of action commonly encompass enamine, iminium, singly occupied 
molecular orbital (SOMO), carbene, and Lewis-base catalysts.  Non-covalent 
organocatalysts depend on weak bonds between the substrate and organocatalyst.  The 
non-covalent modes of action predominantly involve hydrogen bonding, Brønsted base, 
Brønsted acid, bifunctional, and phase transfer catalysts.  While publications related to 
asymmetric organocatalysis continue to flourish, in the interest of brevity, the following 
content will feature a select few chiral organic frameworks that illustrate the innovations 
that have been made in asymmetric organocatalysis.  Particular emphasis will be placed 
on asymmetric organocatalysts that closely relate to the work displayed in this thesis:  𝛼-
functionalizations of carbonyl compounds, oxidations, and peptide related 
organocatalysts.  This review is intended to only cover specific topics, and therefore 
many pioneering works will not be represented.  However, for a more thorough and all-
inclusive understanding of asymmetric organocatalysis, the reader is directed to the 
remarkable multitude of books87, 99, 101, 121 and reviews74, 84, 96, 120, 122-138 that have been 
published.  Some of the more influential works that pertain to asymmetric 
organocatalysis will not be discussed but that are worth mentioning include: Fu’s planar-
chiral catalysts139, MacMillan chiral imidazolidinones for Diels-Alder, Friedel-Craft 
alkylations, direct alkylations of furans and indoles, and Mukaiyama−Michael 
additions110, 140-143,	and Shi144, Yang145, and Denmark146 catalytic scaffolds for 
asymmetric epoxidations. 
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2.6 ASYMMETRIC ORGANOCATALYSIS FOR 𝛼-CARBONYL 
FUNCTIONALIZATIONS  
The earliest report to render a reaction catalytic with an organic catalyst appeared in 
1912 by Bredig and Fiske (Scheme 2.1).82, 147  Although low enantiomeric excesses 
(<10% ee) were detected in catalyzing the addition of hydrogen cyanide to aldehydes, 
this seminal work revealed the possibility of using organic, chiral reagents (i.e. cinchona 
alkaloids in this case) in synthetic chemistry.   







Scheme 2.1 Cinchona alkaloids as chiral catalysts form chiral mandelonitriles















Scheme 2.2 A 1960 enatioselective ketene methanolysis by Pracejus
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reaction through the methanolysis of phenylmethylketene by utilizing an O-
benzoylquinine organocatalyst (Catalyst 3) (76% ee) (Scheme 2.2).  Soon after, Hajos 
and Parish102, and later Wynberg148, independently detailed an intramolecular aldol 
condensation catalyzed by L-proline (Catalyst 4) to afford enantioenriched bicyclic 
intermediates (Scheme 2.3, eq. 1).147  The selectivity of this reaction has been attributed 
to the hydrogen bonding that occurs between the carbonyl starting material and the 
carboxylic acid of the catalyst after enamine formation with the substrate (Scheme 2.3, 
eq. 1, Int-1).   This enantioselective, intramolecular aldol reaction was extended by Hajos 
and Parrish149, as well as Weichert, Sauer, and Eder150, to generate a Robinson 
Annulation product, the Wieland-Miescher ketone. This is an important synthetic 















Scheme 2.3 Intramolecular aldol reactions catalyzed by proline
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(Scheme 2.3, eq. 2).125, 148, 151, 152  These catalytic scaffolds have helped solve major 
synthetic challenges and have demonstrated their applicability in organic synthesis. 
List and Barbas reported a carbon-carbon bond forming reaction by means of a 
direct asymmetric intermolecular aldol condensation.37  Proline was used as the amine-
based catalyst, and similar to the Hajos-Parrish reaction (Scheme 2.3, eq. 1), it has been 
suggested that the enantiofacial selectivity arises from the stereodirecting carboxylate of 
proline (Scheme 2.4, Int-2).108, 125, 153  Further research from Woodward154 and 
Danishefsky155 exhibited the utilization of enamine catalysts in application to natural   
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The ability to use small, organic compounds, such as the natural amino acid 
proline, to catalyze chemical reactions has allowed for an expanded repertoire in the field 
of organocatalysis.  As shown in Scheme 2.6, many carbonyl moieties have been 
functionalized at the ⍺-position with use of L-proline as the organocatalyst.  The 
asymmetric Mannich reaction (Scheme 2.6, eq. 1) can generate syn β-amino ketones and 
aldehydes.113, 153, 156, 157  This has become an attractive enantioselective strategy for 
constructing decorated 𝛼-amino acids and alcohols.153, 157  MacMillan158, Hayashi159, and 
Zhong160 independently published enantioselective methods to assemble new carbon-
oxygen bonds at the alpha position of aldehydes and ketones (Scheme 2.6, eq. 2).  The 
proposed transition state (Scheme 2.6, eq. 2, int-3) involves hydrogen bonding to the 
nitrogen atom of the nitroso species, which has an enhanced Brønsted basic character, 
and allows for O-regioselectivity.161  These procedures have been exploited to produce 
optically active 𝛼-oxy-functionalized carbonyl compounds, which can be transformed 
into biologically relevant chiral compounds.161  Strategies that utilize asymmetric 
organocatalysis to form carbonyl compounds equipped with nitrogen substituents at the 
𝛼-position have been disclosed by Jørgensen 162 and List163 (Scheme 2.6, eq. 3).  These 
approaches can accompany the enantioselective Strecker and Mannich reactions toward 
𝛼-amino carbonyl compounds, however, List and Jørgensen illustrate a direct 𝛼-
amination by reacting enamines with alkyl diazodicarboxylates.162  Proline has also been 
utilized to afford a direct asymmetric catalytic dihydroxylation (Scheme 2.6, eq. 4).  This 
process is the first to exercise small organic catalysts en route to enantiopure anti-1,2-
diols, and has been used as a complementary protocol to the Sharpless dihydoxylation.164  
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This methodology was further expanded by MacMillan in an asymmetric direct aldehyde-
aldehyde coupling (Scheme 2.6, eq. 5).165, 166  The mechanism relies on distinct functions 
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of the two aldehydes, one aldehyde must function as a nucleophilic donor while the other 
operates as an electrophilic acceptor.  The donor aldehyde transposes to an enamine form, 
and permits the enantioinduction to ensue to form the desired product, a β-hydroxy 
aldehyde, which is an important building block for the synthesis of natural products; the 
intermediate is shown in Scheme 2.6, eq. 5, Int-4.  The aforementioned reactions have 
made it possible for small organic catalysts to be applied in various organic reactions, and 




One innovative strategy that has spawned from proline-type catalysts has been the 
utilization of short peptide-based chiral organocatalysts.128, 167-169  Peptide scaffolds are 
highly modular and easy to fine-tune due to the immense “chiral space” provided by the 
various commercially available and structurally diverse amino-acid residues. The easily 
iterative and facile assembly of peptides can be attributed to the development of Fmoc 
solid-phase peptide synthesis (Fmoc SPPS).170-172  Peptides are unique in that they can 
have small molecule characteristics (e.g. relatively low molecular weight, broad substrate 
scope), yet can mimic many sophisticated features of enzymes (e.g. site-selectivity, 
chemoselectivity).173, 174  The synthetic accessibility of peptides allows for large catalyst 
libraries to be generated, and these libraries can be rapidly tested using combinational 
optimization/selection and high-throughput methods.167, 175-177  Asymmetric catalysis 
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mediated by short peptide-based compounds has proven to be a practical approach in 
furnishing enantiopure products.168, 169, 178, 179 
In the 1979, Inoue and Oku catalyzed the cyanation of benzaldehyde to 
cyanohydrine via a catalytically active cyclic dipeptide (Scheme 2.7, eq. 1).  This was the 
first example of utilizing peptide-based chiral catalysts for carbon-carbon bond forming 
reactions.168, 180, 181  Encouraged by these results, cyclic dipeptides were used as chiral 
catalysts for asymmetric epoxidations.182  Soon after, Jacobsen disclosed a highly 
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enantioselective Strecker-type reaction by using a rigidified peptide-urea catalyst 
(Scheme 2.7, eq. 2) .183-186  The direct asymmetric aldolization of acetone with aldehydes 
was established by utilizing tripeptides that incorporate a secondary amine moiety 
(proline) (Scheme 2.8).187  The difference in reactivity and selectivity when using 
catalyst 8 versus catalyst 9 has been ascribed to the secondary structure of the peptide 
chiral catalyst. In fact, the two catalysts give products with opposite absolute 
configurations. 
Remarkable advances in the domain of peptide-based asymmetric organocatalysis 
have been accomplished by the Miller laboratory.128, 167, 169, 173, 178, 179, 188  With short 
peptide catalysts, Miller’s group successfully performed kinetic resolutions to produce 
enantiopure alcohols (Scheme 2.9).189  The enantiodiscrimination of the reaction is 
enabled by a well-documented β-turn secondary conformation190-193 within catalyst 10 
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*
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and catalyst 11, allowing for hydrogen bond interactions to trigger the kinetic 
resolution.169, 188, 194-197 
In Miller’s ensuing publications,  NMR techniques and solvent titrations were 
investigated to confirm the secondary structure of the peptide. They found that the highly 
ordered structure is suggested to be induced through intramolecular hydrogen bonding 
networks that occur within the peptide-based catalysts.189, 198, 199  In 2001, Miller used 
similar tactics to effectively resolve tertiary alcohols, a previously stubborn and difficult 
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Scheme 2.9 Kinetic resolution of hydroxyamide
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The Miller group was able to assemble new carbon-carbon bonds in an 
asymmetric Morita-Baylis-Hillman (MBH) reaction of ketones.201, 202  This 
transformation constructs new carbon-carbon bonds that supply functionalized allylic 
alcohols. The combination of two catalysts, a peptide and proline, were found to promote 
enantioselective Baylis-Hillman reactions (Scheme 2.10, eq. 1),201  and without the dual 
catalysis platform, the reaction is sluggish.  Miller and coworkers also established an 
intramolecular variant by using a two catalytic system that provides highly 
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enantioselective transformations (Scheme 2.10, eq. 2).202  The products obtained contain 
a new substituent at the carbonyl ⍺-position, as well as a newly set stereocenter at the β-
position. 
The concept of utilizing a peptide-based catalyst that contains a conformational 
rigid scaffold has been implemented in various other selective reactions.203-208  In 2015, 
Schreiner kinetically resolved racemic diols, in conjunction with a catalyzed alcohol 
cross coupling, to form enantioenriched esters (Scheme 2.11).209  This enantioselective 
reaction was catalyzed by a peptidic catalyst that incorporates a sterically bulk adamantyl 
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Scheme 2.11 Alcohol cross-coupling for kinetic resolution of diols using peptide catalysts
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Phase transfer catalysts (PTC) have had a substantial impact on the field of 
asymmetric organocatalysis.212-214 O’Donnell213, 215, Corey216, and Lygo212 have applied 
chiral Cinchona alkaloid phase transfer catalysts (PTC) to generate 𝛼-enriched amino 
acid derivatives.  The catalyst is conformationally organized through non-covalent 
interactions, allowing it to possess exquisite facial selectivity to the substrate.99, 215  An 
example is illustrated in Scheme 2.12, in which a Cinchona alkaloid PTC is able to 
effectively trigger an enantioselective monoalkylation at the 𝛼-carbonyl position.212, 213,216 
The advances described above have given the field of organocatalysis exceptional 
applicability.  In particular, peptide-based catalysts have presented themselves as 
multifaceted organic catalysts, in which they portray characteristics of enzymes and small 
molecules.  These unique features have validated the impact that peptidic catalysts can 




















Scheme 2.12 Cinchona alkaloid PTCs for asymmetric !-amino acid derivatives
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have geared toward using “greener” and more environmentally benign catalysts, and 
organocatalysts meet these desires. One area of research that has also gained attraction as 
a versatile, yet eco-friendly strategy has been the implementation of hypervalent iodine 
organic catalysts.  While many remarkable achievements have been made, the integration 
of hypervalent iodine chemistry with peptide-based organocatalysts has remained widely 
unexplored.  Developing methodologies that can exercise the unique aspects of chiral 
peptide-based catalysts and hypervalent iodine species offers a potential new paradigm to 
construct complex molecular skeletons in a highly reactive and enantioselective fashion. 
The next chapter of this thesis will describe the efforts that have been made in utilizing 
chiral hypervalent iodine(III) catalysts as versatile and “greener” alternatives to toxic 
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IODOARENE-CONTAINING ORGANOCATALYSTS FOR HYPERVALENT IODINE(III) 
OXIDATIVE TRANSFORMATIONS  
 
3.1 HYPERVALENT IODINE ORGANOCATALYSIS 
To facilitate asymmetric transformations, the scientific community has turned a great 
deal of attention toward the use of chiral organocatalysts.  Recently, one area that has 
witnessed tremendous growth has been the employment of chiral, hypervalent iodine 
organocatalysts.  As discussed in Chapter 1, hypervalent iodine species can act as highly 
efficient and selective electrophiles and/or oxidants, and are appealing due to their mild 
and environmentally friendly nature.18, 30, 44, 68  Although organic molecules bearing 
hypervalent iodine moieties were discovered over a century ago, chiral hypervalent 
iodine reagents were not utilized as asymmetric organocatalysts until the last few 
decades.  The following chapter will highlight the work that has helped advance 
asymmetric chemistry in the context to hypervalent iodine-mediated catalysis.  Particular 
focus will be placed on chiral hypervalent iodine(III) catalysts that assist in oxidative 
transformations and/or that furnish alpha-functionalized carbonyl products.  For a more 
broad overview of the contributions that have been made toward asymmetric 
transformations mediated by hypervalent iodine compounds, the reader should survey the 
exceptionally thorough books13, 23, 44, 68 and reviews217-226 that have recently appeared.  
Significant hypervalent iodine-mediated developments that will be featured at a minimum 
but that warrant a mention include: hypervalent iodine(V) reagents68, 217, 225-227, 
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asymmetric rearrangements217, 223, 228-230 alkene functionalizations217, 228, 231-233, and 
alcohol oxidations234-236. 
3.2 GENERAL REMARKS ON OXIDATIONS 
At the most basic level, an oxidation/reduction (redox) reaction is a process that 
involves the transfer of an electron from one species to another.  Oxidation refers to a 
loss of electron(s), and reduction indicates a gain in electron(s).  Oxidative reactions are 
central for life and are commonly performed in nature as well as in the laboratory.  In 
fact, approximately 30% of total chemical production involves oxidation, which 
represents the second largest chemical process utilized in industry.237  A functional group 
is commonly converted to a more highly oxidized form by the addition of oxygen and/or 
removal of hydrogen.81  The currently available oxidation methods allow for scientists to 
synthesize many key chemicals and intermediates, including aldehydes, ketones, 
alcohols, epoxides, esters, and carboxylic acids.  Despite the advances that have been 
made toward oxidative transformations, oxidation methods have been traditionally 
dominated by the use of toxic and heavy metal reagents or catalysts.  To further improve 
and expand upon the synthetic chemist’s arsenal of asymmetric oxidation methods, the 
following review will familiarize the reader with the progress that has been made in 
utilizing chiral hypervalent iodine(III) reagents to effectively carry out asymmetric 
oxidative transformations.     
3.3 CHIRAL HYPERVALENT IODINE(III) REAGENTS FOR 
ENANTIOSELECTIVE OXIDATIVE TRANSFORMATIONS  
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3.31 ASYMMETRIC OXIDATION OF SULFIDES TO SULFOXIDES 
Chiral sulfoxides have dominated as premier chiral organosulfur compounds and 
have displayed great importance in many chemical applications.  Two of the more 
impactful areas in which enantiopure sulfoxides have been used are: as chiral auxiliaries 
and chiral ligands in asymmetric synthesis238, 239 and as pharmaceutically active 
compounds240 such as Nexium®, Nuvigil® and Clinoril® (Figure 3.1).  The preparation of 
optically active chiral sulfoxides has been a challenging area of organic chemistry, yet 
there is a growing interest in seeking synthetic routes in order to obtain this valuable class 
of chiral compounds.   
 
The introduction of chiral hypervalent iodine reagents can be attributed to Pribam, 
Amey and Martin. In 1906, Pribam synthesized diphenyliodonium tartrate to use as the 
first chiral hypervalent iodine reagent.241  In the 1970s, Amey and Martin described the 
synthesis of cyclic, chiral iodanes.242  While these were essential discoveries, chiral 
hypervalent iodine compounds were not synthetically utilized until decades later.  In 























(3e) with the use of aryl-l3-iodane reagents (3c) (Scheme 3.1, eq. 1).68, 243  Interestingly, 
the chiral oxidizing agent (3c), which was generated in situ from reacting an L-tartaric 
acid anhydride derivative (3a) with iodosylbenzene (3b), was only able to induce high 
enantioselectivities when a C2-symmetric shape was incorporated into the proposed 
seven-membered ring (3c). When using chiral acetyl-L-lactic acids, the authors reported 
racemic mixtures of sulfoxides.  Koser also created an in situ active chiral I(III) agent by 
adding either (diacetoxyiodo)benzene (3f, PIDA) or iodosylbenzene (3b) to tartaric 
anhydride analogs (3a).244 In contrast to Imamoto’s work, Koser suggested that the active 
chiral iodine(III) benzoyl tartrate reagent was a polymer (3g) rather than a seven-
membered ring as previously proposed (i.e. 3c).   
Varvoglis and co-workers245 generated novel (+)-camphorsulfonic acid 
derivatives (3i) to act as chiral hypervalent iodine(III) reagents, and Chen246 utilized a 
similar methodology for the preparation of organosulfonyloxy analogs (3j) in good 
yields, but poor enantioselectivies (Scheme 3.1, eq. 2).  In 1990, another asymmetric 
strategy toward the synthesis of optically active sulfoxides was detailed by Koser and 
Ray (Scheme 1.3, eq. 3).247  Through ligand exchange, (+)- or (–)-menthol (3k) could be 
attached to an iodine(III) moiety, thereby creating an efficient enantioselective iodine(III) 
reagent (3l).  Following recrystallization and base-mediated hydrolysis, this method  






3.32 ASYMMETRIC OXIDATIVE DEAROMATIZATION 
Aromatic arenes and heteroarenes are ubiquitous in nature and are widely utilized 
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chemists rely on well-established transformations, such as Friedel-Crafts and Sandmeyer 
reactions.  One specific transformation, dearomatization, has perpetually sparked interest 
in the synthetic community.  Dearomatization reactions have the potential to transform 
aromatic substrates into more complex ring systems or into nonaromatic products that can 
act as valuable synthetic building blocks.248-251   
 Siegel and Antony252 were the first to utilize hypervalent iodine reagents for 
dearomatizations, however Kita253 further developed this chemistry by disclosing the first 
enantioselective dearomatization strategy.  Kita’s asymmetric phenolic oxidation was 
carried out with a novel l3-iodane reagent that contained a conformationally rigid 






















The two generally accepted mechanistic pathways for phenolic oxidative 
dearomatization reactions mediated by hypervalent iodine(III) reagents are illustrated in 
Scheme 3.3.254-260  In Pathway A, a ligand exchange occurs between the HI(III) reagent 
B, (e.g. iodobenzene diacetate) and the phenol substrate A, to produce iodonium 
intermediate C1.  The iodine(III) component of C1 collapses into iodobenzene and 
acetate, while concomitantly producing a resonance-stabilized phenoxenium ion D, 
which is subsequently trapped by a nucleophile to furnish the dieonone product E. In 
Pathway B, the dienone product E is produced directly after a nucleophilic attack, via an 
SN2′-type substitution at the para position of the arene ring in C2, which oxidizes the 
phenoxyl group and reductively eliminates the iodine(III) component to iodobenzene and 





































reactions, the optimized conditions should favor Pathway B.220 
Kita’s methodology was later improved to allow for a catalytic variant, in which a 
diiodo chiral scaffold 3o was oxidized by a co-oxidant, m-chloroperbenzoic acid (m-
















3o (R1 = H)
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262  To understand the structural influence the catalyst had on the chiral induction, Kita et 
al. investigated the ortho positioned R1 groups relative to the aryl iodine.263  By 
synthesizing various spirobiindane-containing chiral reagents, they found an ethyl 
substituent in the ortho-position (3p) could increase the enantioselectivity of the 
dearomatizing spirocyclization of napthols up to 92% ee.  With the optimized conditions, 
Kita subjected Ishihara and co-worker’s C2-symmetrical chiral hypervalent iodine(III) 
scaffold (3q)264, 265 to the oxidative dearomatization of naphthols, which returned an 
unsubstituted spirocyclic product in a similar 92% ee (Scheme 3.4, eq. 2).263  It should be 
noted that while this reaction is successful with lower equivalents of the co-oxidant, if 
five or more equivalents of m-CPBA are added, the olefin-containing product is 
selectively oxidized to an epoxide (Scheme 3.4, eq. 2, 3r).264  
This work was extended by Quideau to allow for an iodoarene-mediated 
asymmetric hydroxylative phenol dearomatization, which can provide chiral o-quinols 
(Scheme 3.5, eq. 1, 3u).266  The active catalyst was generated in situ with use of a co-
oxidant, m-CPBA, but as similarly described by Kita and Ishihara, if the co-oxidant is in 
excess, the resulting product undergoes subsequent epoxidation (3v). Harned et. al. 
applied DFT calculations to design tricyclic chiral catalyst 3x, a dimethyl tartrate 
derivative.260, 267  This chiral aryl iodide catalyst was employed in an asymmetric 
oxidative dearomatization reaction to yield enantioenriched p-quinols (Scheme 3.5, eq. 2, 
3y).  Quideau also performed an intramolecular hypervalent iodine-induced oxidative 
dearomatization to generate a 2,5-cyclohexadienone derivative 3aa in 40% ee (Scheme 



























































3.33 ALPHA FUNCTIONALIZATION OF CARBONYLS 
Enantiopure 𝛼-functionalized carbonyl compounds are valuable and versatile 
chiral synthons that enable rapid access to synthetic targets.96, 133, 224, 226   They can be 
used for the construction of complex natural products, pharmaceutical agents, or key 
synthetic intermediates.  For example, Figure 3.2 highlights several pharmaceutically 
active molecules that contain an α-functionalized carbonyl moiety.  A significant amount 
of progress toward the α-functionalization of carbonyl compounds through the use of 
selective hypervalent iodine(III) reagents is presented below. 
The general reactivity profile of carbonyl compounds in the context of 
hypervalent iodine(III) reagents is illustrated in Scheme 3.6.268  Under acidic or basic 
conditions, ketones (Scheme 3.6, eq. 1, 3ab) can equilibrate to their enol/enolate isomers 
(3ac).  A lone pair of electrons from the oxygen can swing down to produce a C=O π-
bond, which breaks the C=C π-bond, and subsequently permits the α-carbon to trap an 
electrophile.  This overall process generates an 𝛼-substituted carbonyl compound (3ad), 
in which the electrophile is trapped at the α-position.  Similarly, the same enolizable 
























carbonyl compound (Scheme 3.6, eq. 2, 3ae) can trap an electrophilic species, in this 
case a hypervalent iodine(III) species, to produce the α-substituted intermediate 3af.  
However, due to the highly electrophilic nature of the iodine(III) species, this unstable 
intermediate is susceptible to a subsequent nucleophilic attack. Upon nucleophilic attack, 
the iodine(III) collapses to a univalent iodine by-product (iodobenzene) via reductive 
elimination, to yield an α-substituted carbonyl product that formally contains a 
nucleophile in the α-position (3ag).  It can be reasoned that this reaction efficiently 













Typical reactivity of enolates with electrophiles



















R, Z = substituent
Nu = Generic nucleophile
E = Generic electrophile
IIII = Generic iodine(III) reagent
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and is considered a hypernucleofuge, allowing for it to act as an excellent leaving group, 
(2) The iodine(III) leaving process is entropically favorable, in which one molecule (3af) 
is split into three molecules (the product 3ag, iodobenzene, and an anionic ligand that 
was supplied by the iodine(III) reagent) (cf. chapter 1, Scheme 1.4), (3) The high stability 
of the iodobenzene by-product thermodynamically drives the reaction forward.  
Therefore, hypervalent iodine(III) compounds have the unique ability to alter the typical 
reactivity profile of enolizable carbonyl compounds by trapping a nucleophile, rather than 
an electrophile, in the α-position; this inversion of polarity is known as an umpolung 
strategy. The umpolung nature of hypervalent iodine(III) species has been exploited in 
various chemical transformations.268, 269   
While	the synthesis of α-functionalized chiral carbonyl compounds has 
immensely advanced over the last decade, the introduction of α-carbonyl substituents in 
an asymmetric fashion mediated by hypervalent iodine compounds has only recently 
emerged.223, 224, 226  In 1990, Ochaia and co-workers synthesized chiral diaryliodonium 
salts (Scheme 3.7, eq. 1, 3ai) to induce the first hypervalent iodine-mediated direct 𝛼-
phenylation of cyclic β-ketoesters (3aj).270  The chiral l3-organoiodane gave a moderate 
enantioinduction (up to 53% ee), but prevailed as a highly regioselective reagent (i.e. no 
O-phenyl congener was isolated).  Metal-free enantioselective arylations were further 
developed by Olofsson and Wirth.14, 230, 271, 272   
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Ishihara, Uyanik, Okamoto, and Yasui developed chiral quaternary 
ammonium(hypo)iodite catalysts (Scheme 3.8, 3al) to supply enantioenriched 
dihydrobenzofuran derivatives (3am) in up to 96% ee.273  The oxidative 
cycloetherification was accomplished by an active iodine catalyst that was generated in 
IPh
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Scheme 3.8 Hypervalent iodine(III)-mediated asymmetric oxidative cycloetherification
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situ with hydrogen peroxide as the co-oxidant.   
While many oxidations mediated by hypervalent iodine(III) compounds have 
been established, they typically rely on the use of stoichiometric amounts of l3-iodanes.  
In 2005, Ochai274 and Kita262 independently disclosed processes that utilize a suitable co-
oxidant (m-CPBA) to render the process catalytic (Scheme 3.9).217, 228, 236, 275  These 
methods allow for the in situ preparation of l3-iodanes, in which the precatalyst (e.g. the 
iodine(I) reagent (3ap)), can be readily oxidized to its active iodine (III) state (3aq) in the 
presence of an acid (e.g. (3an) para-toluenesulfonic acid, p-TsOH), and a stoichiometric 
chemical oxidant (m-CPBA 3ao) (Scheme 3.9).262, 274, 276, 277  If the co-oxidant (3ao) 
selectively reacts with the iodine-containing precatalyst (3ap), rather than the substrate 





































(3at), the catalytic cycle can continue by a re-oxidation of the reduced iodine(I) (3ap) by-
product to regenerate the active HI(III) catalyst (3aq).  
The enantioselective α-functionalization of carbonyl compounds has been an 
attractive approach toward the production of valuable chiral carbonyl synthons.224, 226  
Hypervalent iodine(III) compounds in conjunction with acidic conditions (e.g. p-TsOH) 
can allow for ketones, such as propiophenone, to become susceptible to an 
enantioselective α-oxysulfonylation process, which delivers an enantioenriched 𝛼-
substituted carbonyl compound that is equipped with an excellent leaving group at the α-
carbon stereocenter.  The putative mechanistic pathways of this reaction are shown in 
Scheme 3.10.  Theoretical and experimental evidence has been reported in the literature 
to determine which pathway is operative, yet the reports seem to dispute one another and 
the true course of transformation remains unclear.59, 68, 278, 279  The two competing 
mechanistic proposals for this transformation that have emerged, invoke either an SN2’ or 
an SN2 displacement (Scheme 3.10 , Pathway 1 and Pathway 2 , respectively).277, 280-282  
Both mechanistic pathways commence with the ketone (4a) existing in an acid-catalyzed 
equilibrium with its (E) and (Z) enol tautomers (4c and 4d, respectively). Mechanistic 
Pathway 1 (shown using red arrows) involves the hypervalent I(III) species (4e, Koser’s 
reagent) undergoing a nucleophilic attack from the enol oxygen atom, resulting in an O-
bonded iodono intermediate (4f). This intermediate expels water to form the O-bonded 
iodonium ion (4g). The iodonium intermediate subsequently undergoes an SN2’ 
displacement by the tosylate ion to create the observed product (4h). In this scenario, the 
SN2’ nucleophilic attack is the stereo-defining step.281  Mechanistic Pathway 2 (shown 
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using blue arrows) utilizes the carbon atom of the enol to attack the hypervalent I(III) 
reagent, which leads to a C-bonded iodono intermediate (4i); this is the stereo-defining 
step. This intermediate ejects water to form the C-bonded iodonium ion (4j), which 
undergoes an SN2 displacement from the tosylate ion to form the chiral 𝛼-substituted 
ketone product (4h); in this pathway, the trapping of the enol is the stereo-defining 
step.278, 282-284   
Wirth investigated the first enantioselective approach to catalyzing ⍺-
oxytosylations of ketones with a chiral iodoaryl catalyst (Figure 3.3, 4q).  The chiral 
information of the catalyst is appended on the aryl ring such that it is ortho relative to the 
iodine 285, 286  The ⍺-oxytosylation of propiophenone was conducted in a good yield (78% 


























































Scheme 3.10 Putative mechanistic pathways for the !-oxytosylation of propiophenone mediated by a HI(III) reagent
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cyclic substrate, 1-indanone (4n), was synthesized in a 79% yield with 21% ee (Scheme 
3.11, eq. 2).  Wirth further catalyzed the formation of α-tosyloxylated ketones by 
designing additional iodoarene chiral catalysts.287  One catalyst contains an o-menthyl 
group that can chelate iodine, and supply the chiral propiophenone product in up 42% 
yield and 39% ee (Figure 3.3, 4r).284, 287  Wirth et. al. were able to obtain the ⍺-
oxytosylation product in a higher yield (70%) by synthesizing another ester-containing 
chiral catalyst (Figure 3.3, 4s), yet the enantioselectivity was slightly diminished (26% 
ee).288   


































Moran and Rodríguez synthesized and assessed chiral aryl iodides in an 
intermolecular as well as an intramolecular asymmetric oxidation. (Scheme 3.11, eq. 1 
and eq. 3).289  The most interesting catalyst was a pseudoephedrine derivative (Figure 
3.3, 4t) that oriented the iodine ortho in relation to the chiral information.  In the a- 
oxytosylation of propiophenone, the catalyst supplied the intended product (4l) in a 
moderate yield (59% yield), but with a negligible enantioselectivity (3% ee). 
Nonetheless, catalyst 4t was able to selectively induce the asymmetric oxylactonization 
of 5-oxo-5-phenylvaleric acid in 51% ee (Scheme 3.10, eq. 3), which was a significant 
increase in selectivity over Wirth’s reagent (Figure 3.3, 4s, ~3% ee).288   
Legault’s laboratory was able to apply iodoaryloxazoline-based chiral catalysts 
for ⍺-functionalizations (Figure 3.3, 4u).277, 278  The most effective catalyst was 
comprised of an aryl ring that accommodates an o-methyl and p-chlorine substituent 
(relative to iodine) (4u).  With slow addition of m-CPBA to the reaction mixture, 
propiophenone was converted to ⍺-oxytosylpropiophenone in an 80% yield with a 
stereoinduction of 48% ee (Scheme 3.10, eq. 1, Figure 3.3, 4u).  It should be noted that 
without the ortho methyl substituent, the reaction did not proceed.278    
Through a seven-step synthesis, Zhang was able to synthesize spirobiindane-
based chiral iodoarenes, which he utilized as catalysts in the enantioselective ⍺-
oxytosylation of propiophenone (Scheme 3.11, eq. 1, Figure 3.3, 4v).  With ethyl acetate 
as the optimal solvent, Zhang’s catalyst gave an enantio-enriched product in 53% ee.290  
Brenet, Berthiol, and Einhorn suggested that sterics around the iodine center may play an 
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important role in the chiral induction process.291  This group synthesized a sterically 
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 59% yield, 3% eea
≤ 47% yield, ≤ 51% eec
a ⍺-oxytosylation of propiophenone (Scheme 3.11, eq. 1)
b ⍺-oxytosylation of 1-indanone (Scheme 3.11, eq. 2) 
c oxidatative cyclization of 5-oxo-5-phenylvaleric acid (Scheme 3.11, eq. 3)
Figure 3.3 Select examples of chiral hypervalent iodine(I) precatalysts
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(Figure 3.3, 4w).  In the ⍺-oxytosylation of propiophenone, catalyst 4w imparted an 
enantioselective outcome with up to 46% ee. 
Richardson and Wirth also implemented axial chirality by synthesizing a 
binaphthyl-based chiral diiodo catalyst (Figure 3.3, 4x).286  This catalyst gave poor 
enantioselectivities (£12% ee) but moderate yields (79% yield) in the oxytosylation of 
propiophenone (Scheme 3.11, eq. 1).  Wirth and Mizar further developed protocols that 
employ silyl enol ethers and nucleophiles other than tosylates to broaden the scope of the 
α-functionalization of carbonyl compounds.268, 286, 287  In 2017, Masson disclosed the use 
of chiral, non C2-symmetric iodoarene catalysts for the direct α‑oxysulfonylation of 
ketones (4y).220  This unique catalyst can offer respectable yields (75% yield) and 
enantioselectivities up to 67% ee in the α-oxytosylation of propiophenone (Scheme 3.11, 
eq. 1).  
Legault and Basdevant made great strides in the area of α-oxytosylated ketones.  
By coupling the use of Ishihara’s bis-lactate-derived, C2-symmetric iodoarene catalyst 
scaffold (Scheme 3.12, 4y) and preformed enol acetate substrates (4z), enantio-enriched 
α-oxytosylated ketones (5b) were accessible in synthetically useful yields and 
enantioselectivities (up to 70% yield and 90% ee).292 While this is an impressive feat, the 
requirement to use preformed enol acetates is cumbersome, entailing the in situ 
preparation of lithium diisopropylamide (LDA), a very strong and moisture/air sensitive 
base, as well as a tedious dropwise addition protocol over 13 h.  Furthermore, when 
utilizing these conditions in the direct α-oxytosylation of ketones, this method produces 
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low enantioselectivities. Finally, under catalytic conditions, the only substrate that gave a 
high steroinduction was propiophenone. While a broader scope of ketones underwent the 
reaction in synthetically useful enantioselectivities, they were only evaluated using a 
stoichiometric amount of the chiral catalyst 5a.292 
The previously described studies include some of the pioneering breakthroughs 
that have greatly advanced methodologies designed for catalytic asymmetric oxidative 
transformations.   Nevertheless, a persistent obstacle has been the inability to promote 
hypervalent iodine-mediated organic reactions in an a direct, catalytic, and 
enantioselective manner.  Particularly problematic in this regard are two of the most 
studied hypervalent asymmetric iodine-mediated reactions: the α-oxytosylation of 
propiophenone and the oxidative cyclization of 5-oxo-5-phenylvaleric acid.  These 
particular reactions have been studied for decades, however efficiently promoting the 
formation of products with synthetically useful enantioselectivity and high yields has 
O O
OTsm-CPBA  (1.1 eq.)
MeCN, rt, 13 h
p-TsOH独H2O (1.1 eq)
















proven to be a formidable challenge which warrants further investigation.  Furthermore, 
most of the hypervalent I(III) asymmetric catalysts described in this chapter require 
lengthy and sometimes tedious protocols for their preparation, which limits the ability to 
make iterative changes to the catalyst scaffold for further optimization.  The efforts 
described below aim to resolve the aforementioned obstacles associated with HI(III)-
mediated oxidative transformations by synthesizing and implementing modular and 
tunable iodoarene-containing catalysts that are capable of providing high yielding, 
enantiopure products. 
3.4 IODOARENE-CONTAINING ORGANOCATALYSTS FOR HI(III) 
OXIDATIVE TRANSFORMATIONS  
Our group has investigated the incorporation of an iodoarene functional group 
into a chiral framework, such that the chiral information can be transferred from the 
HI(III) reagent to the substrate in order to generate high yielding, enantioenriched 
products.  We envisioned the use of peptide-based scaffolds, that contain an active 
iodoarene component, to operate as the chiral inducing agent.  As discussed in Chapter 2, 
peptides have the ability to induce high enantioselectivities in organic transformations 
due to the immense chiral space they provide, and can thereby create a chiral 
environment for selective substrate recognition.128, 168, 169  Fmoc Solid-Phase Peptide 
Synthesis (SPPS) techniques allow for the rapid access and evaluation of catalytic 
libraries.293  Figure 3.4 illustrates our envisioned generic peptide-based scaffolds that 
incorporate iodoarene moieties (highlighted in blue) at the N-terminus of a linear (6a) or 
β-turn (6b) scaffold, which has been documented in literature to be nucleated from a D-
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Ala-Pro sequence.128, 169, 173, 190, 294, 295  The overall goal of this research is to unite the 
fields of hypervalent iodine(III) catalysis with peptide-mediated asymmetric synthesis to 
generate chiral HI(III) peptide-based catalysts that can effectively induce enantioselective 
and high yielding outcomes in a range of synthetically useful oxidative transformations. 
 
Initial investigations were focused on the installation of the catalytically active 
iodoarene moiety into a highly modular chiral peptide framework.  We considered that 
this concept can be achieved through a peptide bond, or more specifically a benzamide 
linkage, as portrayed in blue in Figure 3.4.  The amide linkage presents itself as a facile 
method for installing aryl iodo active sites onto a variety of amino acid side chains, 
thereby allowing for iterative modifications.   Therefore, in the context of our strategy,  
probing the influence of an amide bond on the catalysis of the desired transformations 
was critical in order to ensure that this strategy for incorporation of the catalytic site into 




































the steric and electronic properties that affect catalytic performance, a series of twelve 
iodoarene containing amides (Figure 3.5, Catalysts 1-12) were synthesized (Scheme 
3.13, yields shown in parentheses) and then utilized in the direct α-oxytosylation of 
propiophenone.296  A generic amidation reaction, which was used to synthesize the N-
butyl-iodobenzamide organocatalysts, is shown in Scheme 3.13.  This conventional 
amidation reaction allows for an iodoarene-containing carboxylic acid substrate (6c) to 
react with thionyl chloride to form an acyl chloride (6d), which can be displaced by N-
butyl amine to form the desired amide (e.g. Catalyst 3) (Scheme 3.13).   
 
The suite of iodoarene containing catalysts shown in Figure 3.5 were chosen due 
to their varying electronic and steric substituents.  The influence of the electron-
withdrawing amide motif was probed in the α-oxytosylation of propiophenone (Table 
1.1).  The α-oxytosylation reaction was conducted at room temperature on a 0.1 mmol 
scale with acetonitrile as the solvent, para-toluenesulfonic acid monohydrate (p-TsOH･
H2O) as the acid and nucleophile, iodo-benzamide as the catalyst (Catalysts 1-12), and 
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mCPBA as the co-oxidant. A standard work up of the reaction mixture was also 
necessary in order to isolate the desired product for gas chromatography (GC) analysis.  
Reactions were quenched with dimethyl sulfide at prescribed times followed by GC 
analysis. Yields were calculated from a product standard curve that was generated over 
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Catalyst 7 (89%) Catalyst 8 (90%) Catalyst 9 (72%)




Figure 3.5 N-butyl-iodobenzamide catalysts with corresponding amidation yields
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were collected from averaged triplicate runs with tetraglyme being utilized as the internal 
standard. 
Conducting 48-hour reactions revealed the relative rates of the differently 
substituted iodoarene catalysts (Entries 1-12, Table 1.1).  Relative to the iodine, meta- 
and para-positioned amides were more effective as catalysts than ortho-substituted 
amides (Entries 1-3, Table 1.1).  This suggests that the sluggish behavior observed with 
using Catalyst 1 may be due to steric hindrance as well as the inductive electron 
withdrawing nature of the ortho positioned amide.   Catalysts 4-7 were synthesized to 
investigate how electronics and sterics can affect the rate in relation to the parent ortho-
substituted iodoarene (Catalyst 1).  With the aim to diminish the electron-withdrawing 
nature of the amide, an electron donating group (i.e., methoxy) was positioned para to the 
amide substituent (Catalyst 4).  An additional electron donating group, such as a 
methoxy or methyl group, was situated para to the iodine with the intent to generate a 
more electron rich iodine center (Catalysts 4-6).  These analogs were inspired by the 
work done by Wirth284 and Legault278, who reported slight increases in catalytic activity 
when iodine was situated para to an electron-releasing group. With little to no rate 
enhancement detected, these studies indicate that electronics may play a rather minor role 
in the catalytic activity of the iodobenzamides (Table 1.1, entries 4-6). Catalyst 7 was 
created to induce the “hypervalent twist” phenomenon, which in essence, states that 
catalysts can achieve higher relative rates if sterically bulky substituents are located ortho 
to the iodine.278, 284, 297  With an approximate 10 fold increase in rate, the “hypervalent 
twist” phenomenon appears to be validated in our system (Table 1.1, entry 1 vs. entry 7).  
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Legault’s computational research suggests that if a Lewis base (e.g. an amide) is 
positioned ortho to the aryl iodine(I) precatalyst, when activated to iodine(III), the 
catalyst is stabilized, which slows down the ensuing displacement, and therefore 
decreases catalytic reactivity.278  Invoking this reasoning, Catalyst 1 underperforms in 
the oxidative 𝛼-oxytosylation of propiophenone, when compared to Catalyst 2 and 
Catalyst 3 (Table 1.1, entry 1 vs. entries 2 and 3).  This same concept becomes apparent 
when comparing two “hypervalent twist” congeners, Catalyst 7 and Catalyst 8, in which 
a meta positioned amide relative to the iodine, performs at a much higher rate than an 
ortho positioned amide (Table 1.1 entry 7 versus entry 8).  Finally, the “hypervalent 
twist” was probed between meta positioned amide catalysts, Catalyst 8 and Catalyst 9. 
Evidently, the “hypervalent twist” phenomenon is inoperable when the Lewis base and 
the iodine are distal to each other, and instead ortho-positioned steric effects play a large 
role in influencing the rate of catalysis (Table 1.1, entry 8 and 9).  Finally, electron 
donating groups were situated around a meta positioned amide (relative to iodine), which 
gave the α-oxytosylated product in relatively good to quantitative yields (Table 1.1 
entries 10-12).  
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The highest relative rates obtained after 48 h were quantitative yields (Table 1.1 
entries 2, 11, and 12), and as a result these, as well as the other top four catalysts, were 
subjected to a four-hour reaction time in order compare the catalysts prior to completion 
Entry Catalyst Yield (%)a,b
1 1 3 ± 0
2 2 quant.
3 3 82 ± 6
4 4 2 ± 0
5 5 2 ± 0
6 6 3± 0
7 7 29 ± 4
8 8 91 ± 3
9 9 76 ± 3
10 10 67 ± 4
11 11 quant.
12 12 quant.
Table 1.1   Oxidative ⍺-Oxytosylation of Propiophenone (48 h, rt)
a Average yields of triplicate runs employing tetraglyme as the ISTD.











(Table 1.2, entries 1-7).  The catalyst that gave the most significant rate acceleration was 
observed to be Catalyst 11, thereby supporting Wirth284 and Legualt’s277 findings that 
electron donating substituents in the para position (relative to I) can promote increases in 
reaction rates (Entry 6, Table 1.2).  These rate studies provide the idea that attaching the 
amide functionality onto the iodoarene can potentially have tremendous effects on 
catalytic activity.   
 
  
Entry Catalyst Yield (%)a,b
1 2 39 ± 3
2 3 19 ± 3
3 8 28 ± 2
4 9 24 ± 3
5 10 36 ± 1
6 11 44 ± 2
7 12 40 ± 1
Table 1.2   Oxidative α-Oxytosylation of Propiophenone (4 h, rt)
a Average yields of triplicate runs employing tetraglyme as the ISTD.





Catalyst (0.1 equiv) *
MeCN (1 mL)
4 h, r.t.4k 4l
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All 12 catalysts were evaluated in the oxytosylation of propiophenone over a 24 h 
time period at 50 ℃, and the top seven catalysts were further screened at 50 ℃ for 1 hour 
(Table 1.3 and Table 1.4, respectively).  Similar trends were witnessed in the 50 ℃ 
Entry Catalyst Yield (%)a,b
1 1 16 ± 4
2 2 96 ± 2
3 3 96 ± 3
4 4 11 ± 3
5 5 12 ± 2
6 6 16 ± 3
7 7 65 ± 1
8 8 92 ± 4
9 9 quant.
10 10 quant.
11 11 97 ± 2
12 12 60 ± 5
Table 1.3   Oxidative α-Oxytosylation of Propiophenone (24 h/50 ºC)
a Average yields of triplicate runs employing tetraglyme as the ISTD.











trials, as those observed in the room temperature reactions.  The catalyst that repeatedly 
furnished the oxytosylated ketone (4l) in the highest yield was Catalyst 11.  This catalyst 
therefore became our lead catalyst, and provided the oxytosylated ketone in high yields.  
To further investigate how the amide moiety may affect the overall catalytic 
activity of iodoarenes, two significant studies were completed.  The first study entailed 
subjecting a series of structural analogs of lead Catalyst 11 to four-hour reaction 
conditions (Table 1.5, entries 1-7).  The second study involved kinetic 1H NMR rate 
studies involving the best, an intermediate, and an inefficient catalyst (Catalyst 11, 
Entry Catalyst Yield (%)a,b
1 2 63 ± 2
2 3 57 ± 2
3 8 43 ± 1
4 9 52 ± 3
5 10 63 ± 1
6 11 68 ± 1
7 12 48 ± 1
Table 1.4.   Oxidative α-Oxytosylation of Propiophenone (1 h/50 ºC)
a Average yields of triplicate runs employing tetraglyme as the ISTD.











Catalyst 8, and Catalyst 4, respectively)  in order to examine the relative rates of 
oxidation from their iodine(I) to iodine(III) active state (Figure 3.6).  
The structural analog study revealed that an amide bond, which will link the 
active iodoarene containing catalyst and the peptide, is a valid strategy since there is no 
appreciable effect on the catalytic activity when incorporating an amide functionality 
(Table 1.5, entry 2 versus entries 1, 3-7).  It seems that by positioning a methoxy group 
para to the iodine, and placing the iodine meta to the deactivating amide, an effective 
catalyst template is established (i.e. Catalyst 11). This presents a distinct catalytic 
platform that differs from many other HI(III) scaffolds, in which an o-iodo scaffold is 
required for an effective catalytic, chiral outcome (see Figure 3.3).  
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The kinetic 1H NMR rate study demonstrated that more electron rich iodoarenes 
(e.g. Catalysts 11 and 8) oxidize to their active hypervalent iodine(III) state more 
efficiently than electron poor iodoarenes (e.g. Catalyst 4).  Catalyst 11 and Catalyst 8, 
Entry Catalyst Yield (%)a,b
1 3 19 ± 3
2 11 44 ± 2
3 4-iodoanisole 13 33 ± 4
4 4-iodotoluene 14 30 ± 3
5 3-iodotoluene 15 53 ± 1
6
5-iodo-2-methoxy 
benzoic acid 16 40 ± 3
7 Iodobenzene 17 52 ± 2
a Average yields of triplicate runs employing tetraglyme as the ISTD.




































which orient the iodine meta to the amide, access the hypervalent iodine(III) state faster 
than Catalyst 4, which bears an ortho iodine, and performed more effectively as catalysts 
in the α-oxytosylation of propiophenone (Figure 3.6).  Interestingly, the most effective 
catalyst, Catalyst 11, is oxidized to an active hypervalent iodine(III) state at roughly the 
same rate as the mediocre catalyst, Catalyst 8, indicating that catalytic rates may be 
determined by rate of oxidation as well as the subsequent attack from the nucleophile. 

























 The suite of iodo-arene containing catalysts (Catalysts 1-12, Figure 3.5) were 
also applied to an intramolecular transformation, in which a ketocarboxylic acid is 
converted to a ketolactone via oxidative cyclization mediated by hypervalent iodine(III) 
Entry Catalyst Yield (%)a,b
1 2 12 ± 1
2 3 54 ± 3
3 7 24 ± 2
4 8 58 ± 4
5 9 52 ± 4
6 10 64 ± 3
7 11 71 ± 3
8 12 61 ± 3











a Average yields of triplicate runs employing tetraglyme as the ISTD.
b 0.1 mmol scale.
c Isolated yields after silica gel column chromatography.
d 1 mmol scale.
e pTSA•H2O (1.5 eq.), Catalyst (0.2 eq.)












catalysts (Table 1.6).  This is a prominent transformation because not only are lactones 
prevalent in nature, they have found great importance in the synthetic and medicinal 
community.298-300  The catalytic scaffold that achieved the highest yielding product (11b) 
at 50 ℃ was again Catalyst 11, which includes a meta positioned iodine and para 
positioned methoxy group (Table 1.6, entry 7).  The oxidative cyclization of 5-oxo-5-
phenylvaleric acid (4o) was also carried at 1 and 1.3 mmol scales in the presence of either 
10-20 mol % Catalyst 11, to afford the oxylactone (4p) in decent (72%, entry 9) to good 
yields (89 %, entry 10).  
Entry R Product n Time (hr) Temperature (ºC) Yield (%)a,b
1 CH3 18 1 36 50 87
2 OCH3 19 1 40 50 72
3 F 20 1 24 50 94
4 Cl 21 1 24 50 75
5 Br 22 1 24 50 85
6 H 23 0 24 50 94
7 H 4l 1 24 50 99
8 H 4l 1 48 r.t. 94
O









Ar-I Catalyst 11 (0.1 equiv)
MeCN (1 mL)
a Isolated yields after silica gel column chromatography.
b 1 mmol scale.
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To exemplify and assess the value of our most reactive catalyst, Catalyst 11, a 
small substrate scope was evaluated (Table 1.7, entries 1-8).  Propiophenone, 
acetophenone, and propiophenone derivatives with various para-substituents on the 
phenyl ring were successfully synthesized in good isolated yields in up to a 1 mmol scale. 
The previously mentioned studies have allowed our group to understand how an 
amide linkage, which appends the iodine-containing active site to the peptide scaffold, 
influences the catalytic reactivity, and possibly selectivity, in hypervalent iodine(III)-
mediated oxidations.  In the context of the well-known reactivity-selectivity principle 
(RSP)301, which states that there tends to be an inverse relationship between the reactivity 
and selectivity of a reagent, it appears evident that being able to access a tunable scaffold 
may greatly impact the efficiency of the developed asymmetric catalytic system.  With 
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installing the most active catalysts as caps on the N-terminus of the peptide (Figure 3.4 
and Scheme 3.14).  For example, we can mimic the most effective iodoarene benzamide 
(Catalyst 11), by utilizing the carboxylic acid version (6e), and through well-established 
Fmoc solid-phase peptide synthesis, we can cap the N-terminus of peptide-based 
scaffolds with active iodoarenes to quickly build up peptide-based catalyst libraries (e.g. 
Scheme 3.14, 6f and 6g).  The peptide-based scaffolds are amendable to easy iterations 
through the use of various commercially available amino acids that contain diverse side 
chains. 
To diversify the concept further, we next devised strategies that allow for the 
active site to be incorporated anywhere in the peptide sequence.  We generated chiral 
amino acids that allow for the incorporation of the iodine active site into the amino acid 
side-chain, thereby allowing us to assimilate the active site in a new, variable location 
(Figure 3.7).302 
 
This study was designed around the synthesis of Fmoc-protected amino acids that 



























Figue 1. Strategies for i orporating an aryl-iodo active ite into  chiral peptide paradigm
Previous work: Reactive iodoarene-containing n-butyl amide catalysts to be used as caps 
in peptide scaffolds















Figure 3.7  Utilizing Fmoc-SPPS to incorporate iodoarene active sites into the side chain of peptide scaffolds
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linkage.  The initial route involved the synthesis of Nα-protected carboxybenzyl (i.e. Cbz) 
diamino methyl esters that contain an iodoarene active site (Scheme 3.15).  This was 
accomplished by first converting commercially available Cbz-protected diamino acids 
(6h) into their corresponding methyl esters (6i) via thionyl chloride and methanol.  
Through a conventional amidation coupling reaction, involving thionyl chloride and 
triethyl amine, the aryl iodo moiety (6j) was installed onto the side-chain of the diamino 
acid (6k).  This synthetic route is attractive for multiple reasons, chiefly in the fact that it 
is high yielding, and based on an X-Ray crystal structure, little to no racemization occurs 
(see experimental section for X-ray crystallography information).   
This synthetic route successfully provides a suite of Cbz-protected methyl ester 
catalysts (Figure 3.8), which vary in electronic and structural makeup based on their aryl 
iodo active site and the length between the active site and the amino acid scaffold (carbon 
tether length i.e. n =1-4).  Catalysts 1a-1d feature an iodoarene active site with the iodine 
situated in the meta position relative to the amide, with one to four carbons tethered 
between the active site and the amino acid chain.  The most effective iodoarene moiety 
that was uncovered in our previous studies contained a meta positioned iodine, with a 
6i
Quantatative yields































R1 = H, CH3




73-96 % yields over 2 steps
n = 1, 2, 3, 4
6j
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methoxy group para to that element as well (refer back to Figure 3.5, Catalyst 11); this 
functionality was incorporated into Catalysts 2a-2d.  The final catalyst scaffold 
encompassed a methoxy and methyl substituent on the arene ring coinciding with a meta 
positioned iodine (Catalysts 3a-3d).  These catalysts were synthesized in moderate to 
excellent yields (73-96% yields), and were investigated in the direct, catalytic α-
oxytosylation of propiophenone (Table 1.8).  The relative rates for the formation of the 
desired product (4l) were acquired by means of gas chromatography, and the 
enantioselectivities (%ee) were obtained via chiral stationary phase HPLC analysis. 
The direct α-oxytosylation of propiophenone was initially conducted at 24 h at 
room temperature in the presence of 10 mol % catalyst (Table 1.8).  These data suggest 
that an iodoarene that situates the iodine meta to the amide, and methoxy group(s) ortho 
and/or para to the iodine will have a relatively high reaction rate (Table 1.8, entries 5-
12); this recapitulates the conclusions that were found when using the N-butyl-
iodobenzamides as catalysts (refer back to Figure 3.5).  Furthermore, the optimal carbon 

































Catalyst 1a (n = 1), 84 % yield
Catalyst 1b (n = 2), 79 % yield
Catalyst 1c (n = 3), 81 % yield
Catalyst 1d (n = 4), 86 % yield
Catalyst 2a (n = 1), 95 % yield
Catalyst 2b (n = 2), 73 % yield
Catalyst 2c (n = 3), 74 % yield
Catalyst 2d (n = 4), 77 % yield
Catalyst 3a (n = 1), 83 % yield
Catalyst 3b (n = 2), 82 % yield
Catalyst 3c (n = 3), 87 % yield
Catalyst 3d (n = 4), 96 % yield
Figure 3.8 Cbz-protected amino methyl ester catalysts that contain an iodoarene active site
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(Table 1.8, entries 2, 3, 6, 7, 10, and 11).  The Cbz-protected amino methyl ester 
precatalysts that include a 5-iodo-2-methoxy moiety and that contain a two to three 
carbon spacer (Figure 3.8, Catalysts 2b and 2c) were shown to afford the product 4l in 
quantitative yields (Table 1.8, entries 6 and 7).  Two additional precatalysts granted 
quantitative yields (Table 1.8, entries 10 and 11), and those rely on a 5-iodo-2-methoxy-
4-methyl iodoarene scaffold (Figure 3.8, Catalysts 3b and 3c).  The top four catalysts 
were screened in the same reaction conditions, but were quenched with dimethylsulfide 
after four hours; the results are shown in Table 1.9.  While all four catalysts oxidized 
propiophenone (4k) into oxytosylated propiophenone (4l) at about the same relative rate, 
the catalyst that produced the highest yield was Catalyst 3c (49%, Table 1.9, entry 4).  
The structure of Catalyst 3c is derived from ornithine, and the active arene ring bears a 
meta iodine and two electron donating groups (methoxy and methyl).  With no surprise, 







Table 1.8 α-Oxytosylation of Propiophenone (24 h, rt) catalyzed by Cbz-protected amino methyl ester HI(III) catalysts
a GC yield (Average yields of triplicate runs) employing tetraglyme as the ISTD.
b 0.1 mmol scale.

















































n ee of 4l
(%)c
47 ± 3 -1.2
82 ± 3 -0.9
84 ± 1 -1.6








92 ± 3 -0.3
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By utilizing protective group manipulation, the amino acid catalyst can be 
modified such that it is Fmoc-SPPS ready, and can therefore become incorporated into 










2.) TMSI, Dry DCM
1.) NaOH, Dry MeOH
3.) Fmoc-OSu, DIEA







6l (1.8 g, 81 % over 3 steps)
O
O
Table 1.9   Catalytic α-Oxytosylation Propiophenone (4 h, rt)
a GC yield (Average yields of triplicate runs) employing tetraglyme as the ISTD.
b 0.1 mmol scale.

























n ee of 4l
(%)c
46 ± 1 -1.4
42 ± 0 -0.6
42 ± 1 +1.3
49 ± 1 -0.9
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the side chain of a peptide sequence (Scheme 3.16).  The methyl ester can be hydrolyzed 
to a free carboxylic acid in the presence of sodium hydroxide (NaOH).  Subsequently, the 
Cbz protecting group can be removed with the addition of trimethylsilyl iodide (TMSI), 
leaving a free amine.303  To render this molecule as a suitable catalyst for solid-phase 
peptide synthesis, Fmoc-succinimide (Fmoc-OSu) was added for the reprotection of the 
free amine.304, 305  This synthetic process was applied to Catalyst 1a and produced Fmoc-
SPPS compatible compound 6l in 81% over the three steps. By means of standard Fmoc-
SPPS, 6l was incorporated into a small peptide sequence (Ac-Ile-3-I-Dap-Pro-D-Ala-Ala-
Ala) (Figure 3.9).  This proof of concept demonstrates the feasibility to synthesize 
peptide-based scaffolds that incorporate iodoarene active sites into the side chains of the 
amino acids.  Moreover, this gives another valuable synthetic approach to varying where 
the active site can be situated on the peptide scaffold, and thereby allows for an even 




















Figure 3.9 Incorporation of Fmoc SPPS compatible catalyst 6l into a peptide sequence
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To further progress this strategy in generating novel peptide-based iodoarene 
catalysts, we investigated a strategy that can integrate the critical iodoarene active site 
into the backbone of the peptide framework (Figure 3.10, 6m and 6n).  Achieving this 
goal was anticipated through the synthesis of iodoarene containing aniline acetamides 
































































































Catalyst 4a (70% over 2 steps) Catalyst 4b (46% over 4 steps) Catalyst 4c (41% over 4 steps)
Catalyst 4d (55% over 3 steps) Catalyst 4e (9% over 5 steps) Catalyst 4f (73% over 2 steps)
Catalyst 4g (63% over 3 steps) Catalyst 4h (68% over 2 steps)
Figure 3.11  Iodoarene containing aniline derivatives that function as HI(III) catalysts
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The aniline acetamide catalysts were accessed through the chemical manipulation 
of commercially available nitro, amino, iodo, and/or carboxylic acid containing arene 
rings.  As an example, the synthesis of Catalyst 4e is illustrated in Scheme 3.17.  Briefly, 
commercially available 3,5-dinitrobenzoic acid (6o) was partially reduced by iron powder 
in glacial acetic acid to afford nitroaniline 6p.306-308  A diazotization/iodination sequence 
transformed the nitroarene into iodoarene derivative 6q.306, 308-311  The second nitro group 
was reduced in the presence of Mohr’s salt and concentrated ammonium hydroxide to 
give the iodo aniline carboxylic acid 6r in a 68% yield.306, 312  Next, a traditional 
amidation employing thionyl chloride and butyl amine was carries out.  Subsequently, the 
aniline nitrogen was acylated with acetic anhydride to produce the aniline acetamide 
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These catalysts incorporate an aryl iodo active site that is flanked by an electron 
donating substituent, an aniline, and an electron withdrawing substituent, an amide.  The 
electron withdrawing amide functionality is necessary to mimic the peptide linkage that 
we utilize in our strategy for the incorporation of the active site into the peptide scaffold.   
The “push/pull” electronic nature of the compounds, due to the electron-donating aniline 
acetamide and the electron-withdrawing N-butyl amide, respectively, could have 
immense effects on the catalytic performance..  Therefore, these catalysts were subjected 
to the ⍺-oxytosylation of propiophenone in a 24 h reaction at room temperature, as well 
as reaction at 50 ˚C  (Table 1.10 and Table 1.11).  Interestingly, only one catalyst was 
relatively effective in the oxytosylation of propiophenone. Catalyst 4f was drastically 
superior as a catalyst in comparison to the other aniline acetamide derivatives, and 
supplied the oxytosylated propiophenone product 4l in a moderate 73% yield at room 
temperature and 80% yield at 50 ℃ (Table 1.10, entry 6 and Table 1.11, entry 6).  
Catalyst 4f positions the electron withdrawing N-butyl amide moiety in the meta position 
relative iodine while the aniline acetamide is oriented in the para position.  The other 
catalysts showed comparatively poorer catalytic rates.  Although Catalyst 4f and 
Catalyst 4d orient the iodine meta to the amide, Catalyst 4d is more sterically 
incumbered by the ortho aniline.  Comparing the reactivity of these catalysts, Catalyst 4f 
supplies the product in a much higher yield (Table 1.10, 73% vs 17% yield), suggesting 
that sterics may be an important factor when designing aniline acetamide HI(III) 
catalysts.  As our previous studies have shown, evidently, an effective catalyst relies on 
positioning arene substituents in such a way that the iodine is more electron rich.  A 
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catalyst configuration that fits this description involves orienting the iodine meta to the 
electron withdrawing amide, and aligning an electron donating group (i.e. aniline or 
methoxy) para to the iodine.  This study illustrates that drastic effects on catalytic 
activity can be present depending on the positioning of the arene substituents, and gives 
another variance in which the iodoarene active site can be placed in the backbone of the 
peptide scaffold.  
 
 
a Average yields of triplicate runs employing tetraglyme as the ISTD.



































3.5 FUTURE WORK FOR PEPTIDE-BASED HI(III) CATALYSTS 
 
The preceding studies were directed toward oxidations by means of hypervalent 
iodine(III) catalysis, and emphasized how sterics and electronics can affect the catalytic 
performance.  In particular, we explored how an amide linkage, which joins the active 
site to the peptide, influenced the catalytic reactivity.  While the majority of known 
HI(III) catalysts scaffolds orient the necessary chiral information in the ortho position of 
the arene relative to I, in our hands, it appears that orienting the chiral information in the 
a Average yields of triplicate runs employing tetraglyme as the ISTD.





Catalyst (0.1 equiv) *
MeCN (1 mL)
























Table 1.11  Oxidative α-Oxytosylation of Propiophenone Using Aniline Catalysts (24 h/50 ℃)
4k 4l
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meta position can exhibit a higher active catalyst.  Of course, a balance must be struck 
between achieving optimal catalytic activity to ensure high yields while also maintaining 
optimal positioning of the chiral information for productive enantioinduction in the 
transformation.  Furthermore, as demonstrated previously by Legault277 and Wirth229, 
positioning a suitable electron donating group (i.e. methoxy or aniline) para to the iodine, 
can also promote reasonable catalytic activity.  These findings provide a scaffolding 
template that can allow for the construction of highly reactive hypervalent iodine 
catalysts.  The developed methodology is compatible with Fmoc-SPPS, and has been 
validated as a way to generate functional peptides that can be employed as catalysts in a 
variety of synthetic transformations mediated by hypervalent iodine catalysis.  Current 
efforts are focused on installing and evaluating our most reactive iodoarene-containing 
Fmoc-protected amino acids and anilines into peptide scaffolds.  We have demonstrated 
that highly reactive iodoarenes (i.e. Catalyst 11 Figure 3.5, Catalyst 3c Figure 3.8, and 
Catalyst 4f Figure 3.11) can be easily installed anywhere along the peptide scaffold, 
including at the N-terminus, on the side-chain of the amino acid, or within the peptide 
backbone (Figure 3.12).  Libraries of modified peptide scaffolds can be generated in a 
facile manner through the use of well-established Fmoc-SPPS protocols, and these 
compounds have the capability to be utilized as chiral organocatalysts in various HI-
mediated organic transformations, including, but not limited to, the ⍺-oxytoslyation of 
propiophenone, the ⍺-oxytoslyation of 1-indanone, and the oxidative lactonization of 5-
oxo-5-phenylpentanoic acid (Scheme 3.11, eq. 1-3). 
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In the context of the uncertainty related to the involved mechanistic pathway(s) in 
HI(III)-mediated oxidations (refer to Scheme 3.10), another area that warrants further 
investigation is the influence of enol geometry on the reactivity and selectivity of ⍺-
oxytoslyation reactions.  Regardless of which mechanism is operative, the geometry of 
the incoming enol is presumed to substantially affect the enantioselectivity of the 
reaction.  In fact, as described previously (see Scheme 3.12), it seems that Legault and 
Basdevant selectively isolated a single enol acetate stereoisomer in order to induce high 
enantioselectivities in the α-tosyloxylation of ketones.313  Therefore, it is apparent that 
understanding the influence of the enol geometry on enantioselective outcome is of great 













































Iodoarene at N-terminus cap
Iodoarene on side-chain of amino acid Iodoarene within peptide backbone
Figure 3.12 Incorporating the iodoarene active site anywhere within the peptide scaffold
n
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To further clarify this concept, Figure 3.13 illustrates the enol isomers that are 
likely to form from propiophenone in acidic conditions, and Scheme 3.18 represents the 
effect the enol geometry can have on the enantioselective process.  Under acid 
conditions, propiophenone is rapidly distributed into an equilibrium of Z (7a1/7a2) and E 
(7b1/7b2) enol tautomers (Figure 3.13).313  The enols display separate enantiotopic faces, 
in which if looking from the top face (orange arrow), the (Z)-enol (7a1) presents a Re 
enantiotopic face, while the (E)-enol (7b1) presents a Si enantiotopic face; conversely, if 
looking from the back side (green arrow), the enols will undoubtedly show opposite 
enantiotopic faces.  The contrasting enantiotopic faces can lead to divergent selectivities, 
and Scheme 3.18 assists in demonstrating the effect in which the enol geometry can 
impose on the enantioinduction.  Note that this is a simplified illustration in that only the 



















































affected by the E/Z enol population as well.  In short, with the SN2 pathway being 
operative, one could reasonably expect that the (Z)-enol would produce the S-enantiomer 
(7e), while the (E)-enol would likely generate the R-enantiomer (7i) even if the catalyst 
promotes complete facial selectivity during the course of the reaction (Scheme 3.18).  
The geometry of the enol can thus lead to different enantiomeric products, and if a 
mixture of (E)- and (Z)-enols are present in the reaction mixture, the product will reflect 
this ratio and will be generated as a mixture of enantiomers. Therefore, even if a chiral 
catalyst was able to exclusively deliver the iodine(III) to one face of the substrate, the 
enantioselective outcome could only be as selective as the population of (E)- and (Z)-
tautomers present at equilibrium.  On that account, in order to develop a highly 
enantioselective chiral catalyst, considerable attention must be dedicated to controlling, 
or at least understanding, the enol geometry in HI(III)-mediated oxidative reactions.   
One method to control the enol geometry is to selectively synthesize the (E)- and 
(Z)-enol, such that they are stereo-defined, and can be subjected to HI(III)-oxidative 





























































enantioselectivities could be evaluated, and could ultimately provide evidence on the 
influence of the enol geometry.  Our group, as well as others, have been unsuccessful in 
utilizing silyl enol ethers for the catalytic ⍺-oxytoslyation of propiophenone, as the silyl 
group quickly decomposes in acidic conditions (i.e. pTsOH).313, 314   One could envision 
the use of enol/enolate equivalents, such as those shown in Figure 3.14, to selectively 
trap desirable enol confirmations.  In particular, one convenient method to selectively 
control the conversion of ketones to preferred geometries is through the use of boronate 
esters.  Historically, boron reagents have been used to selectively convert ketones into 
enol boronates for directed stereoselective aldol reactions.315, 316  By using tertiary amines 
in the presence of dialkylboron reagents, ketones can be converted into boronate ester 
analogs with very high selectivities and yields (Scheme 3.19).  Brown et. al. utilized 
diisoproylethylamine (DIPEA) as a tertiary amine, and 9-BBN triflate (7k) to generate 
the (Z)-enol boronate of propiophenone (7l) in a 80% yield with a significant selectivity 
of 99:1 (Z:E) (Scheme 3.19, eq. 1).316  By using triethylamine and 
chlorodicyclohexylborane (7m), they were able to afford the (E)-boronate ester (7n) in a 
96% yield with a very high selectivity of 1:99 (Z)/(E) (Scheme 3.19, eq. 2).  With this 
methodology, we could preferentially form the (E)- and/or (Z)-boronate esters of ketones, 
and thereby assess the influence of enol geometry in order to achieve broadly applicable, 










































Figure 3.14 Enol/enolate equivalents of propiophenone as a way to control the enol geometry
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3.6 MACROCYCLES AS CHIRAL HI(III) CATALYSTS 
Recently, our group has explored the implementation of macrocycles as an 
alternative strategy toward achieving high yields and enantioselectivities in HI-mediated 
transformations.  In general, a macrocycle is a molecule that contains at least one cyclic 
framework of eight or more atoms.317, 318  In comparison to their acyclic analogs, 
macrocycles are conformationally restricted, possessing a lower number of rotatable 
bonds, and are thus capable of having powerful stereoselective abilities.317, 319  
Macrocycles are unique in that they combine beneficial features of small molecules, 
including relative ease of synthesis and small molecular weights, and complex 
biomolecules (i.e. enzymes and proteins), such as highly selective target engagement.320  
Macrocycles have been successfully applied as chiral reagents in various asymmetric 
organic reactions.317, 319-326    
We envisioned the use of iodoarene-containing chiral macrocycles to be used as 
chiral catalysts in hypervalent iodine-mediated oxidative transformations (Figure 3.15, 
























can play a significant role in enantioselective recognition.168, 327, 328  This approach has 
the possibility of providing a novel and robust method to generate enantioenriched 
species and reinforce the relationship between structural rigidity and enantioselective 
control.  The routes toward synthesizing iodoarene-containing macrocycles, such as 7o 
and 7p (Figure 3.15), are illustrated in Scheme 3.20.329  The synthesis of Macrocycle A 
began with the conversion of commercially available L-phenylalanine (7q) to ⍺-azido 
acid 7r via a copper(II)-catalyzed diazo transfer; 7r was used at a later synthetic stage.329, 
330  Commercially available propargylamine (7s) was transformed into N-(2,4-
dimethoxybenzyl)propargylamine hydrochloride (7u) by means of a reductive 
elimination with sodium borohydride.  The propargyl hydrochloride 7u was coupled to 
commercially available Fmoc-4-iodo-L-phenylalaine (7v) with the use of an amide 
coupling agent known as hexafluorophosphate azabenzotriazole tetramethyl uronium  
(HATU); this produced the Fmoc-protected, iodoarene containing alkyne 7w in an 88% 
yield.  7w was converted into the azido terminal alkyne 7x in a 69% yield over the 
following two steps: (1) Fmoc deprotection in the presence of diethylamine, (2) HATU -
coupling with the ⍺-azido acid 7r.  Lastly, a copper catalyzed alkyne-azide cycloaddition 
was accomplished with use of sodium ascorbate and a dilute sample of 7x to generate 
Macrocycle A.331-333  Similar synthetic steps were utilized to produce macrocyclic 
derivatives that contained a phenyl (Macrocycle B) or tert-butyl (Macrocycle C) 
substituent, rather than a benzyl group (Macrocycle A) (Figure 3.16).   The macrocycles 
(Macrocycles A-C) and their acyclic precursors (7x-7z) were evaluated in the ⍺-
oxytosylation of propiophenone at room temperature for 24 hours (Figure 3.16).  Under 
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the optimized conditions (i.e. same conditions as Table 1.8), each macrocycle provided 
the oxytosylated product 4l at about the same relative rate (approximately 32-38% yield), 
however, when comparing the enantioselectivity between each cyclic vs. acyclic 
congener, the cyclic catalysts showed slightly improved enantioinductions.  For instance, 
Macrocycle B supplied 4l in a 14 % ee, yet the acyclic counterpart furnished 4l in only 
4% ee.  In comparison to their linear counterpart, the macrocyclic catalysts have 
demonstrated enhanced enantioselectivies, indicating that there may be a relationship 
between the structural rigidity of the iodoarene catalyst and the enantioselectivity output 















































































Current efforts are geared toward synthesizing macrocyclic iodoarene-containing 
derivatives that can further improve the steroinduction process, and corroborate the 
structure-stereoselectivity relationship.  Figure 3.17 exemplifies some of the derivatives 
that could be constructed in order to better understand the role that iodoarene cyclic 
catalysts play in the ⍺-oxytosylation of propiophenone.  One cogent modification 
involves the use of starting materials with the opposite chiral configuration in order to 
furnish enantiomeric (Figure 3.17, 8a) or diastereomeric (8b and 8c) versions of the 
parent macrocycle (Macrocycle A, Figure3.16).  Another idea would be to vary the 
electronics and sterics around the ring that bears the iodine (R group highlighted in pink) 
and/or the chiral substituent that is appended at the gamma position (R group highlighted 
in green) in relation to the active site (Figure 3.17, 8d).  To probe the effect of the 
dimethoxy benzene substituent, one could deprotect the macrocyclic backbone with a 
known protocol, such as with a solution of trifluoroacetic acid, trimethylsilyltriflate and 
anisole (8e converted to 8f).329  A known concept in click-chemistry is that the clickable 
units can favor dimerization, oligomerization, and/or polymerization, thus if the reaction 
conditions are altered so that there is a higher concentration of the azide alkyne (i.e. 7x, 
Figure 3.20) in the reaction mixture, one could form a dimer/oligomer/polymeric species 
(8g).306, 311, 327, 334-336  Another added element of diversity would be to attach the aryl iodo 
active site alpha, rather than delta, to the triazole (8j); this can be envisioned by applying 
a copper(II)-catalyzed diazo transfer to a substrate that already harbors an iodoarene, 




































































































































Macrocycle C yield: 12 % (over 6 steps)
4l yield using Macrocycle C: 32 ± 2a,b
4l % ee using Macrocycle C: 8 % ee (54:46 er)b,c
4l % ee using 11x: 0 % ee (50:50 er)b,c
Macrocycle B yield: 27 % (over 6 steps)
4l yield using Macrocycle B: 38 ± 4a,b
4l % ee using Macrocycle B: 14 % ee (57:43 er)b,c
4l % ee using 11w: 4 % ee (52:48 er)b,c
a Average yields of triplicate runs employing tetraglyme as the ISTD.
b 0.1 mmol scale.












Macrocycle A yield: 21 % (over 6 steps)
4l yield using Macrocycle A: 35 ± 2a,b
4l % ee using Macrocycle A: 12 % ee (56:44 er)b,c
4l % ee using 11v: 4 % ee (52:48 er)b,c
Macrocycle A






























The more eco-friendly nature of hypervalent iodine compounds has attracted attention 
from the scientific community as they can be utilized as sustainable alternatives to more 
toxic, heavy metal and halogen-based reagents.  Recent advancements in the field of 
hypervalent iodine have demonstrated that polyvalent iodine reagents are essential tools 
in synthetic organic chemistry.  Nevertheless, this field of chemistry is still in its infancy 
and has proven to be a demanding discipline. The presented work has assisted in trying to 
improve upon the difficulties associated with hypervalent iodine chemistry.  A 
particularly efficient catalyst framework has been disclosed in which the aryl iodo 
catalytic site sustains an electron rich nature by orienting the iodine meta to the amide, 
and situating an electron donating group para to the iodine.  We can attach this highly 
proficient iodoarene active unit anywhere along a peptide scaffold through a 
straightforward amide linkage. By incorporating iodoarene-containing pre-catalysts into 
small peptide sequences, we have revealed a unique strategy that can potentially render 
hypervalent iodine mediated reactions highly reactive and enantioselective.  Furthermore, 
this approach demonstrates synthetic value due to the modular aspect of the designed 
catalyst scaffolds.  Iodoarene-containing macrocycles have also emerged as a new 
paradigm toward hypervalent-iodine-mediated asymmetric transformations.  The 
macrocycles provide a rigid framework that can potentially induce enantioselectivity, and 
have shown to outperform their acyclic analogs.  Chemists can apply these versatile 
chiral iodine(III) reagents in various synthetic transformations, and due to their easily 
iterative nature, they can be tuned and optimized in regard to the reaction at hand.  This 
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research has assisted in progressing the hypervalent iodine field by designing new and 























General Experimental Information 
All reagents were purchased from commercial suppliers and used without further 
purification. Purification via flash column chromatography was done using silica gel SDS 
60 C.C. 40−63 μm. All known compounds and starting materials had 1H NMR and 13C 
NMR spectra consistent with previous literature reports. 1H NMR and 13C NMR spectra 
were collected at ambient temperature on a 500 or 300 MHz NMR spectrometer. 
Chemical shifts are reported in parts per million (ppm) and referenced to residual solvent 
peaks (i.e., δ 7.28 ppm for 1H NMR, 77 ppm for 13C NMR) in CDCl3, MeOD (i.e., δ 3.31 
ppm for 1H NMR, 49 ppm for 13C NMR), or (CDC3)2SO (i.e., δ 2.50 ppm for 1H NMR, 
39.5 ppm for 13C NMR). Data are presented as follows: chemical shift, integration, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), 
and coupling constants (J, in hertz). Infrared (IR) spectra, reported in cm−1, were 
collected using a Fourier transform spectrophotometer. Bands are characterized as strong 
(s), medium (m), weak (w), and broad (br). Gas chromatograph (GC) analyses were 
conducted using an autosampler and a flame ionization detector (FID). The GC was 
equipped with a 30 m × 0.32 mm × 0.25 μm GC column with an HP-5 stationary phase. 
GC analyses were carried out within the following parameters: inlet temperature: 250.0 
˚C; split injection (4 µL) at 280 mL min-1; column flow: 2.8 mL min-1, constant pressure; 
carrier gas: helium; FID temperature: 300 ˚C; temperature program: 100 ˚C for 3 min.; 
ramp to 320 ˚C at 20 ˚C min-1, hold for 3 min. Enantiomeric excess (% ee) of selective 
products were determined using chiral high performance liquid chromatography (HPLC).  
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Chiral samples were run on an Agilent 1260 Infinity system equipped with a diode array 
detector (G4212-60008), and an Agilent 1260 Infinity auto sampler. The chiral stationary 
column used was a Chiralpak-AD (250mm X 4.6 mm). The mobile phase consisted of 
iso-propyl alcohol/hexanes mixture (50:50). The flow rate was set at 1 mL/min and the 
elution of analytes was monitored at 254 nm. 
 
General Procedure for Preparation of the N-Butyl-iodobenzamides (Figure 3.5, 
Catalysts 1-12 and refer to Scheme 3.13 as the general synthesis is illustrated for 
Catalyst 3). N-Butyl-iodobenzamide Catalysts 1-12 were synthesized from their 
corresponding carboxylic acids via a conventional amidation reaction by the formation of 
the acid chloride and subsequent displacement by n-butyl amine.  
A representative procedure for the synthesis of n-butyl-4-iodobenzamide 
(Catalyst 3) is as follows337: The substrate 4-iodobenzoic acid (0.2 g, 0.66 mmol, 1.0 
equiv.) and triethylamine (0.18 mL, 1.32 mmol, 2.0 equiv.) were dissolved in anhydrous 
DCM (2 mL) and stirred for 5 min at room temperature under nitrogen in a flame-dried 
round-bottom flask. The solution was cooled to 0 °C. Thionyl chloride (0.053 mL, 0.726 
mmol, 1.1 equiv.) was slowly added (dropwise over 20 min), and the resulting solution 
was allowed to stir at 0 °C for 1 hour. The resulting mixture was brought to room 
temperature and stirred for 30 min. This solution was concentrated under vacuum and 
then redissolved in anhydrous DCM (2 mL). To this solution was added (dropwise over 
10 min) 1-butylamine (0.072 mL, 0.726 mmol, 1.1 equiv.), anhydrous DCM (2 mL), and 
triethylamine (0.18 mL, 1.32 mmol, 2.0 equiv.). The resulting solution was stirred 
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overnight at room temperature under nitrogen. The crude mixture was concentrated by 
rotary evaporation, diluted in DCM, and washed with 1 M HCl, and the aqueous layers 
were extracted with DCM (×3). The organic layers were washed with H2O (×2) and 
saturated brine (×1) and dried over sodium sulfate. The resulting product was filtered and 
concentrated by rotary evaporation. The crude product was purified by column 
chromatography on silica gel (20:80 EtOAc:hexanes) to give Catalyst 3 as an orange 
solid (0.2819 g, 93%), mp 121−122 °C. IR (neat): 3312 (br), 3075 (w), 2959 (w), 2929 
(w), 2862 (w), 1632 (s), 1587 (w), 1543, 1468 (w), 1008 (w) cm−1. 1H NMR (500 MHz, 
CDCl3): δ 0.97−0.99 (3H, t, J = 7.5 Hz), 1.39−1.47 (2H, m), 1.59−1.65 (2H, m), 3.44− 
3.48 (2H, m), 6.14 (1H, s, br), 7.50, 7.51 (2H, d, J = 8.5 Hz), 7.79, 7.81 (2H, d, J = 8.0 
Hz) ppm. 13C NMR (500 MHz, CDCl3): δ 13.7, 20.1, 31.7, 39.9, 98.1, 128.5, 134.3, 
137.8, 166.7 ppm. HRMS (ESI): m/z found 304.0200, calcd for C11H15INO (M + H)+ 
304.0198.  
 
General Procedure for α-Oxytosylation of Propiophenone313, 338 (Scheme 3.11, eq. 1 
and Tables 1.1-1.5, Tables 1.7-11, 4l). The relative rates of the prepared Catalysts 1-12, 
Catalysts 1a-3d, and Catalysts 4a-4h were evaluated in the α-oxytosylation of 
propiophenone using the following representative procedure with Catalyst 1. 
Propiophenone 4k (13.3 μL, 0.1 mmol, 1.0 equiv), p-toluenesulfonic acid monohydrate 
(57.1 mg, 0.3 mmol, 3 equiv), m-chloroperoxybenzoic acid (51.8 mg, 0.3 mmol, 3 equiv), 
and N-butyliodobenzamide Catalyst 1 (3.0 mg, 0.01 mmol, 0.1 equiv) were dissolved in 
acetonitrile (1 mL) and stirred for the appropriate time (48, 24, 4, or 1 h) and temperature 
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(room temperature or 50 °C). After the prescribed time, the reaction was quenched upon 
addition of dimethyl sulfide (3 equiv). This solution was concentrated by rotary 
evaporation, diluted in DCM, and washed with aqueous saturated sodium bicarbonate 
(×3). The organic layers were dried over sodium sulfate, filtered, and concentrated by 
rotary evaporation. The resulting product and a 0.05 mmol aliquot of tetraglyme [as 
internal standard (ISTD)] were added to 1 mL volumetric flasks, and the final volume 
was taken to 1 mL with DCM. All trials were run in triplicate and injected into the GC in 
order to evaluate percent yields and their standard deviations (see procedure details 
below).  
 
General Procedure for Preparation of GC Standard Curves. Stock solutions (1 M) of 
the desired tosylated propiophenone 4l and ISTD (tetraglyme) were prepared in DCM. 
Varying amounts of desired product (0.005, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 
0.09, and 0.100 mmol) and a constant 0.05 mmol aliquot of ISTD were added to 1 mL 
volumetric flasks. The final volume was taken to 1 mL with DCM. These samples were 
injected into the GC, and the peak area ratio [(product area)/(ISTD area)] was calculated. 
This ratio was plotted versus the concentration of the desired product to yield a linear 
relationship (r2 values greater than 0.997), thus correlating GC chromatogram peak areas 
with product concentration. Reported yields and standard deviations were collected from 
averaged triplicate runs with tetraglyme (0.05 M) employed as the ISTD.  
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General Procedure for Percent Yield Determination via GC Analysis. GC analyses 
were carried out within the following parameters: inlet temperature, 250 °C; 20:1 split at 
130 mL/min; column flow, 6.5 mL/min; constant pressure; carrier gas, helium; FID 
temperature, 300 °C; temperature program, 100 °C for 3 min, 20 °C/ min ramp to 320 °C. 
Reactions were quenched with dimethyl sulfide (3 equiv) at prescribed times followed by 
GC analysis. Yields were calculated from a standard curve of the product in 
concentrations ranging from 0.005 to 0.1 M. Reported yields and standard deviations 
were collected from averaged triplicate runs with tetraglyme (0.05 M) employed as the 
ISTD. 
 
General Procedure for Scaleup and Isolated Yield Determination (i.e., Data for 
Table 1.7). Utilizing our best catalyst, Catalyst 11, scaled-up syntheses (1 mmol scales) 
of α-oxtosylated propiophenone 4l and a brief substrate scope were conducted to give 
isolated yields for 4l as well as compounds 18-23.  
Representative procedure for the synthesis of 1-oxo-1-p-tolylpropan-2-yl 4-
methylbenzenesulfonate 18 (Table 1.7)277:  4′-methylpropiophenone (149 μL, 1.0 mmol, 
1.0 equiv), p-toluenesulfonic acid monohydrate (571 mg, 3 mmol, 3 equiv), m-
chloroperoxybenzoic acid (518 mg, 3 mmol, 3 equiv.), and iodobenzamide Catalyst 11  
(33 mg, 0.1 mmol, 0.1 equiv.) were dissolved in acetonitrile (10 mL) and stirred for 36 h 
at 50 °C. The reaction was immediately quenched with dimethyl sulfide (3 equiv.). This 
solution was concentrated by rotary evaporation, diluted in DCM, and washed with 
aqueous saturated sodium bicarbonate (×3). The organic layers were dried over sodium 
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sulfate, filtered, and concentrated by rotary evaporation. The crude product was purified 
by column chromatography on silica gel (20:80 EtOAc:hexanes) to give 18 as a white 
solid (0.2783 g, 87%). Rf = 0.29. 1H NMR (300 MHz, CDCl3): δ 1.59, 1.61 (3H, d, J = 
6.9 Hz), 2.44 (6H, s, br), 5.79 (1H, q, J = 7.2 Hz), 7.30−7.27 (4H, m), 7.82−7.63 (4H, m) 
ppm. 13C NMR (90 MHz, CDCl3): δ 18.8, 21.6, 21.7, 76.6, 128.0, 128.9, 129.5, 129.8, 
131.1, 133.5, 144.9, 145.0, 194.3 ppm.  
 
General Procedure for NMR Kinetic Profiles (i.e., Figure 3.6). The activity of 
Catalysts 11, 8, and 4 was evaluated by monitoring oxidation rates of the catalysts from 
their iodine(I) state to their corresponding iodine(III) state. The kinetic profiles were 
generated by dissolving m-chloroperoxybenzoic acid (51.8 mg, 0.3 mmol, 3 equiv) and 
the respective iodobenzamide catalyst (0.01 mmol, 0.1 equiv) in CD3CN (1 mL). Due to 
rapid oxidation of Catalyst 11 and 8, 1H NMR spectra were recorded every 5 min for 1 h 
and then were recorded every hour after the first hour (recorded spectra up to 12 h). 
Catalyst 4 had a slower oxidation rate; thus,1H NMR spectra were recorded every hour 
starting at 0 h (recorded spectra up to 12 h). The percent conversion of the I(I) catalyst to 
its corresponding I(III) was determined via changes in well-resolved NMR signal 
integration values as a function of time.  
 
Characterization Data for All Reported Compounds.  
N-Butyl-2-iodobenzamide, Catalyst 1339 Brown solid (0.2839 g, 94%), mp 90−91 °C. IR 
(neat): 3287 (br), 3055 (w), 2953 (s), 2865 (m),1649 (s), 1585 (m), 1539 (s), 1463 (m), 
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1015 (w) cm−1 . 1H NMR (500 MHz, CDCl3): δ 0.97−1.00 (3H, t, J = 7.0 Hz), 1.40−1.47 
(2H, m), 1.59− 1.65 (2H, m), 3.45−3.49 (2H, m), 6.11 (1H, s, br), 7.18−7.21 (1H, t, J = 
8.0 Hz), 7.73−7.74 (1H, d, J = 8.0 Hz), 7.84 (1H, q, J = 8.0 Hz), 8.10−8.11 (1H, t, J = 1.5 
Hz) ppm. 13C NMR (125 MHz, CDCl3): δ 13.8, 20.2, 31.5, 39.9, 92.4, 128.2, 128.3, 
131.0, 139.8, 142.5, 169.4 ppm. HRMS (ESI): m/z found 304.0204, calcd for C11H15INO 
(M + H)+ 304.0198.  
 
N-Butyl-3-iodobenzamide, Catalyst 2340 White solid (0.2776 g, 92%), mp 70−71 °C. IR 
(neat): 3280 (br), 3063 (m), 2958 (s), 2930 (s), 2870 (m), 1634 (s), 1592 (m), 1555 (s), 
1467 (s), 1062 (w) cm−1; 1H NMR (500 MHz, CDCl3): δ 0.97−1.00 (3H, t, J = 7.5 Hz), 
1.40−1.47 (2H, m), 1.59−1.65 (2H, m), 3.45−3.49 (2H, m), 6.13 (1H, s, br), 7.17−7.20 
(1H, t, J = 7.5 Hz), 7.72, 7.74 (1H, d, J = 10.5 Hz), 7.83, 7.85 (1H, d, J = 8.0 Hz), 8.11 
(1H, s) ppm. 13C NMR (125 MHz, CDCl3): δ 13.8, 20.2, 31.7, 40.0, 94.3, 126.1, 130.2, 
135.9, 137.0, 140.2, 166.0 ppm. HRMS (ESI): m/z found 304.0201, calcd for C11H15INO 
(M + H)+ 304.0198.  
 
N-Butyl-4-iodobenzamide, Catalyst 3 as an orange solid (0.2819 g, 93%), mp 121−122 
°C. IR (neat): 3312 (br), 3075 (w), 2959 (w), 2929 (w), 2862 (w), 1632 (s), 1587 (w), 
1543, 1468 (w), 1008 (w) cm−1. 1H NMR (500 MHz, CDCl3): δ 0.97−0.99 (3H, t, J = 7.5 
Hz), 1.39−1.47 (2H, m), 1.59−1.65 (2H, m), 3.44− 3.48 (2H, m), 6.14 (1H, s, br), 7.50, 
7.51 (2H, d, J = 8.5 Hz), 7.79, 7.81 (2H, d, J = 8.0 Hz) ppm. 13C NMR (500 MHz, 
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CDCl3): δ 13.7, 20.1, 31.7, 39.9, 98.1, 128.5, 134.3, 137.8, 166.7 ppm. HRMS (ESI): m/z 
found 304.0200, calcd for C11H15INO (M + H)+ 304.0198.  
 
N-Butyl-2-iodo-4,5-dimethoxybenzamide, Catalyst 4.341 Brown solid (0.5207 g, 88%), 
mp 104−106 °C; IR (neat): 3264 (br), 2957 (m), 2930 (m), 2869 (w), 1638 (s), 1593 (m), 
1543 (m), 1501 (m), 1025 (w) cm−1; 1H NMR (500 MHz, CDCl3) δ 0.97−1.00 (3H, t, J = 
7.0 Hz), 1.43−1.51 (2H, m), 1.62−1.67 (2H, m), 3.45−3.49 (2H, m), 3.90 (6H, s, br), 5.87 
(1H, s, br), 7.03 (1H, s), 7.22 (1H, s) ppm. 13C NMR (125 MHz, CDCl3) δ 13.8, 20.3, 
31.4, 40.0, 56.1, 56.3, 80.8, 112.0, 122.0, 134.6, 149.2, 150.4, 168.9 ppm. HRMS (ESI): 
m/z found 364.0411, calcd for C13H19INO3 (M + H)+ 364.0410.  
 
N-Butyl-2-iodo-5-methoxybenzamide, Catalyst 5. Brown solid (0.2699 g, 90%), mp 
80−81 °C. IR (neat): 3287 (br), 3069 (w), 2957 (m), 2932 (m), 2862 (w) 1642 (s), 1584 
(m), 1542 (m), 1467 (m), 1009 (w) cm−1. Rf = 0.12 (20:80 EtOAc:hexanes). 1H NMR 
(500 MHz, CDCl3): δ 0.97−1.00 (3H, t, J = 7.0 Hz), 1.43−1.50 (2H, m), 1.62− 1.68 (2 H, 
m), 3.45−3.49 (2H, m), 3.81 (3H, s), 5.82 (1H, s, br), 6.69−6.71 (1H, m), 6.98, 6.99 (1H, 
d, J = 3.0 Hz), 7.70−7.71 (1H, d, J = 9.0 Hz) ppm. 13C NMR (125 MHz, CDCl3): δ 13.7, 
20.2, 31.4, 39.9, 55.6, 80.6, 114.2, 117.6, 140.4, 143.2, 159.7, 169.1 ppm. HRMS (ESI): 
m/z found 334.0310, calcd for C12H17INO2 (M + H)+ 334.0304. 
 
N-Butyl-2-iodo-5-methylbenzamide, Catalyst 6. White solid (0.2250 g, 93%), mp 
106−107 °C. IR (neat): 3292 (br), 2957 (w), 2925 (w), 2864 (w) 1643 (s), 1541 (m), 1458 
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(w), 1012 (w) cm−1. Rf = 0.44 (20:80 EtOAc:hexanes). 1H NMR (500 MHz, CDCl3): δ 
0.98−1.00 (3H, t, J = 7.5 Hz), 1.43−1.51 (2H, m), 1.62−1.68 (2H, m), 2.33 (3H, s), 
3.45−3.49 (2H, m), 5.76 (1H, s, br), 6.92−6.94 (1H, m), 7.23− 7.24 (1H, d, J = 2.0 Hz), 
7.72−7.73 (1H, d, J = 8.0 Hz) ppm. 13C NMR (125 MHz, CDCl3): δ 13.8, 20.2, 20.9, 
31.5, 39.8, 88.2, 129.2, 132.0, 138.4, 139.6, 142.3, 169.5 ppm. HRMS (ESI): m/z found 
318.0374, calcd for C12H17INO (M + H)+ 318.0355. 
 
N-Butyl-2-iodo-3-methylbenzamide, Catalyst 7. Yellow solid (0.2153 g, 89%), mp 
68−69 °C. IR (neat): 3283 (br), 2957 (m), 2686 (w) 1640 (s), 1546 (m), 1476 (m), 1036 
(w) cm−1. Rf = 0.19 (20:80 EtOAc:hexanes). 1H NMR (500 MHz, CDCl3): δ 0.97−1.00 
(3H, t, J = 3.5 Hz), 1.42−1.49 (2H, m), 1.61−1.67 (2H, m), 2.50 (3H, s), 3.45−3.49 (2H, 
m), 5.75 (1H, br), 7.10−7.13 (1H, m), 7.26−7.27 (2H, t, J = 2.0 Hz) ppm. 13C NMR (125 
MHz, CDCl3): δ 13.8, 20.2, 29.2, 31.4, 39.8, 99.3, 125.0, 128.1, 130.3, 142.8, 144.3, 
170.4 ppm. HRMS (ESI): m/z found 318.0377, calcd for C12H17INO (M + H)+ 318.0355. 
 
N-Butyl-3-iodo-2-methylbenzamide, Catalyst 8. Light brown solid (0.2178 g, 90%), 
mp 98−99 °C. IR (neat): 3286 (br), 2955 (w), 2928 (w), 2862 (w), 1634 (s), 1581 (w), 
1536 (m), 1433 (w), 999 (w) cm−1. Rf = 0.28 (20:80 EtOAc:hexanes). 1H NMR (500 
MHz, CDCl3): δ 0.97−1.00 (3H, t, J = 7.5 Hz), 1.40−1.47 (2H, m), 1.58− 1.64 (2H, m), 
2.52 (3H, s), 3.43−3.48 (2H, m), 5.75 (1H, s, br), 6.90−6.93 (1H, t, J = 7.5 Hz), 7.30 (1H, 
d, J = 0.50 Hz), 7.88−7.90 (1H, m) ppm. 13C NMR (125 MHz, CDCl3) δ 13.8, 20.1, 25.6, 
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31.6, 39.7, 103.4, 126.5, 127.3, 138.2, 138.4, 140.5, 169.6 ppm. HRMS (ESI): m/z found 
318.0377, calcd for C12H17INO (M + H)+ 318.0355. 
 
N-Butyl-3-iodo-4-methylbenzamide, Catalyst 9. Brown oil (0.0871 g, 72%). IR (neat): 
3300 (br), 2957 (m), 2929 (m), 2870 (w), 1636 (s), 1600 (w), 1547 (s), 1481 (m), 1032 
(w) cm−1. Rf = 0.33 (20:80 EtOAc:hexanes). 1H NMR (500 MHz, CDCl3): δ 0.97−1.00 
(3H, t, J = 7.5 Hz), 1.40−1.47 (2H, m), 1.59−1.65 (2H, m), 2.48 (3H, s), 3.44−3.48 (2H, 
m), 6.10 (1H, s, br), 7.30 (1H, s), 7.65−7.66 (1H, m), 8.20 (1H, d, J = 2.0 Hz) ppm. 13C 
NMR (125 MHz, CDCl3): δ 13.8, 20.2, 28.1, 31.7, 39.9, 100.9, 126.7, 129.6, 134.0, 
137.4, 145.0, 165.8 ppm. HRMS (ESI): m/z found 318.0377, calcd for C12H17INO (M + 
H)+ 318.0355. 
 
N-Butyl-3-iodo-4-methoxybenzamide, Catalyst 10. Brown solid (0.4105 g, 69%), mp 
71−72 °C. IR (neat): 3315 (br), 2958 (m), 2932 (m), 2870 (w), 1631 (s), 1595 (s), 1548 
(s), 1487 (s), 1016 (w) cm−1. Rf = 0.32 (20:80 EtOAc:hexanes). 1H NMR (500 MHz, 
CDCl3): δ 0.95−0.99 (3H, t, J = 7.5 Hz), 1.38−1.45 (2H, m), 1.58−1.64 (2H, m), 3.42− 
3.46 (2H, m), 3.93 (3H, s), 6.20 (1H, s, br), 6.82−6.84 (1H, d, J = 0.50 Hz), 7.78−7.80 
(1H, m), 8.17−8.18 (1H, d, J = 2.5 Hz) ppm. 13C NMR (125 MHz, CDCl3): δ 13.8, 20.2, 
31.8, 39.9, 56.6, 85.6, 110.2, 128.9, 129.0, 138.1, 160.4, 165.7 ppm. HRMS (ESI): m/z 
found 334.0333, calcd for C12H17INO2 (M + H)+ 334.0304. 
 
 129 
N-Butyl-5-iodo-2-methoxybenzamide, Catalyst 11. White solid (0.2240 g, 75%), mp 
41−42 °C. IR (neat): 3405 (br), 2957 (m), 2930 (m), 2870 (w), 1643 (s), 1586 (m), 1534 
(s), 1477 (s), 1019 (m) cm−1. Rf = 0.31 (20:80 EtOAc:hexanes). 1H NMR (500 MHz, 
CDCl3): δ 0.94−0.97 (3H, t, J = 7.0 Hz), 1.37−1.44 (2H, m), 1.56−1.62 (2H, m), 3.42− 
3.46 (2H, m), 3.94 (3H, s), 6.72,6.74 (1H, d, J = 9.0 Hz), 7.66−7.69 (1H, m), 7.75 (1H, s, 
br), 8.45−8.46 (1H, d, J = 2.0 Hz) ppm. 13C NMR (125 MHz, CDCl3): δ 13.8, 17.6, 20.2, 
31.6, 39.6, 56.2, 83.7, 113.7, 123.9, 140.7, 157.2, 163.7 ppm. HRMS (ESI): m/z found 
334.0333, calcd for C12H17INO2 (M + H)+ 334.0304. 
 
N-Butyl-5-iodo-2-methoxy-4-methylbenzamide, Catalyst 12. Brown solid (0.1164 g, 
98%), mp 117−118 °C. IR (neat): 3401 (br), 2955 (m), 2935 (m), 2859 (w), 1646 (s), 
1593 (m), 1530 (s), 1460 (m), 1033 (w) cm−1. Rf = 0.22 (20:80 EtOAc:hexanes). 1H 
NMR (500 MHz, CDCl3): δ 0.97−0.99 (3H, t, J = 7.0 Hz), 1.39−1.47 (2H, m), 1.58− 1.64 
(2H, m), 2.47 (3H, s), 3.45−3.49 (2H, m), 3.96 (3H, s), 6.86 (1H, s), 7.76 (1H, s, br), 8.58 
(1H, s) ppm. 13C NMR (125 MHz, CDCl3): δ 13.8, 20.3, 28.4, 31.6, 39.5, 56.1, 90.6, 
113.0, 121.1, 142.0, 146.1, 157.3, 163.7 ppm. HRMS (ESI): m/z found 348.0491, calcd 
for C13H19INO2 (M + H)+ 348.0460. 
 
1-oxo-1-p-tolylpropan-2-yl 4-methylbenzenesulfonate,18 (Table 1.7). 
White solid (0.2783 g, 87%). Rf = 0.29 (20:80 EtOAc:hexanes). 1H NMR (300 MHz, 
CDCl3): δ 1.59, 1.61 (3H, d, J = 6.9 Hz), 2.44 (6H, s, br), 5.79 (1H, q, J = 7.2 Hz), 
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7.30−7.27 (4H, m), 7.82−7.63 (4H, m) ppm. 13C NMR (90 MHz, CDCl3): δ 18.8, 21.6, 
21.7, 76.6, 128.0, 128.9, 129.5, 129.8, 131.1, 133.5, 144.9, 145.0, 194.3 ppm. 
 
1-(4-Methoxyphenyl)-1-oxopropan-2-yl 4-Methylbenzenesulfonate, 19 (Table 1.7).313 
White solid (0.2408 g, 72%). Rf = 0.183 (20:80 EtOAc:hexanes). 1H NMR (300 MHz, 
CDCl3): δ 1.59, 1.61 (3H, d, J = 6.9 Hz) 2.43 (3H, s), 3.89 (3H, s), 5.76 (1H, q, J = 6.9), 
7.27−7.30 (2H, m), 7.76, 7.79 (2H, d, J = 8.4), 7.88−7.93 (2H, m) 7.89−7.91 ppm (2H, 
m) ppm. 13C NMR (90 MHz, CDCl3): δ 18.9, 21.7, 55.6, 76.8, 114.0, 126.5, 128.0, 129.7, 
131.2, 133.5, 145.0, 164.1, 193.1 ppm. 
 
1-(4-Fluorophenyl)-1-oxopropan-2-yl 4-Methylbenzenesulfonate, 20 (Table 1.7).277 
White solid (0.3030 g, 94%). Rf = 0.33 (20:80 EtOAc:hexanes). 1H NMR (500 MHz, 
CDCl3): δ 1.60, 1.61 (3H, d, J = 7.0 Hz), 2.44 (3H, s), 5.72 (1H, q, J = 7.0 Hz), 7.14−7.17 
(2H, t, J = 8.0 Hz), 7.29− 7.31 (2H, m), 7.76−7.78 (2H, m), 7.95−7.98 (2H, m) ppm. 13C 
NMR (125 MHz, CDCl3): δ 18.6, 21.7, 76.8, 115.9, 116.1, 128.0, 129.8, 131.6, 131.7, 
133.4, 145.2, 165.1, 167.1, 193.4 ppm. 
 
1-(4-Chlorophenyl)-1-oxopropan-2-yl 4-Methylbenzenesulfonate, 21(Table 1.7).277 
White solid (0.2464 g, 75%). Rf = 0.32 (20:80 EtOAc:hexanes). 1H NMR (500 MHz, 
CDCl3): δ 1.60, 1.61 (3H, d, J = 7.0 Hz), 2.45 (3H, s), 5.71 (1H, q, J = 7.0 Hz), 7.30, 
7.31(2H, d, J = 8.0 Hz), 7.44, 7.46 (2H, d, J = 8.5 Hz), 7.75, 7.77 (2H, d, J = 8.5 Hz), 
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7.85, 7.87 (2H, d, J = 9.0 Hz) ppm. 13C NMR (125 MHz, CDCl3): δ 18.6. 21.7, 76.8, 
128.0, 129.1, 129.8, 130.3, 132.0, 133.3, 140.4, 145.2, 194.0 ppm. 
 
1-(4-Bromophenyl)-1-oxopropan-2-yl 4-Methylbenzenesulfonate, 22 (Table 1.7).338 
White solid (0.3266 g, 85%). Rf = 0.37 (20:80 EtOAc:hexanes). 1H NMR (300 MHz, 
CDCl3): δ 1.59, 1.61 (3H, d, J = 6.9 Hz), 2.44 (3H, s), 5.69 (1H, q, J = 6.9 Hz), 7.31 (2H, 
s), 7.59− 7.63 (2H, m), 7.74−7.80 (4H, m) ppm. 13C NMR (90 MHz, CDCl3): δ 18.6, 
21.7, 76.8, 127.9, 129.2, 129.9, 130.3, 132.1, 132.4, 133.3, 145.2, 194.1 ppm. 
 
α-Tosyloxyacetophenone, 23 (Table 1.7).338 White solid (0.2729 g, 94%). Rf = 0.24 
(20:80 EtOAc:hexanes). 1H NMR (500 MHz, CDCl3): δ 2.47 (3H, s), 5.29 (2H, s), 7.36, 
7.38 (2H, d, J = 8.0 Hz), 7.48−7.51 (2H, m), 7.61−7.64 (1H, m), 7.85−7.88 (4H, m) ppm. 
13C NMR (125 MHz, CDCl3): δ 21.7, 70.0, 128.0, 128.2, 128.9, 129.9, 132.7, 133.8, 
134.2, 145.3, 190.3 ppm. 
 
General Procedure for Preparation of the Iodoarene Amino Methyl Esters 
(Catalysts 1a-3d, Figure 3.8 and Scheme 3.15). 
Iodoarene Nα-Z-amino methyl ester Catalysts 1a-3d were prepared from their 
corresponding Nα-protected Z-diamino acids and iodobenzoic acids.  The Z-diamino 
acids, L-diaminopropanoic acid (Dap), L-diaminobutanoic acid (Dab), L-ornithine (Orn) 
and L-lysine (Lys), were first converted to their corresponding methyl esters and without 
 132 
further purification the free amine side chain was coupled to appropriate iodoarene active 
site (cf. Scheme 3.15).   
A representative two step procedure for the synthesis of Catalyst 1a is as follows:   
Step 1: To a cooled (0 °C) suspension of Nα -Cbz-L-2,3-Diaminopropionic acid (Z-L-
DAP-OH) (5 g, 21 mmol, 1 equiv.) in 100 mL of MeOH was added thionyl chloride (23 
mmol, 1.1 equiv.) over 20 min (dropwise).  The resulting solution was allowed to stir at 
room temperature overnight.  After approximately 18 h, the solvent was removed in 
vacuo, and the residual solid was stirred with 150 mL Et2O for 0.5 h.  The resulting crude 
compound was obtained following rotary evaporation to give Nα-Z-diaminopropanoic 
acid as a white solid, (5.29 g, quant. yield).  
Step 2:  A solution of 3-iodobenzoic acid (4.6 g, 18.5 mmol, 1.0 equiv) and 
trimethylamine (3.78 g, 37.1 mmol, 2 equiv) in anhydrous dichloromethane (150 mL) 
was allowed to stir at room temperature for 10 min while under nitrogen atmosphere.  
The mixture was cooled to 0°C, and after 30 min, thionyl chloride (20.4 mmol, 1.1 equiv) 
was added dropwise and allowed to stir for 1.5 hours. The reaction mixture was brought 
to room temperature, with continued stirring for 30 minutes followed by rotary 
evaporation to dryness.  The reaction mixture was then redissolved in anhydrous DCM 
(150 mL).  A separate solution of the Z-diamino methyl ester (5.15 g, 20.4 mmol, 1.1 
equiv) was prepared by dissolving this substrate in anhydrous DCM (100 mL) followed 
by dropwise addition of triethylamine (3.78 g, 37.1 mmol, 2 equiv).  This freshly 
prepared solution was then slowly added to the flask containing the 3-iodobenzoic acid 
and allowed to stir for 18 h at room temperature under nitrogen. The resulting crude 
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mixture was concentrated by rotary evaporation, diluted in DCM and washed with 1M 
HCl.  The aqueous layers were extracted with DCM (3X).  Organic layers were washed 
with H2O (2X), saturated brine (1X), and dried over sodium sulfate.  Following filtration 
and rotary evaporation, the resulting crude product was purified by column 
chromatography on silica gel (gradient to 1:9 MeOH:DCM) to produce the dark brown 
oil, Catalyst 1a (7.5 g, 84%); Rf  = 0.79 (1:9 MeOH:DCM) ; IR (neat): 3337 (br), 3068 
(m), 3031 (m), 2953 (m), 2930 (m), 1759 (s), 1748 (s), 1643 (m), 1551 (m), 1543 (m), 
1438 (s), 1270 (w), 1066 (w) cm-1; 1H NMR (500 MHz, CDCl3): δ 3.75 (3 H, s), 3.81-
3.84 (2 H, t), 4.51-4.58 (1 H, q), 5.09 (2H, s), 5.30 (Residual DCM solvent peak), 6.19-
6.21 (1 H, d), 7.07-7.13 (1H, t), 7.27-7.39 (5H, m), 7.67-7.70 (1H, d), 7.78-7.81 (1H, d), 
8.11 (1H, s) ppm; 13C NMR (500 MHz, CDCl3) δ 42.3, 53.0, 54.3, 67.3, 94.3, 126.3, 
128.1, 128.3, 128.5, 130.2, 135.8, 135.9, 136.2, 140.6, 156.6, 166.8, 170.8 ppm.  
 
3-Iodoarene-Z-L-Dab-Amino Methyl Ester, Catalyst 1b: dark brown oil, (0.148 g, 74%). 
Rf  = 0.75 ; IR (neat): 3385 (br), 3066 (m), 3040 (m), 2953 (m), 2922 (w), 1760 (s), 1745 
(s), 1644 (s), 1556 (m), 1540 (m), 1454 (w), 1448 (w), 1267 (w), 1062 (w) cm-1; 1H NMR 
(500 MHz, CDCl3) : 1.82-1.83 (1 H, m), 2.20-2.23 (1 H, m),  3.18-3.21 (1 H, m), 3.69 
(3H, s), 3.86-3.88 (1 H, m), 4.46-4.49 (1H, m), 5.14 (2H, s), 5.97 (1H, s, br), 7.13-7.16 
(1H, m), 7.32-7.35 (5H, m), 7.52 (1H, s, br), 7.79-7.81 (2H, m), 8.22 (1H, s) ppm; 13C 
NMR (500 MHz, CDCl3) δ 32.8, 36.1, 51.6, 52.8, 67.4, 94.4, 126.2, 128.1, 128.3, 128.6, 
130.2, 136.0, 136.1, 136.3, 140.4, 156.8, 166.0, 172.6 ppm. 
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3-Iodoarene-Z-L-Lys-Amino Methyl Ester, Catalyst 1c: dark brown oil, (0.167 g, 81%). 
Rf  =0.74 (1:9 MeOH:DCM); IR (neat): 3377 (br), 3070 (m), 3063 (m), 2939 (m), 2926 
(m), 2854 (m), 1758 (s), 1714 (s), 1643 (s), 1566 (m), 1538 (m), 1454 (m), 1380 (w), 
1266 (m), 1063 (w) cm-1; 1H NMR (500 MHz, CDCl3) : 1.68-1.72 (2 H, m), 1.78-1.95 (2 
H, m),  3.41-3.56 (2 H, m), 3.75 (3H, s), 4.39-4.42 (1 H, m), 5.13 (2H, s), 5.58-5.61 (1H, 
d), 6.73 (1H, br), 7.13-7.18 (1H, t), 7.35 (5H, m), 7.74-7.77 (1H, d), 7.80-7.83 (1H, d), 
8.14 (1H, s) ppm; 13C NMR (500 MHz, CDCl3) δ 25.3, 30.4, 39.4, 52.6, 53.3, 67.2, 94.2, 
126.3, 128.1, 128.3, 128.6, 130.2, 136.0, 136.1, 136.5, 140.3, 156.1, 166.1, 172.6 ppm. 
 
3-Iodoaryl-Z-L-Orn-Amino Methyl Ester, Catalyst 1d: dark brown oil, (0.182 g, 86%). Rf  
= 0.78 (1:9 MeOH:DCM); IR (neat): 3366 (br), 3063 (m), 3042 (m) 2940 (m), 2933 (m), 
2861 (m), 1751 (s), 1720 (s), 1692 (s), 1644 (s), 1556 (m), 1538 (m), 1463 (m), 1455 (m), 
1267 (m), 1193 (w), 1052 (w) cm-1; 1H NMR (500 MHz, CDCl3) : 1.45-1.67 (2 H, m), 
1.71-1.87 (2 H, m), 2.05-2.09 (2 H, m), 3.37-3.44 (2 H, m), 3.75 (3H, s), 4.40 (1H, br),  
5.04-5.12 (2H, m), 5.53-5.54 (1H, d), 6.51 (1H, br), 7.11-7.14 (1H, t), 7.34-7.36 (5H, m), 
7.74-7.76 (1H, d), 7.79-7.81 (1H, d), 8.13 (1 h, br)  ppm; 13C NMR (500 MHz, CDCl3) δ 
22.5, 28.7, 32.3, 39.7, 52.5, 53.5, 67.1, 94.2, 126.3, 128.1, 128.2, 128.6, 130.2, 136.0, 
136.2, 136.7, 140.2, 156.2, 166.2, 172.9 ppm. 
 
5-Iodo-2-Methoxy-arene-Z-L-Dap-Amino Methyl Ester, Catalyst 2a: dark brown oil, 
(0.175 g, 95%). Rf  = 0.76 (1:9 MeOH:DCM); IR (neat): 3337 (br), 3068 (m), 3031 (m), 
2953 (m), 2930 (m), 1759 (s), 1748 (s), 1643 (), 1551 (), 1543 (m), 1438 (s), 1270 (w), 
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1066 (w) cm-1; 1H NMR (500 MHz, CDCl3): δ 3.40-3.41 (2 H, m), 3.70 (3 H, s), 3.88 (3 
H, s), 4.33-4.34 (1 H, br), 5.08 (2H, s), 5.59-5.62 (1 H, d), 6.67-6.70 (1H, d), 7.26-7.42 
(5H, m), 7.64-7.67 (1H, d), 7.76 (1H, d), 8.43 (1H, s) ppm; 13C NMR (500 MHz, CDCl3) 
δ 29.0, 39.3, 52.4, 56.2, 66.9, 83.7, 113.7, 123.6, 128.0, 128.1, 128.5, 136.3, 140.6, 141.1, 
156.1, 157.2, 163.9, 172.9 ppm.  
 
5-Iodo-2-methoxy-arene-Z-L-Dab-Amino Methyl Ester, Catalyst 2b: dark brown oil, 
(0.129 g, 68%). Rf  = 0.75 (1:9 MeOH:DCM); IR (neat): 3385 (br), 3066 (m), 3040 (m), 
2953 (m), 2922 (w), 1760 (s), 1745 (s), 1644 (s), 1556 (m), 1540 (m), 1454 (w), 1448 
(w), 1267 (w), 1062 (w) cm-1; 1H NMR (500 MHz, CDCl3) : 1.82-1.87 (1 H, m), 2.18-
2.22 (1 H, m), 3.21-3.23 (1 H, m), 3.68 (3H, s), 3.83-3.87 (1 H, m), 3.95 (3H, s), 4.47-
4.50 (1H, m), 5.13 (2H, s), 5.82-5.84 (1H, d), 6.72-6.74 (1H, d), 7.33-7.36 (5H, m), 7.68-
7.70 (1H, d), 8.34 (1H, s, br), 8.46 (1H, s) ppm; 13C NMR (500 MHz, CDCl3) δ 32.9, 
35.7, 51.7, 52.6,  56.1, 67.1, 83.4, 113.7, 123.4, 128.0, 128.2, 128.6, 136.2, 140.6, 141.3, 
156.5, 157.5, 164.1, 172.8 ppm. 
 
5-Iodo-2-methoxy-Iodoarene-Z-L-Lys-Amino Methyl Ester, Catalyst 2c: dark brown oil, 
(0.140 g, 72%). Rf  = 0.73 (1:9 MeOH:DCM); IR (neat): 3398 (br), 3074 (m), 3052 (m), 
2942 (m), 2932 (m), 2882 (m), 1772 (s), 1728 (s), 1640 (s), 1560 (m), 1544 (m), 1426 
(m), 1378 (w), 1263 (m), 1060 (w) cm-1; 1H NMR (500 MHz, CDCl3) : 1.67-1.78 (2 H, 
m), 1.94-1.97 (2 H, m),  3.48-3.49 (2 H, m), 3.77 (3H, s), 3.95 (3 H, s), 4.43-4.46 (1H, 
m), 5.13 (2H, s), 5.46-5.47 (1H, d), 6.75-6.77 (1H, d), 7.34-7.38 (5H, m), 7.73-7.74 (1H, 
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d), 7.80 (1H, br), 8.48 (1H, s) ppm; 13C NMR (500 MHz, CDCl3) δ 25.6, 30.1, 39.2, 52.6, 
53.7, 56.2, 67.1, 83.8, 113.7, 123.5, 128.1, 128.2, 128.6, 136.2, 140.8, 141.2, 155.9, 
157.2, 163.9, 172.7 ppm. 
 
5-Iodo-2-methoxy-Iodoarene-Z-L-Orn-Amino Methyl Ester, Catalyst 2d: dark brown oil, 
(0.140 g, 70%). Rf  = 0.76 (1:9 MeOH:DCM); IR (neat): 3378 (br), 3058 (m), 3048 (m) 
2936 (m), 2940 (m), 2858 (m), 1760 (s), 1728 (s), 1700 (s), 1640 (s), 1562 (m), 1530 (m), 
1458 (m), 1458 (m), 1270 (m), 1190 (w), 1048 (w) cm-1; 1H NMR (500 MHz, CDCl3) : 
1.41-1.48 (2H, m), 1.61-1.67 (2H, m), 1.72-1.79 (1H, m), 1.89-1.93 (1H, m),  3.42-3.50 
(2H, m), 3.75 (3H, s), 3.94 (3H, s), 4.36-4.41 (1H, m), 5.12 (2H, s), 5.47-5.48 (1H, d), 
6.73-6.75 (1H, d), 7.36 (5H, m), 7.70-7.72 (1H, d), 7.77 (1H, s, br), 8.49 (1H, s) ppm; 13C 
NMR (500 MHz, CDCl3) δ 22.6, 29.1, 32.1, 39.3, 52.4, 53.8, 56.2, 66.9, 83.8, 113.7, 
123.6, 128.1, 128.2, 128.5, 136.3, 140.8, 141.2, 156.0, 157.2, 163.9, 172.9 ppm. 
 
5-Iodo-2-methoxy-4-mehtyl-Z-L-Dap-Amino Methyl Ester, Catalyst 3a: dark brown oil, 
(0.149 g, 83%). %). Rf  = 0.76 (1:9 MeOH:DCM); IR (neat): 3348 (br), 3072 (m), 3026 
(m), 2950 (m), 2936 (m), 1760 (s), 1748 (s), 1640 (s), 1551 (s), 1538 (m), 1440 (s), 1262 
(w), 1060 (w) cm-1; 1H NMR (500 MHz, CDCl3): 2.45 (3 H, s), 3.79 (3 H, s), 3.80-3.88 
(2H, m), 3.89 (3H, s), 4.54-4.55 (1H, d), 5.09-5.16 (2H, m), 6.01-6.03 (1H, d), 6.84 (1H, 
s), 7.31-7.35 (5H, m), 8.07 (1H, s, br), 8.52 (1H, s) ppm; 13C NMR (500 MHz, CDCl3) δ 
17.6, 28.5, 41.5, 54.8 (Residual DCM solvent peak), 54.8, 56.1, 67.0, 90.6, 113.0, 120.2, 
128.0, 128.2, 128.5, 136.2, 142.1, 146.9, 156.1, 157.5, 164.9, 171.1 ppm. 
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5-Iodo-2-methoxy-4-mehtyl -Z-L-Dab-Amino Methyl Ester, Catalyst 3b: dark brown oil, 
(0.152 g, 82%). %). Rf  = 0.74 (1:9 MeOH:DCM); IR (neat): 3390 (br), 3062 (m), 3040 
(m), 2948 (m), 2926 (w), 1760 (s), 1752 (s), 1642 (s), 1560 (m), 1548 (m), 1468 (w), 
1442 (w), 12664 (w), 1058 (w) cm-1; 1H NMR (500 MHz, CDCl3) : 1.84-1.89 (1H, m), 
2.16-2.25 (1H, m),  2.45 (3H, s), 3.19-3.24 (1H, m), 3.68 (3H, s), 3.83-3.87 (1H, m), 3.96 
(3H, s), 4.48-4.49 (1H, d), 5.14 (2H, s,), 5.73-5.74 (1H, d), 6.85 (1H, s), 7.32-7.39 (5H, 
m), 8.30 (1H, s, br), 8.56 (1H, s) ppm; 13C NMR (500 MHz, CDCl3) δ 17.7, 28.5, 33.0, 
35.6, 51.7, 55.9, 67.1, 90.4, 112.9, 120.7, 128.0, 128.2, 128.6, 136.2, 141.9, 146.4, 156.4, 
157.6, 164.1, 172.8 ppm. 
 
5-Iodo-2-methoxy-4-mehtyl -Z-L-Lys-Amino Methyl Ester, Catalyst 3c: dark brown oil, 
(0.165 g, 87%). Rf  = 0.76 (1:9 MeOH:DCM); IR (neat): 3390 (br), 3076 (m), 3060 (m), 
2944 (m), 2924 (m), 2849 (m), 1760 (s), 1712 (s), 1648 (s), 1572 (m), 1544 (m), 1456 
(m), 1388 (w), 1264 (m), 1066 (w) cm-1; 1H NMR (500 MHz, CDCl3) : 1.60-1.68 (2H, 
m), 1.72-1.95 (2H, m,),  2.46 (3H, s), 3.46-3.47 (2H, d), 3.76 (3H, s), 3.94 (3 H, s), 4.42-
4.43 (1H, d), 5.12 (2H, s), 5.48-5.49 (1H, br), 6.86 (1H, s), 7.37 (5H, m), 7.79 (1H, s, br), 
8.56 (1H, s) ppm; 13C NMR (500 MHz, CDCl3) δ 25.7, 28.5, 30.1, 39.1, 52.5, 53.7, 56.1, 




5-Iodo-2-methoxy-4-mehtyl -Z-L-Orn-Amino Methyl Ester, Catalyst 3d: dark brown oil, 
(0.187 g, 96%). Rf  = 0.77 (1:9 MeOH:DCM); IR (neat): 3398 (br), 3078 (m), 3052 (m) 
2956 (m), 2940 (m), 2858 (m), 1750 (s), 1728 (s), 1690 (s), 1648 (s), 1554 (m), 1532 (m), 
1464 (m), 1442 (m), 1266 (m), 1190 (w), 1040 (w) cm-1; 1H NMR (500 MHz, CDCl3) : 
1.19-1.25 (2H, m), 1.65-1.77 (2H, m), 1.91 (2H, m), 2.42 (3H, s). 3.42-3.44 (2H, m,) 3.72 
(3H, s), 3.90 (3H, s), 4.38-4.40 (1H, d), 5.09 (2H, s), 5.64-5.67 (1H, d), 6.82 (1H, s), 
7.24-7.38 (5H, m), 7.78 (1H, s, br), 8.50 (1H, s) ppm; 13C NMR (500 MHz, CDCl3) δ 
25.7, 28.5, 29.5, 29.9, 39.1, 52.5, 53.7, 56.1, 66.9, 90.6, 112.9, 120.8, 128.0, 128.2, 128.5, 
136.2, 141.9, 146.3, 156.0, 157.3, 163.9, 172.7 ppm. 
 
Synthesis of 3-iodoarene-Nα-Fmoc-L-diaminopropionic acid, 6l, occurred over 3 steps 
including: 
Hydrolysis of Iodoarene Amino Methyl Ester Catalyst 1a. The iodoarene amino methyl 
ester Catalyst 1a (10 g, 20.7 mmol) was dissolved in dioxane (50-100 mL) and cooled to 
0 °C. Sodium hydroxide (2N) (10 equiv.) was slowly added and the resulting mixture was 
allowed to stir for 18 hours at room temperature. The organic solvent was evaporated off, 
and then H2O (mL) was added.  The solution was acidified to pH ≈ 6 with 3M HCl. This 
solution was extracted with EtOAc (x4) and the organic layers were washed with brine 
(x1) and dried over Na2SO4.  The crude product was obtained following rotary 
evaporation, and carried on to next step without purification. 
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Cbz deprotection of Catalyst 1a303 While under at argon atmosphere, the hydrolyzed 
product (2.5 g, 5.3 mmol) was dissolved in anhydrous DCM (60 mL).  The solution was 
cooled to 0 °C, and trimethylsilane (11.7 mmol, 2.2 equiv.) was slowly added.  This 
mixture was stirred at 0 °C for 3 h, and then 12 h at room temperature.  The mixture was 
concentrated to dryness and the residue was taken up in water.  The pH was adjusted to ≈ 
6 with 0.2N NaOH, and the pale-yellow precipitate was collected, dried via high pump 
vacuum, and carried on to the next step without purification. 
 
N-Fmoc Protection (6l)304 A round-bottomed flask was charged with the amino acid 
(1.34 g, 4 mmol), H2O (100 mL),  and diisopropylethylamine (DIPEA) (0.78 g, 6.02 
mmol, 1.5 equiv).  The reaction was cooled in an ice bath, followed by the addition of 
Fmoc-OSu (1.47 g, 4.37 mmol, 1.1 equiv) in MeCN (100 mL) and was stirred for 30 
minutes. The reaction was stirred at room temperature overnight.  The solvent was 
rotovapped off, and the resulting mixture was dissolved in water (100 mL) and then 
acidified with 2N HCl to pH ~ 3.  The aqueous layer was extracted with ethyl acetate 
(x3), and dried over Na2SO4.  The crude product was purified via column 
chromatography (gradient from 100% DCM to 1:9 MeOH/DCM) to give 6l: off white 
solid, (1.8 g, 81% over 3 steps); Rf  = 0.14 (Gradient 1:9 MeOH:DCM); IR (neat): 3480 
(br), 3180 (w), 2571 (br), 1697 (br), 1635 (m), 1601 (br), 1558 (m), 1447 (m), 1423 (m), 
1404 (m), 1354 (m), 1288 (w), 1249 (w), 736 (s), (m), 1426 (m), 1378 (w), 1263 (m), 
1060 (w) cm-1; 1H NMR (500 MHz, (MeOD) : 3.39-3.76 (1H, m), 3.82-3.85 (1H, dd), 
4.18-4.20 (1H, m), 4.23-4.27 (1H, m), 4.37-4.40 (2H, m), 7.18-7.20 (1H, d), 7.21-7.27 
 140 
(2H, m), 7.28 (1H, br), 7.35-7.39 (2H, m ), 7.63-7.64 (2H, m), 7.77-7.86 (4H, m), 8.17 
(1H, s) ppm; 13C NMR (500 MHz, MeOD) δ 42.1, 42.3, 54.4, 66.7, 93.3, 119.5, 124.9, 
126.3, 126.8, 127.3, 129.9, 136.1, 136.3, 140.2, 141.1, 143.9, 157.1, 167.5, 174.4 ppm. 
 
 
Crystal Structure of Catalyst 2a (C20H21IN2O6) 
Crystal Structure Report for D8_2036_MS163_EtOH  
A specimen of C20H21IN2O6, approximate dimensions 0.027 mm x 0.029 mm x 0.388 
mm, was used for the X-ray crystallographic analysis. The X-ray intensity data were 
measured. 
The integration of the data using an orthorhombic unit cell yielded a total of 16298 
reflections to a maximum θ angle of 25.50° (0.83 Å resolution), of which 3958 were 
independent (average redundancy 4.118, completeness = 99.5%, Rint = 3.30%, Rsig = 
3.06%) and 3792 (95.81%) were greater than 2σ(F2). The final cell constants of a = 
4.8220(2) Å, b = 13.9582(6) Å, c = 31.7890(14) Å, volume = 2139.60(16) Å3, are based 
upon the refinement of the XYZ-centroids of reflections above 20 σ(I). The calculated 
minimum and maximum transmission coefficients (based on crystal size) are 0.8771 and 
1.0000.  
 
The structure was solved and refined using the Bruker SHELXTL Software Package, 
using the space group P 21 21 21, with Z = 4 for the formula unit, C20H21IN2O6. The final 
anisotropic full-matrix least-squares refinement on F2 with 268 variables converged at R1 
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= 2.31%, for the observed data and wR2 = 5.49% for all data. The goodness-of-fit was 
1.123. The largest peak in the final difference electron density synthesis was 0.380 e-/Å3 
and the largest hole was -0.994 e-/Å3 with an RMS deviation of 0.087 e-/Å3. On the basis 









Table 1. Sample and crystal data for D8_2036_MS163_EtOH.  
Identification code D8_2036_MS163_EtOH 
Chemical formula C20H21IN2O6 
Formula weight 512.29 g/mol 
Temperature 140(2) K 
Wavelength 0.71073 Å 
Crystal size 0.027 x 0.029 x 0.388 mm 
Crystal system orthorhombic 
Space group P 21 21 21 
Unit cell dimensions a = 4.8220(2) Å α = 90° 
 b = 13.9582(6) Å β = 90° 
 c = 31.7890(14) Å γ = 90° 
Volume 2139.60(16) Å3  
Z 4 
Density (calculated) 1.590 g/cm3 
Absorption coefficient 1.534 mm-1 
F(000) 1024 
 
Table 2. Data collection and structure refinement for 
D8_2036_MS163_EtOH.  
Theta range for data 
collection 2.41 to 25.50° 
Index ranges -5<=h<=5, -16<=k<=16, -38<=l<=38 
Reflections collected 16298 
Independent 
reflections 3958 [R(int) = 0.0330] 
Max. and min. 
transmission 1.0000 and 0.8771 
Structure solution 
technique direct methods 
Structure solution 
program SHELXT-2014 (Sheldrick 2014) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2014 (Sheldrick 2014) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / 
parameters 3958 / 2 / 268 
Goodness-of-fit on F2 1.123 
Δ/σmax 0.002 
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Final R indices 3792 data; I>2σ(I) R1 = 0.0231, wR2 = 0.0542 






Largest diff. peak and 
hole 0.380 and -0.994 eÅ
-3 




Table 3. Atomic coordinates and 
equivalent isotropic atomic displacement 
parameters (Å2) for 
D8_2036_MS163_EtOH.  
U(eq) is defined as one third of the trace of 
the orthogonalized Uij tensor.  
 x/a y/b z/c U(eq) 
I1 0.79969(5) 0.51368(2) 0.84588(2) 0.03603(10) 
O1 0.2988(6) 0.36512(15) 0.70696(8) 0.0313(6) 
O2 0.0091(5) 0.66481(18) 0.58967(9) 0.0304(6) 
O3 0.3672(5) 0.5705(2) 0.61011(9) 0.0329(7) 
O4 0.7479(11) 0.3631(2) 0.54951(12) 0.0906(16) 
O5 0.0397(9) 0.2617(2) 0.58074(10) 0.0547(9) 
O6 0.9626(6) 0.63738(18) 0.70624(8) 0.0356(7) 
N1 0.9333(7) 0.4510(2) 0.68548(10) 0.0284(7) 
N2 0.9346(6) 0.5114(2) 0.59928(9) 0.0244(6) 
C1 0.0008(8) 0.4135(2) 0.61069(12) 0.0254(8) 
C2 0.8597(7) 0.3844(2) 0.65225(12) 0.0279(8) 
C3 0.1616(8) 0.4393(2) 0.70849(11) 0.0232(8) 
C4 0.2450(7) 0.5185(2) 0.73803(10) 0.0224(7) 
C5 0.1532(8) 0.6143(2) 0.73659(11) 0.0259(8) 
C6 0.2565(9) 0.6807(2) 0.76521(12) 0.0327(10) 
C7 0.4453(8) 0.6535(3) 0.79560(12) 0.0312(9) 
C8 0.5329(8) 0.5594(3) 0.79791(11) 0.0264(8) 
C9 0.4360(7) 0.4932(2) 0.76886(10) 0.0244(7) 
C10 0.1249(8) 0.5807(3) 0.60082(12) 0.0241(8) 
C11 0.1987(9) 0.7463(2) 0.58822(13) 0.0337(9) 
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 x/a y/b z/c U(eq) 
C12 0.0578(8) 0.8230(2) 0.56285(12) 0.0271(8) 
C13 0.8394(8) 0.8757(2) 0.57918(12) 0.0297(9) 
C14 0.7114(10) 0.9464(3) 0.55561(13) 0.0373(9) 
C15 0.8026(11) 0.9651(3) 0.51527(13) 0.0427(10) 
C16 0.0182(10) 0.9139(3) 0.49849(13) 0.0430(12) 
C17 0.1467(9) 0.8422(3) 0.52222(12) 0.0353(10) 
C18 0.9123(10) 0.3451(3) 0.57604(13) 0.0369(10) 
C19 0.9662(16) 0.1877(3) 0.55087(17) 0.079(2) 
C20 0.8745(11) 0.7350(3) 0.70233(14) 0.0444(12) 
 
Table 4. Bond lengths (Å) for 
D8_2036_MS163_EtOH.  
I1-C8 2.094(4) O1-C3 1.230(4) 
O2-C10 1.347(4) O2-C11 1.460(5) 
O3-C10 1.213(5) O4-C18 1.184(5) 
O5-C18 1.324(5) O5-C19 1.447(6) 
O6-C5 1.371(5) O6-C20 1.433(4) 
N1-C3 1.331(5) N1-C2 1.451(5) 
N1-H1 0.83(2) N2-C10 1.335(5) 
N2-C1 1.449(5) N2-H2 0.84(2) 
C1-C18 1.518(5) C1-C2 1.540(5) 
C1-H1A 1.0 C2-H2A 0.99 
C2-H2B 0.99 C3-C4 1.505(5) 
C4-C9 1.390(5) C4-C5 1.409(5) 
C5-C6 1.391(5) C6-C7 1.380(6) 
C6-H6 0.95 C7-C8 1.383(5) 
C7-H7 0.95 C8-C9 1.387(5) 
C9-H9 0.95 C11-C12 1.503(5) 
C11-H11A 0.99 C11-H11B 0.99 
C12-C13 1.385(6) C12-C17 1.387(5) 
C13-C14 1.385(5) C13-H13 0.95 
C14-C15 1.381(6) C14-H14 0.95 
C15-C16 1.370(6) C15-H15 0.95 
C16-C17 1.398(6) C16-H16 0.95 
C17-H17 0.95 C19-H19A 0.98 
C19-H19B 0.98 C19-H19C 0.98 
C20-H20A 0.98 C20-H20B 0.98 
C20-H20C 0.98   
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Table 5. Bond angles (°) for 
D8_2036_MS163_EtOH.  
C10-O2-C11 115.3(3) C18-O5-C19 116.1(4) 
C5-O6-C20 118.9(3) C3-N1-C2 121.6(3) 
C3-N1-H1 117.(3) C2-N1-H1 120.(3) 
C10-N2-C1 121.6(3) C10-N2-H2 118.(3) 
C1-N2-H2 119.(3) N2-C1-C18 110.4(3) 
N2-C1-C2 111.4(3) C18-C1-C2 109.4(3) 
N2-C1-H1A 108.5 C18-C1-H1A 108.5 
C2-C1-H1A 108.5 N1-C2-C1 110.4(3) 
N1-C2-H2A 109.6 C1-C2-H2A 109.6 
N1-C2-H2B 109.6 C1-C2-H2B 109.6 
H2A-C2-H2B 108.1 O1-C3-N1 121.7(3) 
O1-C3-C4 120.0(3) N1-C3-C4 118.3(3) 
C9-C4-C5 118.1(3) C9-C4-C3 115.5(3) 
C5-C4-C3 126.3(3) O6-C5-C6 122.9(3) 
O6-C5-C4 117.2(3) C6-C5-C4 119.9(3) 
C7-C6-C5 120.7(3) C7-C6-H6 119.6 
C5-C6-H6 119.6 C6-C7-C8 120.0(3) 
C6-C7-H7 120.0 C8-C7-H7 120.0 
C7-C8-C9 119.6(3) C7-C8-I1 121.1(3) 
C9-C8-I1 119.3(3) C8-C9-C4 121.6(3) 
C8-C9-H9 119.2 C4-C9-H9 119.2 
O3-C10-N2 125.8(4) O3-C10-O2 124.4(4) 
N2-C10-O2 109.7(3) O2-C11-C12 106.8(3) 
O2-C11-H11A 110.4 C12-C11-H11A 110.4 
O2-C11-H11B 110.4 C12-C11-H11B 110.4 
H11A-C11-H11B 108.6 C13-C12-C17 118.8(4) 
C13-C12-C11 121.4(3) C17-C12-C11 119.8(4) 
C14-C13-C12 121.0(4) C14-C13-H13 119.5 
C12-C13-H13 119.5 C15-C14-C13 119.7(4) 
C15-C14-H14 120.2 C13-C14-H14 120.2 
C16-C15-C14 120.3(4) C16-C15-H15 119.8 
C14-C15-H15 119.8 C15-C16-C17 120.0(4) 
C15-C16-H16 120.0 C17-C16-H16 120.0 
C12-C17-C16 120.3(4) C12-C17-H17 119.9 
C16-C17-H17 119.9 O4-C18-O5 125.2(4) 
O4-C18-C1 124.9(4) O5-C18-C1 109.9(4) 
O5-C19-H19A 109.5 O5-C19-H19B 109.5 
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H19A-C19-H19B 109.5 O5-C19-H19C 109.5 
H19A-C19-H19C 109.5 H19B-C19-H19C 109.5 
O6-C20-H20A 109.5 O6-C20-H20B 109.5 
H20A-C20-H20B 109.5 O6-C20-H20C 109.5 
H20A-C20-H20C 109.5 H20B-C20-H20C 109.5 
 
Table 6. Anisotropic atomic displacement parameters (Å2) 
for D8_2036_MS163_EtOH.  
The anisotropic atomic displacement factor exponent takes the 
form: -2π2[ h2 a*2 U11 + ... + 2 h k a* b* U12 ]  
 U11 U22 U33 U23 U13 U12 





O1 0.0403(15) 0.0195(12) 0.0343(14) -0.0048(10) -0.0065(13) 0.0047(13) 
O2 0.0202(14) 0.0244(13) 0.0465(18) 0.0080(12) -0.0037(12) -0.0041(11) 
O3 0.0165(14) 0.0351(15) 0.0470(18) 0.0040(13) -0.0014(12) -0.0002(11) 
O4 0.161(5) 0.0463(18) 0.065(2) -0.0160(17) -0.073(3) 0.018(3) 
O5 0.090(3) 0.0275(15) 0.047(2) -0.0080(14) -0.007(2) 0.0066(17) 
O6 0.0535(19) 0.0239(14) 0.0293(15) 0.0009(11) -0.0023(14) 0.0127(13) 
N1 0.0320(18) 0.0263(16) 0.0268(17) -0.0040(14) -0.0028(15) 0.0036(14) 
N2 0.0180(14) 0.0236(16) 0.0315(16) 0.0035(14) -0.0048(13) -0.0004(14) 
C1 0.027(2) 0.0226(18) 0.027(2) -0.0001(16) -0.0052(17) 0.0016(16) 
C2 0.031(2) 0.0291(17) 0.0236(18) -0.0010(16) -0.0021(17) -0.0055(14) 
C3 0.028(2) 0.0228(17) 0.0189(18) 0.0012(14) 0.0092(16) -0.0007(17) 
C4 0.0250(19) 0.0213(15) 0.0208(16) 0.0008(13) 0.0066(13) -0.0009(15) 
C5 0.032(2) 0.0225(17) 0.0228(19) 0.0028(14) 0.0046(16) 0.0023(16) 
C6 0.050(3) 0.0167(15) 0.031(2) -0.0005(14) 0.0083(19) 0.0020(17) 
C7 0.044(2) 0.0234(19) 0.026(2) -0.0076(16) 0.0058(18) -0.0100(17) 
C8 0.027(2) 0.0300(19) 0.0222(19) 0.0010(15) 0.0035(15) -0.0067(16) 
C9 0.0280(17) 0.0204(17) 0.0248(18) -0.0018(15) 0.0058(14) -0.0007(15) 
C10 0.026(2) 0.027(2) 0.0194(18) 0.0030(15) 0.0016(15) 0.0008(16) 
C11 0.0254(19) 0.0292(18) 0.047(2) 0.0026(16) -0.003(2) -0.0099(18) 
C12 0.029(2) 0.0209(18) 0.031(2) 0.0001(15) -0.0038(17) -0.0116(16) 
C13 0.034(2) 0.0301(18) 0.025(2) -0.0001(15) 0.0012(17) -0.0107(18) 
C14 0.041(2) 0.0285(17) 0.042(2) -0.0021(17) 0.000(2) -0.002(2) 
C15 0.058(3) 0.029(2) 0.041(2) 0.0072(17) -0.014(2) -0.007(2) 
C16 0.062(3) 0.044(3) 0.024(2) 0.0060(19) 0.003(2) -0.018(2) 
C17 0.040(3) 0.033(2) 0.033(2) -0.0041(17) 0.0063(18) -0.0077(18) 
C18 0.057(3) 0.029(2) 0.026(2) 0.0027(17) -0.005(2) -0.0030(19) 
C19 0.154(6) 0.032(2) 0.051(3) -0.017(2) -0.004(4) 0.000(3) 
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 U11 U22 U33 U23 U13 U12 
C20 0.064(3) 0.030(2) 0.039(3) 0.0063(18) 0.005(2) 0.018(2) 
 
Table 7. Hydrogen atomic coordinates 
and isotropic atomic displacement 
parameters (Å2) for 
D8_2036_MS163_EtOH.  
 x/a y/b z/c U(eq) 
H1 -0.141(7) 0.5044(19) 0.6864(13) 0.03 
H2 -0.232(5) 0.527(3) 0.5959(12) 0.03 
H1A 0.2062 0.4082 0.6144 0.031 
H2A -0.3441 0.3841 0.6484 0.033 
H2B -0.0815 0.3189 0.6602 0.033 
H6 0.1965 0.7455 0.7638 0.039 
H7 0.5150 0.6996 0.8149 0.037 
H9 0.5018 0.4291 0.7700 0.029 
H11A 0.3759 0.7276 0.5748 0.04 
H11B 0.2381 0.7697 0.6170 0.04 
H13 -0.2234 0.8631 0.6070 0.036 
H14 -0.4385 0.9820 0.5672 0.045 
H15 -0.2846 1.0137 0.4991 0.051 
H16 0.0804 0.9270 0.4707 0.052 
H17 0.2954 0.8065 0.5105 0.042 
H19A 0.0715 0.1294 0.5571 0.119 
H19B -0.2328 0.1742 0.5529 0.119 
H19C 0.0101 0.2095 0.5223 0.119 
H20A -0.2609 0.7403 0.6795 0.067 
H20B -0.2110 0.7559 0.7288 0.067 
H20C 0.0351 0.7757 0.6961 0.067 
 
Table 8. Hydrogen bond distances (Å) and angles 







N1-H1...O6 0.83(2) 2.02(3) 2.688(4) 137.(4) 
N2-H2...O3 0.84(2) 2.08(3) 2.879(4) 160.(4) 
C2-








C7-H7...O1 0.95 2.58 3.202(4) 123.7 
C20-
H20B...O1 0.98 2.58 3.508(5) 157.2 
 
 
Synthesis of Ac-Ile-3-I-Dap -Pro-D-Ala-Ala-Ala Peptide, Figure 3.9:  
Compound 6l was installed into a peptide as described: Following standard Fmoc-SPPS 
protocols, peptide precatalyst 6l, with the sequence, Ac-Ile-3-I-Dap -Pro-D-Ala-Ala-Ala, 
was prepared on solid support using the commercially available Rink Amide MBHA 
resin (200 mg, 0.3–0.8 meq/g, 200-400 mesh). Rink Amide MBHA resin comes pre-
loaded with an Fmoc-protected amine for the preparation of C-terminal amide peptides. 
Therefore, amino acid residues were built on the solid support beginning at the C-
terminus, more specifically Ala-Ala-D-Ala-Pro-3-I-Dap-Ile. Double couplings were 
achieved using a 5 equiv. excess of the appropriate Fmoc-amino acid, HCTU as the 
coupling agent, and DIPEA in DMF as the solvent. Fmoc-deprotections were completed 
upon triple treatments with a basic solution of 20% 4-methylpiperidine in DMF. A step-
wise procedure for the Fmoc-solid-phase synthesis of the peptide is given below. 
Resin Swelling: The Rink Amide MBHA resin (200 mg) was added to the barrel of a 10 
mL fritted syringe and swelled by a 4 mL DCM wash, followed by soaking for 5 min. in 
an additional 5 mL of DCM. The residual DCM was purged from the syringe and the 
resin was washed with DMF (3 x 4 mL).  
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Fmoc-Deprotection: The initial Fmoc-deprotection of the Rink Amide resin was 
performed by three sequential one-min treatments with 2 mL of 20% 4-methylpiperidine 
in DMF solution. The deprotected resin was then washed three times with 5 mL of DMF, 
resulting in a free amine ready for the first amino acid coupling.  
 
Amino acid couplings: The peptide was assembled on the solid-support beginning at the 
C-terminus. Therefore, 5 equiv. (relative to resin loading) of Fmoc-L-alanine, HCTU, and 
DIPEA were added to a 3 ml screw-top vial. The solids were then dissolved in 1 mL of 
DMF. This prepared mixture was then taken up into the fritted syringe, containing the 
resin, and agitated for 2 min. This first coupling mixture was then ejected. The resin was 
subsequently treated with a second aliquot of the Fmoc-L-alanine amino acid mixture for 
2 min. Following this double amino acid coupling procedure, the resin was once again 
washed with DMF (3 x 5 mL). The Nα-Fmoc group was then removed following the 
above described Fmoc-deprotection protocol in order to achieve the next amino acid 
residue coupling of another Fmoc-L-alanine residue. This deprotection-coupling pattern 
was repeated until the desired amino acid residues were assembled as follows: Resin-Ala-
Ala-D-Ala-Pro-3-I-Dap-Ile. Where the 3-I-Dap amino acid residue represents the 
incorporation of Catalyst 1a as its Fmoc-SPPS ready derivative 3-iodoarene-Nα-Fmoc-L-
diaminopropionic acid, 6l.  
 
N-terminal Acetate Capping: The fully assembled peptide, sequence Ile-3-I-Dap -Pro-D-
Ala-Ala-Ala, was N-caped with an acetate group following double, 5 min, treatments 
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with a 4 mL aliquot of a 5% acetic anhydride in DMF solution. After the allotted time for 
the double treatment, the solution was ejected from the syringe into a waste container and 
the resin was washed with DMF (3 x 5 mL).  
 
Peptide Cleavage and Isolation: Following N-terminal acetate capping of the resin-bound 
peptide, the resin was washed with DCM (3 x 5 mL), and methanol (3 x 5 mL). The resin 
was dried in a vacuum oven at room temperature for 24 h. The resin-bound peptide was 
cleaved from and R-side chain deprotected via a 2 h treatment with an acidic cleavage 
cocktail of trifluoroacetic acid: H2O: triisopropylsilane (95:4.5:0.5). Following, 
evaporation of the cleavage cocktail and precipitation with ice cold ether, the peptide was 
isolated as a white powdery solid and characterized by MALDI-TOF mass spectrometry. 
Ac-Ile-3-I-Dap -Pro-D-Ala-Ala-Ala peptide precatalyst as shown in Figure 3.9: white 




A representative procedure for the n-butyl amidation of Catalysts 4a-4h is as follows, 
using the starting materials for Catalyst 4a as an example337:  
To a flame dried round bottom flask was added 3-amino-2-iodobenzoic acid 4aa 
(1.1 g, 4.18 mmol, 1.0 equiv) and triethylamine (1.17 mL, 8.4 mmol, 2.0 equiv) in 












1.) NEt3, Dry DCM
SOCl2 (0ºC)














for 5 min at room temperature under nitrogen.  The solution was cooled to 0 °C. Thionyl 
chloride (0.34 mL, 4.6 mmol, 1.1 equiv) was slowly added (dropwise over 20 min), and 
the resulting solution was allowed to stir at 0 °C for 1 h. The resulting mixture was 
brought to room temperature and stirred for 30 min. This solution was concentrated under 
vacuum and then redissolved in anhydrous DCM (40 mL). To this solution was added 
(dropwise over 10 min) 1-butylamine (0.45 mL, 4.6 mmol, 1.1 equiv), anhydrous DCM 
(20 mL), and triethylamine (1.17 mL, 8.4 mmol, 2.0 equiv). The resulting solution was 
stirred overnight at room temperature under nitrogen. The crude mixture was 
concentrated by rotary evaporation, diluted in DCM, and washed with 1 M HCl, and the 
aqueous layers were extracted with DCM (×3). The organic layers were washed with H2O 
(×2) and saturated brine (×1) and dried over sodium sulfate. The resulting product was 
filtered and concentrated by rotary evaporation. The crude product was purified by 
column chromatography on silica gel (Gradient to 95:5 DCM:MeOH + 2% NEt3) to give 
3-amino-N-butyl-2-iodobenzamide (4ab) as a yellow solid (0.98 g, 74%). 1H NMR (500 
MHz, MeOD): δ 0.98−1.01 (3H, t), 1.46−1.52 (2H, m), 1.60−1.66 (2H, m), 3.26−3.30 
(2H, q), 6.58-6.60 (1H, dd), 6.82-6.84 (1H, d), 7.12-7.15 (1H, d) ppm. 13C NMR (500 
MHz, CDCl3): δ 13.8, 20.1, 31.3, 39.7, 46.3 (residual DCM), 82.3, 115.3, 116.9, 129.0, 
143.8, 147.8, 170.4 ppm.  
 
A representative procedure for the acetylation of Catalysts 4a-4h is as follows, 
using Catalyst 4a as an example337:  
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3-amino-N-butyl-2-iodobenzamide 4ab (0.50 g, 1.06 mmol) in tetrahydrofuran 
(THF) (10 mL) was mixed with a mixture of acetic anhydride (1 mL, 10.6 mmol) and 
pyridine (86 μL, 1.06 mmol), and the mixture was stirred overnight at RT. The reaction 
mixture was then acidified with 1% HCl and the final product was extracted into ethyl 
acetate (3 X 20 mL). The organic phase was washed with brine, dried over sodium 
sulfate and concentrated in vacuo to give the crude product.  The crude product was 
purified by column chromatography on silica gel (Gradient to 50:50 EtOAc:Hex) to give 
Catalyst 4a as a yellow solid (0.53 g, 94%). IR (neat): 3264 (br), 2920 (s), 2851 (m), 
1643 (s), 1543 (m), 1454 (m), 1257 (m), 1092 (w), 1018 (s), 799 (s) cm-1. 1H NMR (500 
MHz, CDCl3): δ 0.95−0.98 (3H, t), 1.41−1.50 (2H, m), 1.60−1.63 (2H, m), 2.33 (3H, s), 
3.41-3.43 (2H, t), 6.28 (1H, s, br), 6.98-6.99 (1H, d), 7.20-7.29 (1H, m), 7.87-7.94 (1H, 
d)  ppm. 13C NMR (500 MHz, CDCl3): δ 13.8, 20.2, 24.6, 31.4, 39.8, 90.5, 123.6, 128.9, 
129.4, 139.0, 144.0, 168.8, 169.7 ppm.  
 
General Synthesis of Catalyst 4b (Org. Lett. 2018, 20, 2345-348): 
 
 
A representative procedure for diazotization/iodination is described using 4ba as 
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2-amino-4-nitro-carboxylic acid 4ba (1.82 g, 10 mmol) was added to a 100 mL 
round bottom flask.  To this flask was added conc. HCl (14 mL) and water (14 mL).  The 
suspension was cooled in an ice bath to 0 ℃. When cooled, sodium nitrite (0.83 g, 12 
mmol, 1.2 equiv.) in 5 mL of water was slowly added. The reaction was stirred for 30 
minutes at 0 ℃. Subsequently, KI (3.32 g, 20 mmol, 2 equiv.) in in 5 mL of water, was 
slowly (over 10 minutes) added to the solution. The reaction was heated to 90 ℃ for 90 
minutes. The reaction was cooled and quenched with a saturated solution of sodium 
sulfite, and then transferred to a 500 mL separatory funnel with ethyl acetate.  This was 
acidified with conc. HCl (pH~2). The product was extracted with EtOAc (3x) then dried 
over magnesium sulfate and filtered. The filtrate was concentrated and used without 
further purification to give 2-iodo-4-nitrobenzoic acid (4bb) as a yellow solid (0.98 g, 
72%). 1H NMR (500 MHz, MeOD): δ 5.04 (1H, br), 7.91-7.93 (1H, d), 8.28-8.29 (1H, d), 
8.75 (1H, s) ppm. 13C NMR (500 MHz, MeOD): δ 92.3, 122.5, 130.4, 135.1, 142.6, 
148.6, 167.4 ppm. 
 
A representative procedure for iron assisted nitro reduction is described using 4bb 
as the substrate (Org. Lett. 2011, 13, 24, 6488-6491): 
4-amino-2-iodobenzoic acid, 4bc: 
 To a two-neck round bottom flask was added a solution NH4Cl (0.547 g, 10.2 
mmol, 3 equiv.) in H2O (10 mL) and EtOH (10 mL).  To this was added iron powder 
(1.14 g, 20.5 mmol, 6 equiv.), and the suspension was warmed to 60 ℃ for 30 minutes.  
2-iodo-4-nitrobenzoic acid (4bb) (1g, 3.41 mmol, 1 equiv.) was then added in small 
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portions, and the reaction temperature was elevated to 80 ℃.  The reaction was 
monitored via TLC, and when the reaction was complete, the mixture was cooled in an 
ice bath (0 ℃) and basified with NaOH (5N, pH>7) and filtered to remove the excess 
iron powder.  The filtrate was evaporated via rotary evaporation, and the residue was 
acidified by 6N HCl (pH~3).  The mixture was then filtered again and washed with 
MeOH/DCM (v/v = 1/1).  The filtrate was concentrated to give 4-amino-2-iodobenzoic 
acid, 4bc (0.81 g, 90%).  1H NMR (500 MHz, MeOD): δ 6.63-6.65 (1H, d), 7.32 (1H, s), 
7.74-7.75 (1H, d) ppm. 13C NMR (500 MHz, MeOD): δ 95.8, 112.5, 120.5, 126.2, 132.7, 
152.7, 167.9 ppm. 
 
4-acetamido-2-iodobenzoic acid, 4bd: 
 4bd was synthesized using the representative procedure for the acetylation as 
stated above.  By using 4-amino-2-iodobenzoic acid (4bc) as the starting material, 4-
acetamido-2-iodobenzoic acid (4bd) was synthesized in a 90% yield (0.85 g). 1H NMR 
(500 MHz, MeOD): δ 2.15 (3H, s), 7.65-7.66 (1H, d), 7.84-7.86 (1H, d), 8.35 (1H, s) 
ppm. 13C NMR (500 MHz, MeOD): δ 22.6, 93.7, 118.0, 129.8, 131.3, 131.4, 142.1, 




4-acetamido-N-butyl-2-iodobenzoic acid, Catalyst 4b: 
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 Catalyst 4b was synthesized using the representative procedure for the n-butyl 
amidation as stated above by using 4-acetamido-2-iodobenzoic acid (4bd) as the starting 
material.  Catalyst 4b as a yellow solid (0.53 g, 79%). IR (neat): 3290 (br), 3263 (br), 
2928 (s), 2859 (w), 1636 (s), 1589 (m), 1519 (m), 1369 (m), 1300 (w), 1258 (m), 833 (s) 
cm-1. 1H NMR (500 MHz, CDCl3): δ 0.93−0.96 (3H, t), 1.40−1.44 (2H, m), 1.60−1.63 
(2H, m), 2.07 (3H, s), 3.36-3.40 (2H, t), 6.86 (1H, s, br), 7.00-7.02 (1H, d), 7.29-7.30 
(1H, d), 7.75 (1H, s), 9.40 (1H, br) ppm. 13C NMR (500 MHz, CDCl3): δ 13.8, 20.2, 24.4, 
31.4, 39.9, 92.2, 119.7, 127.9, 130.7, 137.3, 140.1, 169.7, 169.9 ppm. 
 
General Synthesis of Catalyst 4c: 
 
 
5-amino-2-iodobenzoic acid, 4cc: 
 By using 4ca as the substrate, and applying the representative procedure for 
diazotization/iodination, followed by the iron assisted nitro reduction, as described above, 
gave the product (without purification) 5-amino-2-iodobenzoic acid (4cc) in a 65% yield 
(1.87 g) over the two steps.  1H NMR (500 MHz, MeOD): δ 8.01-8.05 (1H, d), 8.29-8.32 
(1H, d), 8.57 (1H, s) ppm. 13C NMR (500 MHz, MeOD): δ 101.6, 124.4, 125.7, 137.6, 
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By using 4cc as the substrate and applying the representative procedure for the n-
butyl amidation as described above, 5-amino-N-butyl-2-iodobenzamide (4cd) was 
synthesized (76%, 0.92 g).  1H NMR (500 MHz, MeOD): δ 0.99-1.05 (3H, m), 1.38-1.47 
(2H, m), 1.52-1.67 (2H, m), 3.31-3.51 (2H, m), 7.25 (1H, br), 7.82-7.89 (2H, m), 8.22 
(1H, s) ppm. 13C NMR (500 MHz, MeOD): δ 12.8, 19.8, 31.2, 39.5, 93.3, 126.1, 129.9, 
135.9, 136.5, 140.1, 166.9 ppm. 
 
5-acetamido-N-butyl-2-iodobenzoic acid, Catalyst 4c: 
By using 4cd as the substrate and applying the representative procedure for the 
acetylation as described above,  Catalyst 4c was synthesized (84%, 0.92 g).  IR (neat): 
3746 (w), 2955 (w), 2924 (w), 2866 (w), 1670 (s), 1589 (s), 1466 (m), 1385 (w), 829 (m) 
cm-1. 1H NMR (500 MHz, CDCl3): δ 0.98−1.00 (3H, t), 1.44−1.50 (2H, m), 1.64−1.68 
(2H, m), 2.18 (3H, s), 3.44-3.48 (2H, t), 6.09 (1H, s, br), 7.18-7.20 (1H, d), 7.42-7.43 
(1H, d), 7.86 (1H, s), 8.38 (1H, br) ppm. 13C NMR (500 MHz, CDCl3): δ 13.8, 20.2, 24.5, 
31.4, 39.9, 92.3, 119.8, 128.2, 130.8, 137.5, 139.9, 169.2, 169.6 ppm. 
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A representative procedure for the hydrolysis of methyl esters is illustrated with -
4-amino-3-iodobenzoic acid (4db) (J. Comb. Chem. 2004, 6, 3, 407-413.): 
To a 150 mL round bottom flask was added KOH (6.9 mmol, 0.39 g, 1 equiv.) 
in 50 mL of MeOH/H2O (v/v = 1/1).  To this solution was added 4da (6.9 mmol, 1.9 g, 
1 equiv.). The resulting mixture was heated at 75 °C for 20 h. The reaction mixture was 
concentrated in vacuo to one-half of its original volume. The residue was acidified 
(pH~4) with 1 N HCl. The white precipitate was collected by filtration and then dried 
under vacuum to give 4db (99%, 1.78 g) as an off-white powder. 1H NMR (500 MHz, 
MeOD): δ 6.77-6.78 (1H, d), 7.76-7.77 (1H, d), 8.27 (1H, s). 13C NMR (150 MHz, 
MeOD) δ 80.2, 112.5, 119.8, 130.9, 141.1, 152.6, 167.6 ppm. 
 
4-amino-N-butyl-3-iodobenzamide, 4dc: 
By using 4db as the substrate and applying the representative procedure for the n-
butyl amidation as described above, 5-amino-N-butyl-2-iodobenzamide (4dc) was 
synthesized (84%, 1.02 g).  1H NMR (500 MHz, CDCl3): δ 0.86-0.87 (3H, m), 1.31 (2H, 
m), 1.49-1.50 (2H, m), 3.32 (2H, m), 4.51 (2H, s), 6.47 (1H, br), 6.62-6.64 (1H, d), 7.50-
7.52 (1H, d), 8.04 (1H, s) ppm. 13C NMR (500 MHz, CDCl3): δ 13.8, 20.2, 31.8, 39.8, 
82.8, 113.4, 125.6, 128.4, 138.2, 149.7, 166.1 ppm. 
 
4-acetamido-N-butyl-3-iodobenzamide, Catalyst 4d: 
By using 4db as the substrate and applying the representative procedure for the 
acetylation as described above, Catalyst 4d was synthesized (84%, 1.02 g).  IR (neat): 
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3259 (br), 2955 (w), 2924 (w), 1663 (s), 1632 (s), 1516 (s), 1373 (m), 1296 (m), 1038 
(m), 883 (w) cm-1.  1H NMR (500 MHz, CDCl3): δ 0.96-0.98 (3H, m), 1.38-1.46 (2H, m), 
1.58-1.64 (2H, m), 2.28 (3H, s), 3.43-3.47 (2H, m), 6.33 (1H, br), 7.63 (1H, s), 7.66-7.68 
(1H, d), 8.26-8.29 (1H, d) ppm. 13C NMR (500 MHz, CDCl3): δ 13.8, 20.2, 25.0, 31.7, 
39.6, 89.3, 120.6, 127.4, 131.8, 138.1, 140.7, 165.4, 168.5 ppm. 
 
General Synthesis of Catalyst 4e (Chem. Eur. J. 2009, 15, 9424 – 9433): 
 
3-amino-5-nitribenzoic Acid, 6p: 
In a 100 ml round bottom flask was added 3,5- dinitrobenzoic acid 6o (1 g, 4.7 
mmol) and 20 ml glacial acetic acid. This heterogeneous mixture was slowly heated up to 
120 °C, and turned to homogeneous as the temperature increased. After the temperature 
of solution increased to 120 °C, Fe powder (0.77 g, 13.8 mmol) was added with stirring 
(this was added over ten portions within 30 minutes). The reaction mixture was kept at 
120 °C for 15 min, and then poured over ice and water, followed by extracted with ethyl 
acetate (x3). The organic phase was washed saturated aqueous Na2CO3 (x3) and brine 
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(x1), dried over sodium sulfate and concentrated in vacuo to give 6p as a yellow powder 
(0.39 g, 45%). 1H NMR (500 MHz, MeOD): δ 8.65 (1H, s), 8.72 (1H, s), 8.74 (1H, s) 
ppm. 13C NMR (500 MHz, CDCl3): δ 92.9, 123.2, 133.8, 135.5, 143.7, 148.5, 164.5 ppm. 
 
3-iodo-5-nitrobenzoic acid, 6q: 
 By using 6p as the substrate, and applying the representative procedure for 
diazotization/iodination, as described above, the product 6q was synthesized in a 59% 
yield (2.6 g). 1H NMR (500 MHz, DMSO): δ 7.49 (1H, s), 8.59-8.61 (1H, s), 8.70 (1H, s) 
ppm. 13C NMR (500 MHz, DMSO): δ 93.5, 123.8, 134.4, 135.5, 144.2, 148.4, 164.8 
ppm. 
 
3-amino-5-iodobenzoic acid, 6r: 
Compound 6q (1.3 g, 4.4 mmol) was dissolved in 20 ml conc. ammonia. To this 
solution, (NH4)2Fe(SO4)2 (10.5 g, 26.7 mmol) in 20 ml H2O was added. After refluxing 
for 10 min, the mixture was filtered through celite and the solution was cooled down to 
ambient temperature. The pH of the solution was adjusted to ~4 with conc. HCl and then 
extracted with ethyl acetate (x3). The combined organic layers were washed with brine 
(x1), dried over sodium sulfate and evaporated in vacuo to give 6r as a yellow solid (1.2 
g, 68%). 1H NMR (500 MHz, MeOD): δ 7.24 (1H, s), 7.29 (1H, s), 7.57 (1H, s) ppm. 13C 




3-acetamido-5-iodobenzoic acid, 6s: 
 6s was synthesized using the representative procedure for the acetylation as stated 
above.  By using 6q as the starting material, 6s was synthesized in a 73% yield (0.85 g). 
1H NMR (500 MHz, MeOD): δ 2.01 (3H, s), 8.03 (1H, s), 8.13 (1H, s), 8.30 (1H, s) ppm. 
13C NMR (500 MHz, MeOD): δ 23.9, 94.1, 121.1, 133.4, 134.3, 134.7, 141.4, 167.8, 
171.9 ppm. 
 
3-acetamido-N-butyl-5-iodobenzamide, Catalyst 4e: 
 Catalyst 4e was synthesized using the representative procedure for the n-butyl 
amidation as stated above by using 6s as the starting material.  Catalyst 4e (0.53 g, 64%). 
IR (neat): 3279 (br), 2955 (w), 2928 (w), 2866 (w), 1635 (m), 1589 (m), 1535 (s), 1312 
(m), 1280 (m), 1258 (m), 867 (m) cm-1. 1H NMR (500 MHz, CDCl3): δ 0.88−0.91 (3H, 
t), 1.32−1.37 (2H, m), 1.53−1.57 (2H, m), 2.13 (3H, s), 3.34-3.36 (2H, m), 7.13 (1H, s, 
br), 7.68 (1H, s), 7.87 (1H, s), 8.14 (1H, s), 9.50 (1H, br) ppm. 13C NMR (500 MHz, 
CDCl3): δ 0.88−0.91 (3H, t), 1.32−1.37 (2H, m), 1.53−1.57 (2H, m), 2.13 (3H, s), 3.34-
3.36 (2H, m), 7.13 (1H, s, br), 7.68 (1H, s), 7.87 (1H, s), 8.14 (1H, s), 9.50 (1H, br) ppm 
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 4fb was synthesized using the representative procedure for the acetylation as 
stated above.  By using 4fa as the starting material, 4fb was synthesized in 87% yield 
(0.53 g). 1H NMR (500 MHz, MeOD): δ 2.21 (3H, s), 7.85-7.87 (1H, d), 8.36-8.39 (2H, 
m) ppm. 13C NMR (500 MHz, MeOD): δ 25.1, 85.9, 119.4, 123.3, 140.9, 142.1, 143.8, 
169.9, 171.4 ppm. 
 
2-acetamido-N-butyl-5-iodobenzamide, Catalyst 4f: 
 Catalyst 4f was synthesized using the representative procedure for the n-butyl 
amidation as stated above by using 4fb as the starting material.  Catalyst 4f (0.53 g, 
64%). IR (neat): 2955 (w), 2932 (w), 2870 (w), 1670 (s), 1589 (s), 1466 (m), 1385 (w), 
1339 (w), 1278 (w), 829 (m) cm-1. 1H NMR (500 MHz, CDCl3): δ 0.98−1.01 (3H, t), 
1.42−1.50 (2H, m), 1.68−1.74 (2H, m), 2.64 (3H, s), 4.06-4.09 (2H, m), 7.32-7.34 (1H, 
d), 7.95-7.97 (1H, d), 8.57 (1H, s) ppm. 13C NMR (500 MHz, CDCl3): δ 13.9, 20.2, 24.4, 




General Synthesis of Catalyst 4g: 
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3-amino-4-iodobenzoic acid, 4gb: 
Using the representative procedure for the hydrolysis of methyl esters, 4gb was 
synthesized (99%, 1.75 g) as an off yellow powder. 1H NMR (500 MHz, MeOD): δ 
7.03-7.04 (1H, d), 7.44 (1H, s), 7.71-7.72 (1H, d). 13C NMR (150 MHz, MeOD) δ 88.3, 
114.9, 119.2, 131.6, 138.8, 148.3, 168.4 ppm. 
 
3-amino-N-butyl-4-iodobenzamide, 4gc: 
By using 4gb as the substrate and applying the representative procedure for the n-
butyl amidation as described above, 5gc was synthesized (74%, 0.98 g).  1H NMR (500 
MHz, CDCl3): δ 0.92-0.97 (3H, m), 1.34-1.39 (2H, m), 1.41-1.59 (2H, m), 3.37-3.44 (2H, 
m), 4.31 (2H, s), 6.34 (1H, br), 6.74-6.78 (1H, d), 7.21 (1H, s), 7.63-7.66 (1H, d) ppm. 
13C NMR (500 MHz, CDCl3): δ 13.8, 20.2, 31.7, 39.8, 87.3, 113.2, 117.2, 136.2, 139.0, 
147.2, 167.1 ppm. 
 
3-acetamido-N-butyl-4-iodobenzamide, Catalyst 4g: 
By using 4gb as the substrate and applying the representative procedure for the 
acetylation as described above, Catalyst 4g was synthesized (86%, 0.82 g).  IR (neat): 
2955 (w), 2924 (w), 2867 (w), 2465 (br), 2403 (br), 1628 (s), 1558 (m), 1447 (s), 1396 
(w), 1280 (m), 1014 (s), 752 (s) cm-1.  1H NMR (500 MHz, MeOD): δ 0.96-0.99 (3H, m), 
1.39-1.44 (2H, m), 1.59-1.62 (2H, m), 2.21 (3H, s), 3.35-3.81 (2H, m), 7.39-7.42 (1H, d), 
7.88 (1H, s), 7.97-7.99 (1H, d) ppm. 13C NMR (500 MHz, MeOD): δ 12.8, 19.8, 21.9, 
31.2, 39.5, 98.9, 125.6, 126.0, 135.5, 139.3, 139.5, 167.4, 170.8 ppm. 
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By using 4ha as the substrate and applying the representative procedure for the n-
butyl amidation as described above, 4hb was synthesized (76%, 0.67 g).  1H NMR (500 
MHz, CDCl3): δ 0.98-1.01 (3H, m), 1.42-1.47 (2H, m), 1.60-1.65 (2H, m), 3.44-3.48 (2H, 
m), 6.24 (1H, br), 7.10-7.11(1H, d), 7.17-7.18 (1H, d), 7.36 (1H, s), 744.-7.46 (1H, m) 
ppm. 13C NMR (500 MHz, CDCl3): δ 13.8, 20.2, 31.4, 39.9, 99.3, 114.5, 119.9, 130.3, 
131.7, 150.6, 167.5 ppm. 
 
2-acetamido-N-butyl-4-iodobenzamide, Catalyst 4h: 
By using 4hb as the substrate and applying the representative procedure for the 
acetylation as described above, Catalyst 4h was synthesized (90%, 0.82 g).  IR (neat): 
3340 (br), 2958 (m), 2870 (w), 1682 (s), 1543 (m), 1501 (s), 1396 (s), 1273 (m), 1153 
(w), 775 (w) cm-1.  1H NMR (500 MHz, CDCl3): δ 0.98-1.01 (3H, m), 1.42-1.48 (2H, m), 
1.62-1.67 (2H, m), 2.20 (3H, s), 3.44-3.47 (2H, m), 6.39 (1H, br), 7.12-7.14 (1H, d), 7.39 
(1H, s), 7.41-7.42 (1H, d), 8.99 (1H, br) ppm. 13C NMR (500 MHz, CDCl3): δ 13.8, 20.2, 
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General procedure for azido acid synthesis by diazo transfer330, 342:  
Triflyl azide preparation using 7r as an example:  
 
To a round bottom flask was added sodium azide (3.94 g, 6.05 mmol) was added 
distilled H2O (15 mL) and DCM (30 mL).  This solution was cooled to 0 ℃, and stirred 
for 20 minutes.  Triflyl anhydride (2.04 mL, 12.1 mmol) was added slowly over 10 min 
with stirring continued for 2 h. The mixture was placed in a separatory funnel and the 
DCM phase removed. The aqueous portion was extracted with DCM, and the organic 
fractions, containing the triflyl azide, were combined and washed with saturated Na2CO3 
(x1) and used without further purification.  
In a separate round-bottomed flask was added the L-phenylalanine 7q (1.0 g, 6.05 
mmol), K2CO3 (1.67 g, 12.1 mmol), Cu(II)SO4 pentahydrate (9.66 mg, 60.5 μmol), 
distilled H2O (9 mL) and MeOH (18 mL). The triflyl azide from the previous step was 
dissolved in DCM (15 mL) and was added to this separate flask. The mixture was stirred 
at ambient temperature and pressure overnight. Subsequently, the organic solvents were 
removed under reduced pressure and the aqueous slurry was diluted with H2O (50 mL). 













buffer (50 mL) and extracted with EtOAc to remove sulfonamide by-product. The 
aqueous phase was then acidified to pH 2 with conc. HCl. The product was obtained from 
another round of EtOAc extractions.  The EtOAc extracts were combined, dried (Na2SO4) 
and evaporated to dryness giving 0.71 g of the pale oil (7r) in 61% yield with no need for 
further purification. 
1H NMR (300 MHz, CDCl3) δ 11.4 (1H, br), 7.31-7.40 (m, 5H), 3.25-3.24 (dd, J = 5.0, 
8.8 Hz, 1H), 3.05-3.05 (dd, J = 5.0, 13.9 Hz, 1H) ppm. 
13C NMR (100 MHz, CDCl3) δ 174.3, 136.0, 129.3, 128.7, 127.3, 63.1, 37.4 ppm. 
 
The procedure above was used to generate L-phenylglycine (8k) and L-tert-Leucine (8l) 
azide derivatives.329 
L-phenylglycine azide (8k),Yellow oil, in 75%: 1H NMR (300 MHz, CDCl3) δ 
11.9 (1H, br), 7.50-7.46 (m, 5H), 5.13 (s, 1H) ppm.13C NMR (100 MHz, CDCl3) δ 174.9, 













L-tert-Leucine azide (8l), clear oil in 73%: 1H NMR (300 MHz, CDCl3) δ 11.66 
(1H, br), 3.75 (s, 1H), 1.08 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 175.6, 71.7, 35.7, 
26.5. 
 
N-(2,4-dimethoxybenzyl)propargylamine hydrochloride (7u)329: Propargylamine (2.0 g, 
36.2 mmol) and 2,4-dimethoxybenzaldehyde (5.0 g, 30.2 mmol) were dissolved in 
anhydrous MeOH (100 mL) and stirred for 2 h. To the resulting clear solution was added 
sodium borohydride (2.0 g, 54.0 mmol) in several portions. The suspension was stirred 
for 2 h. After dilution with ether (200 mL), 2 M NaOH (40 mL) was added to quench the 
reaction. The organic layer was washed with water (x2), brine, and dried over Na2SO4. 
After filtration the volatiles were evaporated in vacuo and the sticky residue was 
dissolved in methanol (50 mL). To this 12 M HCl (4 mL) was added and the volatiles 
were removed under reduced pressure. The residue was dissolved in MeOH/EtOAc (1:4, 
80 mL) followed by addition of hexanes (ether can be added to induce crystallization). 
The resulting crystals were collected by filtration and dried to give 7u (6.7 g, 92%) as its 
HCl salt. 1H NMR (500 MHz, MeOD) δ 7.31-7.30 (1H, d, J = 8 Hz), 6.67 (1H, s), 6.61-












3.29-3.28 (t, J = 3 Hz, 1H); 13C NMR (100 MHz, MeOD) δ 161.1, 157.8, 132.2, 108.6, 
103.9, 97.5, 78.7, 71.9, 57.2, 55.8, 44.7, 35.7. 
 
General procedure for amino acid coupling toward macrocycles329: In a round bottom 
flask was added the carboxylic acid component (1.1 eq) and DCM/DMF (4:1) at a 
concentration ~0.4 M.  To this solution was added DIPEA (2.2 eq). The solution was 
cooled to 0ºC and HATU (1 eq) was added. This solution was stirred at 0 ºC for 10 
minutes at, and then a solution of the amine component (1 eq) in DMF at a concentration 
of ~0.5 M was added. The reactions were reacted at 0 ºC and followed by TLC until 
complete.  Work-up was accomplished by diluting the reaction mixture with EtOAc 
followed by successive washing with 0.5 M KHSO4 (3×) and brine. After drying with 
Na2SO4 and filtration, the solvents were removed via rotary evaporation and the residue 
was purified by flash chromatography (gradient up to 50:50 EtOAc/Hexanes) or moved 
on to the next step without purification. 
 
General procedure for the Fmoc deprotection: In a round bottom flask was added the 
Fmoc-protected peptide.  This was dissolved in acetonitrile / diethylamine (2:1) 
(concentration ~0.1 M) and then stirred for 1 hr, and concentrated under vacuum. The 
resulting residue was exchanged with acetonitrile (x3) to remove excess diethylamine and 
used directly in the next coupling step. 
General procedure for Copper(II) catalyzed macrocyclization via Click reaction331-333:  
 169 
Azido-alkyne 7x (1 equiv) was dissolved in H2O and tert-butanol (2:1) at a concentration 
of 1 mM. An aqueous solution of CuSO4∙5H2O (1M, 20 mL) and sodium ascorbate (1 M, 
100 mL) were added. After stirring at room temperature for 12 h, water (50 mL) was 
added and the mixture was extracted with ethyl acetate (3 x 20 mL). The combined 
organic layers were washed with brine (20 mL), dried with Na2SO4, concentrated, and the 
residue was purified by flash column chromatography (gradient up to 1:9 MeOH/DCM) 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3-Iodoaryl-Z-L-Orn-Amino Methyl Ester, Catalyst 1d 
 
 




































































































































































































































































































































































































































































































































































































Iodo-2-methoxy-arene-Z-L-Dab-Amino Methyl Ester, Catalyst 2b 
 





















































































































































































































































































































































5-Iodo-2-methoxy-Iodoarene-Z-L-Lys-Amino Methyl Ester, Catalyst 2c 








































































































































































































































































































































































































































































































































































































































































































































5-Iodo-2-methoxy-4-methyl -Z-L-Lys-Amino Methyl Ester, Catalyst 3c 
 































































































































































































































































































































































































































































































































































































































































































































































4-amino-2-iodobenzoic acid, 4bc 
  






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SP−4−43 (1H) (MeOD) (300 Bruker)





















































3-amino-5-iodobenzoic acid, 6r (Scheme 3.17) 
  






































































































































SP−4−44 (1H) (MeOD) (300 Bruker) 






























































SP−4−44 (13C) (MeOD) (300 Bruker) 
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3-acetamido-5-iodobenzoic acid, 6s (Scheme 3.17) 
 
  




























































































































SP−4−45 (1H) (MeOD) (500 Bruker)



























































3-acetamido-N-butyl-5-iodobenzamide, Catalyst 4e (Scheme 3.17) 
























































































































































































































































SP−4−41 (1H) (MeOD) (500 Bruker)





























































2-acetamido-N-butyl-5-iodobenzamide, Catalyst 4f 
 
  



















































































































































SP−4−42 (1H) (CDCl3) (Fr. 13−21) (500 Bruker)


















































































3-amino-4-iodobenzoic acid, 4gb 
 
  




















































































3-amino-N-butyl-4-iodobenzamide, 4gc  
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IODOARENE-CONTAINING BIODEGRADABLE X-RAY MATERIALS  
 
4.1 INTRODUCTION 
Synthetic materials exhibiting contrast imaging properties have become vital to 
the field of biomedical imaging. However, polymeric biomaterials typically lack imaging 
contrast properties for deep tissue imaging. This chapter details the synthesis and 
characterization of a suite of aryl-iodo monomers, which were used to prepare iodinated 
polyesters using a pre-functionalization approach. Commercially available 4-iodo-
phenylalanine or 4-iodobenzyl bromide served as the starting materials for the synthesis 
of three iodinated monomeric moieties (a modified lactide, morpholine-2,5-dione, and 
caprolactone), which under a tin-mediated ring-opening polymerization (ROP), generated 
their respective polyesters (PE) or poly(ester amides) (PEA). An increase in X-ray 
intensity of all synthesized iodine-containing polymers, in comparison to noniodinated 
poly(lactic acid) (PLA), validated their functionality as radio-opaque materials. The 
iodinated-poly(lactic acid) (iPLA) material was visualized through varying thicknesses of 





4.2 MEDICAL IMAGING AND X-RAYCONTRAST AGENTS 
 
Medical imaging, a technique that provides structural visualization inside the body, aides 
in the study of specific morphological changes within living and nonliving systems.343, 344  
One particular imaging modality, X-ray radiography, is frequently used as a diagnostic 
tool for noninvasive, in vivo, real-time examinations of three-dimensional opaque objects. 
X-ray imaging can be used to monitor response, degradation, and defects of biomedical 
devices.345  Concerns over the long-term stability of prolonged or permanent implantable 
devices have led to the development of polyester-based materials due to their desirable 
properties (i.e. biocompatibility, biodegradability, and facile synthesis).346-351  The 
evolution of biodegradable polyester devices, like staples, stents, sutures, and implants, 


















































Figure 4.1 Utilizing iodinated monomers for X-ray enhancements
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have had a significant impact on the biomedical field.346, 352, 353  Perhaps the most 
noteworthy advantage is their ability to be degraded and excreted from the body, 
obviating the need for their removal or surgical revision. This can be vital in major 
surgical procedures such as fracture fixation, spinal fixation, and abdominal wall 
repair.346, 353  While commercially available polyester devices have seen a considerable 
amount of use in the biomedical field, their in vivo performance can be difficult to predict 
and evaluate due to the complex biological environment associated with tissues.353, 354  
Therefore, the real-time monitoring of these devices is critical in order to understand their 
performance and fate in the body. The major drawback of polyester-based devices is that 
they lack inherent contrast imaging properties, making it difficult to visualize the area of 
interest. Imaging techniques are useful only when the intensity of a signal is sufficient 
enough to distinguish the target from surrounding tissues or materials. This issue 
becomes even more evident when imaging materials through deep tissue or when 
monitoring minor defects in biomaterials.355  Recent advancements have addressed such 
problems through the improvement of contrast-enhancing agents, which can enrich the 
quality of images.346 Iodine-containing small organic compounds remain at the forefront 
as contrast media due to the ability of heavy iodine atoms to highly absorb X-rays. With 
this overall strategy in mind, Van Horn, Whitehead, and Alexis have generated 
degradable iodine-bearing polyesters by utilizing conjugation strategies356 and oxime 
“Click” ligation reactions.357  More recently, this group has conducted a post-
polymerization modification reaction between poly(e-caprolactones) and iodinated 
hydroxylamines.358  The modified poly(e-caprolactones) displayed an increase in X-ray 
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contrast when compared to previously reported monoiodinated materials. Our strategy 
builds upon these reports, in which we explored the ring-opening polymerization of 
mono-iodinated monomers, omitting the need for post-polymerization modification. 
Further, in contrast to the previous studies, the strategy employed herein hinges on the 
irreversible incorporation of the iodine-containing motif through the formation of key 
carbon-carbon bonds.  This report details the design, synthesis, and applicability of 
iodine-containing monomers for the synthesis of biocompatible polyesters as X-ray 
contrast imaging agents.  
 
4.3 DESIGNING BIODEGRADABLE X-RAY CONTRAST AGENTS 
 
We designed four target monomers each bearing a 4-iodobenzyl moiety to impart X-ray 
opacity of the resulting polymer materials. Specifically, we designed lactide 4c, 
morpholinediones 4e and 4f, and caprolactone 4j (Scheme 4.1). These monomers were 
designed with the twin goals of maintaining high reactivity in the tin-catalyzed 
polymerization reaction, but also incorporated the aryl-iodo motif by the formation of a 
stable, non-reversible carbon-carbon bond. The syntheses of lactide 4c and 
morpholinediones 4e and 4f all commenced with commercially available 4- 
iodophenylalanine (4a). Lactide 4c was synthesized in two steps. 
Diazotization/hydrolysis of 4a to provide the a-hydroxy carboxylic acid 4b was followed 
by acylation/substitution with 2-bromopropionyl chloride, thus resulting in 4-iodo-benzyl 
lactide 4c (34–43% over two steps). The methyl substituted morpholinedione 4e (42–48% 
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over two steps) and non-substituted derivative 4f (35–41% over two steps) were 
synthesized through an acylation/base-induced cyclization sequence employing 2-
bromopropionyl chloride and chloroacetyl chloride, respectively. Lastly, the 4- iodo-
benzyl-caprolactone 4j was assembled in three straightforward steps. First, pyrrolidine 
and cyclohexanone were refluxed in toluene to afford enamine 4h in 87–94% yield. 
Second, the aryliodo moiety was incorporated via enamine alkylation with 4-iodo-
benzylbromide to provide substituted ketone 4i in 71% yield. The final step supplied the 
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with m-chloroperbenzoic acid. The corresponding polyesters were synthesized using 
standard ring-opening polymerization techniques (Scheme 4.2).  
 
 
To target a predictable ratio of copolymers, a conventional thermal ring-opening 
polymerization with tin(II) 2-ethylhexanoate was exploited.346, 359 Isolation of the final 
products was carried out by means of precipitation in cold methanol followed by 
centrifugation at –9 ˚C for 5 min followed by freeze-drying for 3 days. The polymers 
were then stored –20 ˚C before use. The resulting iodinated polyesters were characterized 
by 1H NMR and FTIR spectroscopy. An illustrative example of the 1H NMR and FTIR 
spectra comparing the iodinated and non-iodinated poly(lactic) acid, along with its 
monomeric precursor 4c, can be seen in Figure 4.2. The presence of the 4-iodobenzyl 
moiety in monomeric aryl-iodo lactide 4c is readily apparent based on the downfield 













Iodinated Lactide (iLA 4c) Iodinated Polylactide (iPLA)
Scheme 4.2 Tin-mediated ring opening polymerization
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NMR spectrum, indicating that the aryl-iodo functionality is stable throughout the ring-
opening process. Additionally, the downfield shift of the alpha proton signal in the PLA 
spectra confirm successful polymerization (Figure 4.2 [A]). Furthermore, the FT-IR 
spectra displays a peak at 1755 cm-1 that corresponds to the carbonyl stretching frequency 
(Figure 4.2 [B]). A peak at 2955 cm-1 , corresponding to sp2 C-H stretches, is apparent in 







Next, the X-ray contrast properties of the synthesized iodinated polyesters were 
evaluated using X-ray imaging methodology (recorded in Hounsfield units). Figure 4.3 
illustrates that the aryliodo containing polymers have an increased relative X-ray 
intensity when compared to unmodified iodine-free PLA (Figure 4.3a). The significance 
of substituents on the polymeric backbone can be seen by comparing the substituted and 
Figure 1 [A] 1H NMR spectral overlay of (1a) lactide, (1b) aryl-
iodo lactide (iLA), (1c) poly(lactic) acid (PLA), and (1d) aryl-iodo 
poly(lactic) acid (iPLA). [B] FTIR characterization of the aryl-iodo 




non-substituted morpholinedione polyesters. The polymer of the iodine-containing 
modified morpholinedione (iPMMD), which bears an additional methyl-substituent, 
contains a lower iodine-weight concentration than the non-substituted iodinated polymer 
of morpholinedione (iPMD), and in theory should have a lower X-ray intensity. 
However, to our surprise, iPMMD is able to absorb X-rays more efficiently than the non-
methylated analog (iPMD). The iodinated lactide and substituted morpholinedione 
polyesters exhibited comparable X-ray intensities, which can be attributed to their similar 
chemical structures and molecular weights. The 4-iodobenzylcaprolactone (iCL) 
monomer, provided an iodine-containing poly(-e-caprolactone) (iPCL). Unlike 
commonly used PLA/PLG polymers, PCL polymers slowly degrade into less acidic, low 
molecular weight by-products, preventing the generation of a toxic environment.360 
Although the relative X-ray intensity of iPCL was lower than the iPLA and iPMMD 
materials, the access to a class of bioresorbable X-ray enhancing polycaprolactones may 











We selected the iPLA material for further studies based on its strong X-ray 
contrasting properties coupled with its relative ease of synthesis from economical, readily 
available starting materials. A poly(lactic acid) copolymer iPLA(iLA/LA) which 
incorporated a 50:50 ratio of non-iodinated lactic acid to iodinated lactic acid was 
generated, and was shown to have a comparable relative X-ray intensity (~2445 HU) to 
the fully iodinated PLA (~ 2450 HU). We were motivated by the fact that the copolymer 
could achieve similar X-ray intensity as the homopolymer iPLA, yet it bears only half the 
amount of iodine possibly due to higher reactivity with non-iodinated LA monomers 
resulting in a copolymer with a larger molecular weight than the iPLA homopolymer. To 
further investigate the strategy of incorporating non-iodinated subunits into contrast 
enhancing polymers, we copolymerized lactide with varying ratios of the iodinated 
monomer (Figure 4.3b). As expected, there was a direct correlation between the X-ray 
Figure 2 (a) Relative X-ray intensity of iodinated polymers compared to non-
iodinated PLA. (b) Relative X-ray intensity of iodinated and non-iodinated PLA 
copolymer with varying ratios
ure 4.3 
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intensity and the amount of iodinated monomer used. The resulting intensity values in 
Figure 4.3b are consistent with a gradual increase of iLA monomer in the 
copolymerization process of poly(lactic) acid. PLA (100% LA), PLA (iLA: LA; 25:75), 
PLA (iLA: LA; 50:50), PLA (iLA: LA; 75:25) showed ~ 1800 HU, ~ 6000 HU, ~ 10700, 
~ 18550 HU respectively. To validate the successful incorporation of iLA into the 
copolymer, we probed the relative X-ray intensity of the copolymerization at 6, 12, and 
24-hour time points (Figure 4.4a).  
The increase in X-ray intensity over time confirms the effective incorporation of 
iLA into the resulting copolymer. Figure 4.4b depicts the generated polymeric pellets 
used in the copolymerization time study, taking the noniodinated PLA with low contrast 
as a control showing the gradual increase in the intensity over reaction time. persistent 
obstacle frequently encountered in medical imaging is the visualization of biomedical 
devices through deep tissue. In order to explore the potential of the synthesized polymeric 
materials to help overcome this obstacle, in vitro imaging of iPLA powder was performed 
through varying thicknesses (i.e. 0, 2, and 5 cm) of chicken tissue. As seen in Figure 
4.4c, effective visualization of the iPLA material was observed through 5 cm-thick 










Lastly, the weight loss of iPLA was monitored over an eight-day period, giving a 
degradation profile as seen in Figure 4.5. The overall decrease of weight percentage 
confirms that the aryl-iodo functionality does not disrupt the biodegradability of the 
polymer, and the hydrolysis of ester bonds release water soluble monomers and 
Figure 3 Quantitative measurements of relative X-ray intensity. (a) Relative X-ray 
intensity of iodinated poly(lactic) acid (iPLA) synthesized using various reaction times, 
in comparison to iodinated polycaprolactone (iPCL). (b) Depiction of polymeric pellets 
(10 mg) composed of poly(lactic) acid (PLA), iodinated polycaprolactone (iPCL), and 
iodinated poly(lactic) acid (iPLA) copolymers synthesized using 6, 12, and 24 hours 




oligomers.361  As described in Figure 4.5, the degradation rate profile of iPLA gradually 



















A series of monomers bearing a 4-iodoobenzyl moiety (i.e. lactides, morpholines 
and caprolactones) were synthesized leveraging straightforward transformations to 
Figure 4 Degradation of iPLA pellets over time 
(days) which was incubated into PBS (pH 7.4) at 
37 oC
Figure 4.5 Degradation of iPLA pellets 
over time (days) which was incubated 
into PBS (pH 7.4) at ℃ 37 . 
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prepare biomaterials with X-ray contrast properties. Unlike post-polymerization 
functionalization methodology of biomaterials such as polyesters, it incorporates the 
critical iodine atom into each monomeric unit, therefore maximizing iodine content 
within the resulting polymer. The modified polyesters were evaluated as viable contrast 
X-ray imaging agents, with emphasis on their potential use in deep tissue imaging. The 
iodine-containing polyesters that exhibited the highest  
X-ray intensities were the modified iodo-morpholinedione polymer (iPMMD) and the 
iodopoly(lactic) acid (iPLA). Lastly, we probed the degradation profile of iPLA, and 
confirmed that the covalently bound iodine does not perturb the biodegradability of the 
polyester. Iodine containing X-ray contrast agents have demonstrated clinical relevance 
within the field of medical imaging. Iodinated polymeric contrast-enhancing materials, 
being biodegradable, and therefore less toxic, have the potential to further improve 
medical imaging capabilities. This work demonstrates a highly concise and easily 
modified strategy to synthesize biodegradable and biocompatible X-ray visible materials.  
 
4.5 FUTURE WORK 
Another potential application is to use polymers prepared from related functional 
monomers as nanoparticle drug carriers.362-365  Polyester-based nanoparticles can serve as 
a vehicle for drug delivery as they can supply therapeutic agents in a controlled manner, 
and biodegrade from the body after the drug is released.365, 366  Furthermore, polyesters 
are tunable scaffolds, in which many properties (i.e. thermal transitions, mechanical 
strength, degradability, crystallinity) can be tailored for various applications.366 
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In this respect, our polyester-based monomers can be functionalized with drug 
conjugates, including chemotherapeutics (e.g. doxorubicin and O6-benzylguanine) and 
antimicrobial agents (e.g. chlorinated hydantoins) (Figure 4.6).  As shown in Figure 4.6, 
functionalizing a polyester (i.e. lactide or caprolactone) with a carboxylic acid moiety, 
allows for an amine drug to be easily appended the side-chain of the polyester through a 
conventional amidation reaction.  With the drug is attached, the polyester can be 
polymerized by means of tin-mediated ring-opening polymerization (ROP), thereby 
creating a drug delivery platform.  Due to their biocompatible and biodegradable nature, 
polyester drug delivery platforms can reduce toxicity and minimize patient adverse 
effects, while also potentially elevating drug loading and therapeutic efficiency.366 Such 
an application has the ability to advance the field of medicine and improve upon the 
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4.6 Experimental Section 
Materials: All reagents and chemicals were obtained from commercial sources and used 
without further purification unless stated otherwise. Water was purified on a Millipore 
Direct-Q S Water Purification System. Acetonitrile was dried by refluxing over 
phosphorous pentoxide (P2O5) and distilling under nitrogen prior to use.  Lactic acid, 
synthesized monomers, and Na2SO4 were vacuum-dried overnight in the reaction vessel 
before use. All isolated products were purified by flash column chromatography using 
silica gel SDS 60 C.C. 40−63 μm. All known compounds and starting materials had 1H 
NMR and 13C NMR spectra consistent with previous literature reports.  1H and 13C NMR 
spectra were recorded at ambient temperature on a 500 MHz NMR spectrometer 
(Bruker). Proton and carbon chemical shifts were reported in parts per million (ppm) 
downfield from tetramethylsilane (TMS) with reference to the deuterated solvent as the 
internal standard (i.e., δ 7.26 ppm for 1H NMR, 77 ppm for 13C NMR in CDCl3). Data are 
presented as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, br = broad, m = multiplet), and coupling constants (J, in Hertz). 
Infrared (IR) spectra, reported in cm−1, were collected using a Shimadzu IRAffinity-1S 
Fourier transform spectrophotometer. Bands are characterized as strong (s), medium (m), 
weak (w), and broad (br).  Melting points were recorded on a DigiMelt MPA160 
apparatus. 
A Tingle 325MVET X-ray machine was used to perform the X-ray imaging  (51 kVp, 
300 mA, and 5 millisecond exposure time). Due to its lack of radio-opaque properties and 
frequent use in biomedical applications, PLA was chosen as the control.  All X-ray 
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images were processed, and image intensities quantified using ImageJ (NIH) normalized 




α-hydroxy-4-iodo-benzenepropionic acid (2); Typical Procedure[19]  
To a flame dried round bottom flask equipped with a stir bar was added 4-Iodo-L-
phenylalanine (17.2 mmol, 5.0 g, 1.0 equiv) and 0.5 M H2SO4 (34.4 mmol, 2.0 equiv).  
The reaction was stirred for 10 minutes or until the solution was homogeneous.  The 
solution was cooled to 0 ºC and a solution of sodium nitrite (7.1 g, 103 mmol, 6.0 equiv) 
in H2O (50 mL) was added dropwise.  The reaction was stirred at 0 ºC for an additional 4 
h, and then allowed to warm to room temperature.  The resulting solution was stirred at 
room temperature for 24 hours (monitored completion by TLC).  The reaction mixture 
was extracted with diethyl ether (3 x 50 mL), and the organic phases were combined and 
washed with brine (50 mL) and dried over anhydrous sodium sulfate.  The drying agent 
was filtered off, and the filtrate was concentrated in vacuo.  The crude product was 
recrystallized from hexane-diethyl ether to give α-hydroxy-4-iodo-benzenepropionic acid 
as a yellowish white solid (74%, 3.7 g). 
1H NMR (500 MHz, DMSO-d6): δ 2.75 (dd, 1H, 1J = 13.92 , 2J = 4.32 Hz), 2.93 (dd, 1H,  
1J = 13.7 , 2J = 8.3 Hz), 4.16 (dd, 1H, 1J = 7.9 , 2J = 4.4 Hz),7.06  (d, 2H, 1J = 7.8 Hz), 
7.62  (d, 2H, 1J = 7.8 Hz) ppm. 
13C NMR (125 MHz, DMSO-d6): δ 64.9, 70.6, 91.9, 131.9, 136.7, 137.9, 174.9 ppm.  
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(3S)-3-(4-iodobenzyl)-6-methyl-1,4-dioxane-2,5-dione (3); Typical Procedure[20]  
To a flame dried round bottom flask equipped with a stir bar and under argon was added 
α-hydroxy-4-iodo-benzenepropionic acid (5.1 mmol, 1.5 g, 1.0 equiv), triethylamine 
(0.79 mL, 5.6 mmol, 1.1 equiv), and dry MeCN (25 mL) while under argon.  This 
solution was cooled to 0 ºC, followed by the dropwise addition of 2-bromopropionyl 
chloride (0.57 mL, 5.6 mmol, 1.1 equiv).  The mixture was stirred for 30 min.  
Triethylamine (0.79 mL, 5.6 mmol, 1.1 equiv) was added and the reaction was stirred at 
70 ºC for 3-5 h.  The reaction was cooled to room temperature, quenched with 1M HCl 
(25 mL) and extracted with EtOAc (3 x 25 mL). The combined organic phases were 
washed with H2O (25 mL), brine (25 mL), and dried over anhydrous sodium sulfate.  The 
drying agent was filtered off, and the filtrate was concentrated in vacuo.  The crude 
product was purified by column chromatography (gradient 70:30 hexanes:EtOAc) as a 
yellow oil, which solidified upon storage in the freezer (M.p. 121-122 ºC, 58 %, 1.03 g). 
Rf = 0.26 (70:30 hexanes:EtOAc) 
1H NMR (500 MHz, CDCl3): δ 1.60 (d, 3H, 1J = 6.7 Hz), 3.19 (dd, 1H, 1J = 14.8 , 2J = 
7.5 Hz ), 3.40 (dd, 1H, 1J = 14.9, 2J = 4.0 Hz ) 4.96  (q, 1H 1J = 6.7 Hz), 5.06 (dd, 1H, 1J 
= 3.9 , 2J = 7.7 Hz), 7.08 (d,  1J = 8.3 Hz), 7.66 (d,  1J = 8.3 Hz) ppm. 
13C NMR (125 MHz, CDCl3): δ 15.9, 35.7, 72.5, 76.1, 93.1, 131.9, 134.2, 137.8, 166.0, 
166.7 ppm.  
IR (neat): 2995 (w), 2932 (w), 1769 (s), 1738 (s), 1485 (w), 1250 (s) cm−1.  
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(S)-2-((R)-2-bromopropanamido)-3-(4-iodophenyl)propionic acid (4); Typical 
Procedure[21-23]  
To a flame dried round bottom flask, equipped with a stir bar was added 4-Iodo-
L-phenylalanine (6.9 mmol, 2.0 g, 1.0 equiv), and 20 mL H2O:Et2O  (1:1 (V/V)).  To this 
solution was added 4 M NaOH (8 mL) and stirred until all solids dissolved; this solution 
was then cooled to 0 ºC.  In a separate flame dried vial was added 2-bromopropionyl 
chloride (0.76 mL, 7.6 mmol, 1.1 equiv) and 4 M NaOH (8 mL).  The vial solution was 
added (dropwise) to the round bottom flask while maintaining a temperature of 0 ºC and a 
pH of 11 throughout the addition (4 M NaOH added to maintain pH via dropping funnel) 
.  After completion of the reaction (monitored by TLC), the reaction was warmed to room 
temperature and the ether layer was separated in a separatory funnel.  The aqueous layer 
was acidified with concentrated HCl to pH of 1, and extracted with ethyl acetate (4 x 25 
mL).  The combined organic phases were washed with brine and dried over anhydrous 
sodium sulfate.  The drying agent was filtered off, and the filtrate was concentrated in 
vacuo.  The white, solid crude product was placed under high vacuum and used in next 
step without further purification. 
 
 (3S,6S)-3-(4-iodobenzyl)-6-methylmorpholine-2,5-dione (5); Typical Procedure[21-24] 
To a flame dried round bottom flask equipped with a stir bar was added crude (S)-2-((R)-
2-bromopropanamido)-3-(4-iodophenyl)propionic acid (6.8 mmol, 2.9 g, 1 equiv) and 
DMF (25-30 mL) followed by triethylamine (1.04 mL, 7.5 mmol, 1.1 equiv).  The 
mixture was heated to 90 ºC for 12 h under N2.  When reaction was completed 
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(monitored by TLC), the mixture was allowed to stand overnight in the freezer.  The 
crystallized salt and DMF/TEA were filtered, and the filtrate was concentrated in vacuo.  
Residual DMF was removed by adding toluene to the sample, followed by rotary 
evaporation (repeated 4 times).  Further purification was performed by recrystallizing in 
chloroform and cold Et2O to furnish a white solid (M.p. 147-148 ºC, 1.12 g, 48 % over 2 
steps). 
1H NMR (500 MHz, DMSO-d6): δ 1.13 (d, 3H, 1J = 6.9 Hz), 3.02 (d, 2H, 1J = 5.1 Hz), 
4.67 (t, 1H, 1J = 5.0 Hz ), 4.99  (q, 1H, 1J = 6.8 Hz), 7.09  (d, 2H, 1J = 8.1 Hz), 7.68 (d, 
2H, 1J = 8.2 Hz) ppm. 
13C NMR (125 MHz, CDCl3): δ 16.8, 36.1, 54.2, 74.6, 93.3, 132.7, 136.5, 137.4, 168.5, 
168.6 ppm.  
IR (neat): 3202 (br), 1747 (s), 1694 (s), 1483 (w), 1375 (m), 1315 (m) cm−1.  
 
(S)-2-(2-chloroacetamido)-3-(4-iodophenyl)propionic acid (6)[21-24] 
Following the typical procedure of 4 was obtained by using chloroacetyl chloride in place 
of 2-bromopropionyl chloride.  The yellow colored crude product was used in next step 
without further purification. 
(S)-3-(4-iodobenzyl)morpholine-2,5-dione (7)[21-24]  
Following the typical procedure of 5, but using 6 as the starting material, the product was 
obtained as an off-white solid. (M.p. - ºC, 1.12 g, 41 % over 2 steps). 
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1H NMR (500 MHz, DMSO-d6): δ 1.13 (d, 3H, 1J = 6.90 Hz), 3.02 (d, 2H, 1J = 5.10 Hz), 
4.67 (t, 1H, 1J = 4.98 Hz ), 4.99  (q, 1H, 1J = 6.84 Hz), 7.09  (d, 2H, 1J = 8.10 Hz), 7.68 
(d, 2H, 1J = 8.15 Hz) ppm. 
13C NMR (125 MHz, CDCl3): δ 16.8, 36.1, 54.2, 74.6, 93.3, 132.7, 136.5, 137.4, 168.5, 
168.6 ppm.  
 
1-Cyclohexenylpyrrolidine (9); Typical Procedure[25] 
While under N2, a flame dried round bottom flask equipped with a stir bar and dean stark 
trap (with activated 4 Å molecular sieves) was charged with cyclohexanone (4.22 mL, 
40.8 mmol, 1 equiv), dry toluene (20 mL), and pyrrolidine (6.02 mL, 73.4 mmol, 1.8 
equiv).  The mixture was refluxed under N2 for 5-7 h. The solvent and excess pyrrolidine 
were removed in vacuo. The crude product was used without further purification to afford 
the colorless product. (5.8 g, 94%).  
1H NMR (500 MHz, CDCl3): δ 1.38-1.43 (m, 2H), 1.52-1.55 (m, 2H), 1.66-1.68 (m, 4H), 
1.95-1.96 (m, 2H), 2.02-2.03 (m, 2H), 2.84-2.85 (m, 4H), 4.10-4.16 (m, 1H) ppm.  
13C NMR (125 MHz, CDCl3, with traces of toluene present): δ 22.9, 23.3, 24.5, 26.9, 
27.4, 47.2, 93.3, 142.9 ppm.  
 
2-(4-iodobenzyl)cyclohexan-1-one (10); Typical Procedure[26] 
While under N2, a flame dried round bottom flask equipped with a stir bar was charged 
with 4-iodobenzyl bromide (4.9 g , 16.5 mmol, 1 equiv) and dry toluene (30 mL).  When 
homogeneous solution formed, the flask was charged with 1-cyclohexenylpyrrolidine 
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(2.5 g, 16.5 mmol , 1 equiv).  The mixture was refluxed under N2 for 18 h.  H2O (30 mL) 
was added and the solution was heated for an additional hour.  The solvent was 
evaporated under vacuum, and the residue was extracted with diethyl ether. The ether 
phase was washed consecutively with 5% HCl, 5% NaHCO3 solution, and water, then 
dried, and evaporated. The residue was purified via silica gel chromatography eluted with 
hexanes/ethyl acetate (9:1) to provide a white solid (3.7 g, 71 %). 
1H NMR (500 MHz, CDCl3): δ 1.15-3.02 (m, 11H), 6.79 (d, 2H, 1J = 8.3 Hz), 7.42 (d, 
2H, 1J = 8.3 Hz) ppm.  
13C NMR (125 MHz, CDCl3): δ 25.1, 27.9, 33.5, 35.1, 42.1, 52.0, 91.2, 131.4, 137.2, 
140.1, 211.4 ppm.  
 
7-(4-iodobenzyl)oxepan-2-one (11); Typical Procedure[27. 28] 
While under N2, a flame dried round bottom flask equipped with a stir bar was charged 
with 2-(4-iodobenzyl)cyclohexan-1-one (1.5 g, 4.8 mmol, 1 equiv) and CHCl3 (50 mL).  
The solution was cooled to 0 ºC, and to this solution was added mCPBA (77% reagent) 
(14.3 mmol, 3 equiv). The mixture was stirred at room temperature for 2-3 d (monitored 
by TLC), and the reaction mixture was quenched with an sat. Na2S2O3 aqueous solution. 
The aqueous layer was extracted with CHCl3 (x3). The combined organic layer was 
washed with sat. NaHCO3 aqueous solution and brine.  The organic layers were dried 
over Na2SO4, filtered, and concentrated in vacuo. The residue was purified via silica gel 
chromatography eluted with a gradient of hexanes:ethyl acetate (2:8) to provide a 
colorless oil (1.07 g, 68%). Rf = 0.69 (1:9 hexanes:EtOAc) 
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1H NMR (500 MHz, CDCl3): δ 1.33-2.78 (m, 10H), 4.28-4.3 (m, 1H), 6.85 (d, 2H, 1J = 
8.1 Hz), 7.40 (d, 2H, 1J = 8.2 Hz) ppm.  
13C NMR (125 MHz, CDCl3): δ 22.9, 28.3, 33.8, 34.9, 42.1, 80.7, 92.2, 131.7, 136.9, 
137.6, 175.2 ppm.  
IR (neat): 2924 (w), 2857 (w), 1726 (s), 1483 (w), 1173 (m), 1007 (w) cm−1.  
 
 
Example Procedure for Conventional Ring-Opening Polymerization:  
 
Polymers were synthesized using ring opening polymerization with lactic acid as the 
initiator and tin (II) 2-ethylhexanoate as the catalyst. Prior to use, the monomer, lactic 
acid, sodium sulfate, and stir bar were vacuum-dried overnight in the reaction vessel. The 
reaction vessel was equipped with a reflux condenser, and the reagents were dissolved in 
anhydrous toluene while under a nitrogen atmosphere. When the reaction reached 120 ºC, 
tin(II) 2-ethylhexanoate was added, and the reaction was allowed to stir at this 
temperature for 24 h. The resulting polymer was partitioned between chloroform and 
water, and the chloroform phase was collected (3x). The chloroform phases were 
combined and dried over MgSO4. The filtrate was collected and the desired polymer 
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CHAPTER FIVE 
SYNTHESIS OF DIAZACYCLOBUTENES VIA A FORMAL [2 + 2] CYCLOADDITION 
5.1 PREFACE 
This abridged chapter describes a formal [2 + 2] cycloaddition between electron-rich 
alkynes and triazolinediones to generate rather unexplored chemical moieties known as 
diazacyclobutenes.  The research described in this chapter was conducted in collaboration 
with a fellow colleague, Chandima J. Narangoda (Clemson University, advisor: Dr. 
Daniel C. Whitehead) and will therefore only be described briefly. For a more detailed 
account, the reader is encouraged to read the current and future published peer reviewed 
articles that the Whitehead group publishes.367, 368  
5.2 INTRODUCTION 
The field of organic chemistry perpetually challenges and motivates scientists to design, 
develop and implement new synthetic methodologies in order to construct target 
compounds.  One common chemical moiety that chemists continually aspire to create are 
cyclic frameworks.  Cyclic compounds, which contain at least one connected series of 
atoms that form a ring, have proven to be important in all aspects of life.  In particular, 
cyclic species have found significance as biologically and pharmaceutically relevant 
compounds (i.e. agrochemicals, medicines, dyes, optical materials etc.).369  One 
important synthetic strategy to assemble cyclized products has been the use of 
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cycloaddition reactions.369, 370  Cycloadditions allow for two or more new bond 
formations to manifest from a single manipulation.  Cycloadditions have been utilized by 
chemists to create various cyclic moieties, including nitrogen containing heterocyclic 
compounds.  
Diazacyclobutenes are a unique class of nitrogen-containing heterocycles 
containing two nitrogen atoms and a carbon-carbon double bond constrained within a 
four-membered ring (Scheme 5.1, 5d). 
 
   
This scaffold has gained some attention in the scientific community due to their apparent 
non-aromatic character, even though they formally obey Hückel’s (4n+2) rule of 
aromaticity.371-381  Nevertheless, the diazacyclobutene motif has been relatively 
inaccessible due to the limited number of synthetic methodologies reported in the 
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rather ineffective, and consequently, less than 10 total examples of this molecular 
scaffold have been disclosed (Figure 5.2).373, 378-381   
 
Our group has recently designed a convenient [2 + 2] cycloaddition between  
electron-rich alkynes (5a) and a triazolinedione derivative (5c, 4-phenyl-1,2,4- 
triazoline-3,5-dione or PTAD) to construct diazacyclobutene derivatives (5d, Scheme 
5.1).367  It should be noted that sulfide and selenide alkynes were employed due to their 
electron donating ability, thereby creating a more electron rich alkyne.  
The production of the diazacyclobutenes began with the synthesis of sulfur- 
and/or selenium-containing alkynes (5b). These alkynes were synthesized by means of an 
n-butyl lithium (nBuLi)-assisted deprotonation of a terminal alkyne (5a), producing a 
lithium acetylide, which can supply the targeted alkyne (5b) with use of elemental sulfur 
(Condition A) or an appropriate dialkyl sulfide or selenide (Condition B).367, 382, 383  
With optimized reaction conditions, the generated alkynyl sulfides or selenides (5b) 
underwent the desired cycloaddition upon refluxing in the presence of acetonitrile 































Figure 5.1 Historical examples of diazacyclobutene motifs
Ar Ar
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To investigate this methodology, an assortment of alkynyl sulfides and selenides 
were synthesized and treated with PTAD to create a small library of diazacyclobutene 
derivatives (Figure 5.2).  By using sulfur phenylacetylene derivatives, we first varied the 
substituent located on the sulfur/selenium atom (R2).  The carbon chain length was 
altered, and shorter, as well as longer alkyl chains, supplied the corresponding product in 
moderate to good yields (Figure 5.2, 5i-5n, 7789% yields).  A benzyl (5o) and aryl (5p) 
functional group residing on the sulfur atom provided diazacyclobutene derivatives in 62 
and 85% yields, respectively.  Compound 5p was also produced in an 81% yield when 
carried out at a 6 mmol scale.  Next, we modified the R1 substituent with an aryl moiety.  
Arenes that contain either a para-positioned electron donating (5q–5s) or electron 
withdrawing (5t and 5u) group yielded products with good efficiency (74–92%).  When 
the R1 and R2 substituents were both alkyl groups (5v–5x), the transformation was also 
successful, ranging from moderate to good yields (56–94%).  Finally, selenide alkynes 
were used in the [2 + 2] cycloaddition, and proceeded to give good diazacyclobutene 




5i (89% yield) 5j (84%, yield) 5k (80% yield) 5l (77% yield)
5m (78%, yield) 5n (81% yield) 5o (62% yield) 5p (85% yield)(81% yield, 6 mmol scale)
5q (92% yield) 5r (77% yield) 5s (74% yield) 5t (85% yield)
5u (83% yield) 5v (61% yield) 5w (56% yield) 5x (94% yield)
5y (80% yield) 5z (93% yield)
Figure 5.2 Substrate scope in a [2 + 2] cycloaddition to diazacyclobutene motifs
R1 Y
R2
Y = S or Se
N N
N OO


































































The previous work demonstrated a simple, yet efficient protocol that involves a formal [2 
+ 2] cycloaddition between electron rich alkynes and PTAD to generate 
diazacyclobutenes.  This chemistry has been extended to synthesize another rarely 
accessible molecular scaffold, 2-imidothioimidates (Scheme 5.2, 5ac).368  
A reaction between sulfide or selenide alkynes (5b) with open-chain 
azodicarboxylates (5aa) form a [2 + 2] cycloadduct (5ab), which quickly experiences a 
4p conrotatory cycloreversion to provide N,N-dicarbamoyl 2-iminothioimidates (Scheme 
5.2, 5ac).  The substrate scope involving the use of diethyl azodicarboxylate (DEAD, 
5ad) and sulfide/selenide alkynes (5b) is shown in Figure 5.3; it should be noted that 
although it is not described in this text, we have been successful with employing other 
azodicarboxylates using this strategy, and the reader is directed to our publication for 
further details.368  Next, the alkyl chain (R2) situated on the sulfur/selenium atom was 
explored.  Shorter (5ae-5ah) and longer (5ai-5aj) alkyl chains supplied the desired 2-
imidothioimidates in good to great yields (73–99%).  By using aryl and benzyl moieties 
at the R2 position, phenyl (5ak) and benzyl (5al) substituted N,N-dicarbamoyl 2-
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studies involved substituting arenes at the R1 position of the alkyne, while maintaining a 
methyl sulfide motif (5am-5aq).  Electron donating groups in the para-position of the 
arene were highly effective using these reaction conditions (5am and 5an), however 
withdrawing donating groups in the aryl para-position gave mediocre yields (5ao and 
5ap).  Modifying R1 with alkyl substituents such as n-butyl gave lower yields (40% for 
5aq and 45% for 5ar), while a cyclopropyl substituent gave a moderate yield of 77% 
(5as).  Finally, selenide 2-imidothioimidate derivatives could be produced using this 
protocol, and supplied products in good yields (76% for 5at and 73% for 5au). 
 The work discussed herein demonstrates the high synthetic potential for sulfur 
and selenium-containing alkynes to undergo a [2 + 2] cycloaddition with both cyclic (i.e. 
PTAD) or acyclic (i.e. DEAD) azodicarboxylates to create novel chemical moieties.  The 
rarely accessible diazacyclobutene and 2-imidimidates motifs were synthesized in a 
simple, facile manner with moderate to good yields.  These protocols have the ability to 
enrich the synthetic applications of cycloadditions and provide new strategies for 
































































































































































































































Figure 5.3 Substrate scope of 2-imidothioimidates
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5.3 FUTURE WORK 
Ongoing research involves the use of alternative electron rich alkynes such as 
ynols (5aw) and ynamides (5aab) to expand the developed synthetic methodologies 
(Scheme 5.3).  These can be realized by using established synthetic procedures.  For 
instance, a Corey Fuchs reaction, followed by a copper-catalyzed coupling of 
dibromoalkenes with phenols can afford oxygen containing alkynes (Figure 5.3, eq. 1, 
5aw).  The ynol ethers could be subjected to our reaction conditions, with cyclized and 
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open-chain azodicarboxylates, to afford oxygen-containing diazacyclobutenes and 2-
imidimidates (Figure 5.3, eq. 1, 5ax, eq. 2, 5ay).384-387  Similarly, nitrogen-containing 
alkynes, called ynamides (5aab), can be synthesized from commercially available, cheap, 
vinyl dichlorides (5aaa).388, 389  These are relatively unexplored chemical scaffolds, and 
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All reagents were purchased from commercial sources and used without 
purification. THF and acetonitrile were dried prior to use over sodium/benzophenone and 
phosphorous pentoxide, respectively. 1H and 13C NMR spectra were collected on Bruker 
Avance 300 MHz, 500 MHz and JOEL Eclipse 500 MHz NMR spectrometers using 
CDCl3. Chemical shifts are reported in parts per million (ppm). Spectra are referenced to 
residual solvent peaks. Infrared spectroscopy data were collected using a Shimadzu 
IRAffinity-1S instrument (with MIRacle 10 single reflection ATR accessory) operating 
over the range of 400 to 4000 cm-1 . Flash silica gel (40-63 µm) was used for column 
chromatography. All known compounds were characterized by 1H and 13C NMR and are 
in complete agreement with samples reported elsewhere. All new compounds were 
characterized by 1H and 13C NMR, ATR-FTIR, HRMS, XRD, and melting point (where 
appropriate). TGA analysis was performed using TGA instrument SDT Q600 V20.9 
Build 20 over the range of 200 – 800 ˚C, with a ramp rate of 20 ˚C/min under a flow of 













In a flame dried 2-neck round bottom flask was added a stir bar and a solution of 
the terminal alkyne (1 equiv) in THF (5 mL for 1 mmol of alkyne) under argon 
atmosphere. A septum was placed over the round bottom inlets and the solution was 
cooled to -78 ˚C. A solution of n-BuLi (1.1 equiv., 1.6 M in hexane) was added. The 
reaction solution was stirred for 30 min, and 1 equiv. of finely ground sulfur powder was 
added by briefly removing one of the septa and then replacing it. The resulting mixture 
was stirred for 1 hour at -78 ˚C. The resulting mixture was allowed to gradually warm to 
0 ˚C until the sulfur was completely consumed, thus producing the lithium alkynyl 
thiolate (red color). The corresponding alkyl halide (5.0 mmol, 1 equiv.) was then added 
in a dropwise fashion. After 4 h the reaction mixture was quenched with saturated 
aqueous NH4Cl (5 mL for 1 mmol of alkyne). The reaction mixture was then poured into 
a separatory funnel, and the aqueous layer was extracted with diethyl ether (3 x 5 mL for 
1 mmol of alkyne). The combined ether extracts were washed with saturated aqueous 
brine (5 mL for 1 mmol of alkyne). The organic layer was then dried over Na2SO4, 
decanted, and the solvent was evaporated by rotary evaporation. The crude residue was 




Condition B:  
To a flame dried round bottom flask, equipped with a magnetic stir bar and a 
septum, was added a solution of the terminal alkyne (1 equiv.) dissolved in THF (1 mL 
284 
for 1 mmol of alkyne). The solution was then cooled to -78 ˚C and n-BuLi (1.1 equiv., 
1.6 M in hexane) was added dropwise. This solution was stirred for 10 min after which 
dimethyl disulfide (1.2 equiv.) was added at -78 ˚C. The solution was then allowed to 
warm to room temperature and stirred for 1 h. The reaction mixture was quenched with 
saturated aqueous NH4Cl (5 mL for 1 mmol of alkyne) and extracted with ethyl acetate (3 
x 5 mL for 1 mmol of alkyne). The combined organic layers were dried over Na2SO4, 
decanted, and concentrated by rotary evaporation. The crude mixture was purified by 
flash chromatography (silica gel, hexanes) to yield the desired alkynyl sulfide. 
General procedure for the synthesis of diazacyclobutenes: 
To a flame dried round bottom flask equipped with a stir bar was added a solution 
of 4-phenyl1,2,4-triazoline-3,5-dione (PTAD) (1 equiv.) in dry acetonitrile (5 mL for 1 
mmol of PTAD). To this stirring solution was added dropwise a solution of alkynyl 
sulfide or alkynyl selenide (1.3 equiv.) in dry acetonitrile (5 mL for 1.3 mmol of alkynyl 
substrate). Then the round bottom flask was attached to a water-cooled condenser and the 
mixture was refluxed for 24 hours. The resultant mixture was concentrated under reduced 
pressure and purified via flash chromatography with hexane and ethyl acetate (gradient 
from 100% hexane to 80:20 hexane/ethyl acetate) to afford the corresponding 
diazacyclobutene. 
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General Procedure for the synthesis of N,N-dicarbamoyl 2-iminothioimidates 
To a flame-dried round bottom flask equipped with a water-cooled condenser and a 
stir bar was added a solution of azodicarboxylate (1 mmol,1 equiv.) and 5 mL of dry 
acetonitrile under nitrogen. To this stirring solution was added dropwise a solution of 
alkynyl sulfide (1.3mmol, 1.3 equiv.) in 5 mL of dry acetonitrile. The mixture was then 
refluxed for 24 hours.  The resultant mixture was concentrated under reduced pressure 
and purified via flash chromatography with hexanes and ethyl acetate (100% hexanes to 
80:20 hexanes/ethyl acetate) to afford the corresponding α-imidothioimidate product. 
Characterization data for N,N-dicarbamoyl 2-iminothioimidates 
5ae 
Colorless liquid; Yield: 74% (239 mg); IR (neat): 2981 (w), 2931 (w), 1716 (s), 1627 
(m), 1577 (m), 1446 (m), 1365 (m), 1207 (s), 1091 (m), 1033 (m), 864 (w), 690 (m) cm-
1;1H-NMR (300 MHz, CDCl3) δ = 7.83 (d, J = 6.6 Hz, 2H), 7.52 (t, J = 7.4 Hz, 1H), 7.42 
(t, J = 7.3 Hz, 2H), 4.27 (q, J = 7.1 Hz, 2H), 4.08 (q, J = 6.8 Hz, 2H), 2.47 (s, 3H), 1.30 
(t, J = 7.1 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ = 175.6, 166.2, 
160.8, 159.2, 133.0, 132.4, 128.7, 128.7, 63.0 (2C), 14.3, 14.1, 14.0; HRMS (ESI+): 










Colorless liquid; Yield: 99% (334 mg); ; IR (neat): 2981 (w), 2931 (w), 2870 (w), 1716 
(s), 1627 (m), 1577 (m), 1446 (m), 1365 (m), 1207 (s), 1091 (m), 1033 (m), 864 (m), 690 
(m) cm-1;1H-NMR (300 MHz, CDCl3) δ = 7.76 (d, J = 6.5 Hz, 2H), 7.44 (t, J = 7.3 Hz, 
1H), 7.34 (t, J = 7.4 Hz, 2H), 4.19 (q, J = 7.1 Hz, 2H), 3.99 (q, J = 6.9 Hz, 2H), 3.02 (q, J 
= 7.3 Hz, 2H), 1.23 (t, J = 7.3 Hz, 6H), 1.05 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ = 174.6, 166.0, 160.4, 158.8, 132.7, 132.1, 128.5, 128.4, 62.6 (2C), 25.6, 13.8, 










Colorless liquid; Yield: 73% (256 mg); IR (neat): 2970 (w), 2931 (w), 1716 (s), 1627 
(m), 1577(m), 1446 (w), 1365 (m), 1284 (w), 1207 (s), 1091 (m), 1033 (m), 864 (w), 729 
(m), 690 (m)cm-1;1H-NMR (300 MHz, CDCl3) δ = 7.82 (d, J = 7.1 Hz, 2H), 7.52 (t, J = 
7.3 Hz, 1H), 7.42 (t, J = 7.3 Hz, 2H), 4.27 (q, J = 7.1 Hz, 2H), 4.06 (q, J = 7.1 Hz, 2H), 
3.07 (q, J = 7.2 Hz, 2H), 1.69 (sextet, J = 7.3 Hz, 2H), 1.31 (t, J = 7.1 Hz, 3H), 1.13 (t, J 
= 7.1 Hz, 3H), 0.98 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ = 175.0, 166.5, 
160.7, 159.1, 132.9, 132.5, 128.8, 128.6, 62.9 (2C), 33.3, 21.5, 14.1, 13.8, 13.2;HRMS 











Colorless liquid; Yield: 83% (303 mg); IR (neat) : 2958 (w), 2931 (w), 2870 (w), 1716 
(s), 1627 (m), 1577 (m), 1446 (m), 1365 (m), 1207 (s), 1091 (m), 1033 (m), 864 (w), 783 
 334 
(m), 729 (m), 690 (m) cm-1;1H-NMR (300 MHz, CDCl3) δ = 7.79 (d, J = 7.2 Hz, 2H), 
7.48 (t, J = 7.3 Hz, 1H), 7.38 (t, J = 7.5 Hz, 2H), 4.24 (q, J = 7.1 Hz, 2H), 4.03 (q, J = 7.1 
Hz, 2H), 3.06 (t, J = 7.3 Hz, 2H), 1.60 (p, J = 7.3 Hz, 2H), 1.5-1.2 (m, 5H), 1.10 (t, J = 
7.1 Hz, 3H), 0.86 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ = 174.7, 166.3, 
160.6, 159.0, 132.8, 132.5, 128.7, 128.5, 62.8 (2C), 31.1, 29.9, 21.7, 14.0, 13.7, 13.2; 










Colorless liquid; Yield: 80% (303 mg); IR (neat): 2954 (w), 2931 (w), 2858 (w), 1720 
(s), 1627 (m), 1577 (m), 1446 (m), 1365 (m), 1280 (w), 1207 (s), 1091 (m), 1033 (m), 
783 (m), 729 (m), 690 (m) cm-1;1H-NMR (300 MHz, CDCl3) δ = 7.76 (d, J = 6.54 Hz, 
2H), 7.44 (t, J = 7.3 Hz, 1H), 7.34 (t, J = 7.5 Hz, 2H), 4.20 (q, J = 7.1 Hz, 2H), 4.00 (q, J 
= 6.90 Hz, 2H), 3.02 (t, J = 7.2 Hz, 2H), 1.58 (p, J = 7.0 Hz, 2H), 1.4-1.15(m, 7H), 1.05 
(t, J = 7.1 Hz, 3H), 0.79 (t, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ = 174.6, 166.1, 
160.4, 158.8, 132.7, 132.2, 128.5, 128.3, 62.6 (2C), 31.1, 30.4, 27.4, 21.7, 13.8, 13.5, 












Light yellow liquid; Yield: 73% (307 mg); IR (neat): 2924 (m), 2854 (w), 1720 (s), 1627 
(m), 1577 (m), 1446 (m), 1365 (m), 1207 (s), 1091 (m), 1033 (m), 910 (m), 783 (m), 729 
(m), 688 (m) cm-1;1H-NMR (300 MHz, CDCl3) δ = 7.77 (d, J = 6.63 Hz, 2H), 7.45 (t, J = 
7.3 Hz, 1H), 7.36 (t, J = 7.4 Hz, 2H), 4.21 (q, J = 7.1 Hz, 2H), 4.00 (q, J = 7.0 Hz, 2H), 
3.03 (t, J = 7.2 Hz, 2H), 1.59 (p, J = 7.1 Hz, 2H), 1.4-1.12 (m, 13H), 1.07 (t, J = 7.1 Hz, 
3H), 0.79 (t, J = 6.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ = 175.0, 166.4, 160.7, 159.1, 
132.9, 132.5, 128.8, 128.6,62.9, 62.8, 31.6, 31.5, 28.9, 28.8, 28.6, 27.9, 22.4, 14.1, 13.9, 













Light yellow solid; Yield: 77% (296 mg); Mp: 70-71˚C;IR (neat) : 2981 (w), 1724 (s), 
1712 (s), 1631 (m), 1612 (m), 1577 (w), 1477 (m), 1442 (m), 1207 (s), 1095 (w), 1022 
(m), 968 (m), 860 (w), 752 (s), 686 (s) cm-1; 1H-NMR (300 MHz, CDCl3) δ = 7.54 (d, J = 
7.4 Hz, 2H), 7.50-7.20 (m, 6H), 7.15 (t, J = 7.5 Hz, 2H), 4.38 (q, J = 7.1 Hz, 2H), 4.28 
(broad q, J = 7.1 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H), 1.35 (t, J = 7.1 Hz, 3H); 13C NMR 
(125 MHz, CDCl3) δ = 173.9, 165.5, 161.3, 159.6, 135.8, 133.2, 132.5, 130.3, 129.0, 
128.4, 128.2, 126.1, 63.23, 63.16, 14.2, 14.1; HRMS (ESI+): Calcd for C20H21N2O4S, 












Colorless liquid; Yield: 83% (330 mg); IR (neat):2978 (w), 1716 (s), 1627 (w), 1577 (m), 
1492 (w), 1450 (w), 1207 (s), 1087 (m), 1026 (m), 910 (w), 729 (w), 690 (w) cm-1; 1H-
NMR (300 MHz, CDCl3) δ = 7.81 (d, J = 6.2 Hz, 2H), 7.51 (t, J = 7.0 Hz, 1H), 7.40 (t, J 
= 7.7 Hz, 2H), 7.35-7.16 (m, 5H), 4.34 (s, 2H), 4.23 (q, J = 7.1 Hz, 2H), 4.10 (q, J = 7.1 
Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
= 174.2, 165.9, 160.6, 158.9, 134.6, 132.9, 132.3, 130.4, 129.1, 128.7, 128.5, 127.7, 
62.88, 62.86,35.8, 14.0, 13.7; HRMS (ESI+): Calcd for C21H23N2O4S, [M+H]+ 399.1379 











Colorless liquid; Yield: 88% (296 mg); IR (neat):2978 (w), 2927 (w), 1716 (s), 1627 (m), 
1600 (m), 1462 (w), 1446 (w), 1411 (w), 1388 (w), 1365 (m), 1292 (m), 1207 (s), 1180 
(m), 1091 (s), 1033 (s), 914 (m), 821 (w), 775 (w), 729 (s) cm-1; 1H-NMR (300 MHz, 
CDCl3) δ = 7.71 (d, J = 7.26 Hz, 2H), 7.21 (d, J = 7.9 Hz, 2H), 4.24 (q, J = 7.1 Hz, 2H), 
4.07 (q, J = 6.74 Hz, 2H), 2.44 (s, 3H), 2.35 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H), 1.14 (t, J = 
7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ = 175.7, 166.0, 160.8, 159.1, 144.0, 129.6, 
129.3, 128.7, 62.79, 62.77, 21.5, 14.2, 14.0, 13.7; HRMS (ESI+): Calcd for C16H21N2O4S, 
[M+H]+ 337.1222 Found m/z 337.1241. 
5an 
Colorless liquid; Yield: 95% (335 mg); IR (neat): 2978 (w), 2931 (w), 2839 (w), 1716 
(s), 1593 (s), 1570 (w), 1508 (m), 1462 (w), 1442 (w), 1207 (s), 1168 (s), 1091 (m), 1026 
(s), 910 (m), 840 (m), 729 (s)cm-1; 1H-NMR (300 MHz, CDCl3) δ = 7.77 (d, J = 8.4 Hz, 
2H), 6.87 (d, J = 8.9 Hz, 2H), 4.22 (q, J = 7.1 Hz, 2H), 4.06 (q, J = 7.0 Hz, 2H), 3.79 (s, 
3H), 2.42 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H), 1.13 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ = 175.6, 165.3, 163.6, 160.9, 159.1, 130.9, 124.7, 114.0, 62.8, 62.7, 55.3, 14.1, 




Colorless liquid; Yield: 47% (168 mg); IR (neat): 2978 (w), 2927 (w), 1716 (s), 1627 
(m), 1589 (m), 1400 (w), 1365 (w), 1207 (s), 1087 (s), 1029 (s), 864 (w), 783 (w), 725 
(m) cm-1;1H-NMR (300 MHz, CDCl3) δ = 7.77 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 8.6 Hz, 
2H), 4.26 (q, J = 7.1 Hz, 2H), 4.10 (q, J = 7.1 Hz, 2H), 2.47 (s, 3H), 1.30 (t, J = 7.1 Hz, 
3H), 1.17 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ = 175.4, 165.4, 160.6, 159.0, 
139.5, 130.9, 130.0, 129.0, 63.1(2C), 14.3, 14.1, 13.8; HRMS (ESI+): Calcd for 










Colorless liquid; Yield: 69% (270 mg); IR (neat): 2981 (w), 1724 (s), 1631 (w), 1577 
(w), 1411 (w), 1323 (s), 1211 (s), 1168 (m), 1126 (m), 1064 (s), 1033 (w), 1014 (w), 848 
(m), 771 (w), 748 (w)cm-1; 1H-NMR (300 MHz, CDCl3) δ = 7.95 (d, J = 7.4 Hz, 2H), 
7.68 (d, J = 8.4 Hz, 2H), 4.27 (q, J = 7.1 Hz, 2H), 4.09 (q, J = 6.9 Hz, 2H), 2.49 (s, 3H), 
1.30 (t, J = 7.1 Hz, 3H), 1.16 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ = 175.5, 
165.5, 160.4, 159.1, 135.8, 134.3 (q, 2JCF = 32.8 Hz), 129.1, 125.7 (q, 3JCF = 3.7 Hz), 
123.5 (q, 1JCF = 272.7 Hz), 63.33, 63.25, 14.3, 14.1, 13.9; HRMS (ESI+): Calcd for 















Light yellow liquid; Yield: 40% (121 mg) ; IR (neat): 2958 (w), 2931 (w), 1716 (s), 1662 
(w), 1608 (w), 1500 (w), 1465 (w), 1365 (w), 1215 (s), 1095 (w), 1033 (m), 948 (w), 914 
(w), 732 (m) cm-1;1H-NMR (300 MHz, CDCl3) δ = 4.4-4.1 (m, 4H), 2.48 (t, J = 7.8 Hz, 
2H), 2.41 (s, 3H), 1.56 (p, J = 7.6 Hz, 2H), 1.40-1.23 (m, 8H), 0.86 (t, J = 7.3 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ = 171.2, 161.7, 160.6, 159.7, 62.9, 62.8, 27.8, 23.3, 15.1, 
338 
14.1, 14.0, 13.7, 13.5; HRMS (ESI+): Calcd for C13H22N2O4SNa, [M+Na]+ 325.1198 
Found m/z 325.1210. 
5ar 
Light yellow liquid; Yield: 45% (155 mg); IR (neat): 2958 (w), 2931 (w), 2870 (w), 1724 
(s), 1662 (w), 1604 (m), 1462 (w), 1365 (w), 1215 (s), 1095 (w), 1037 (m), 948 (w), 914 
(w), 779 (w), 732 (w)cm-1;1H-NMR (300 MHz, CDCl3) δ = 4.19 (m, 4H), 2.99 (t, J = 7.3 
Hz, 2H), 2.47 (t, J = 7.6 Hz, 2H), 1.7-1.48 (m, 4H), 1.48-1.22 (m, 10H), 1.00-0.80 (m, 
6H); 13C NMR (75 MHz, CDCl3) δ = 171.4, 161.0, 160.5, 159.8, 62.8, 62.7, 30.6, 30.0, 
29.5, 27.7, 22.3, 21.8, 14.1, 14.0, 13.4, 13.3; HRMS (ESI+): Calcd for C16H29N2O4S, 
[M+H]+ 345.1848 Found m/z 345.1862. 
5as 
Colorless liquid; Yield: 77% (220 mg); IR (neat): 2981 (w), 2931 (w), 1716 (s), 1651 
(m), 1583 (m), 1444 (w), 1382 (w), 1365 (m), 1219 (s), 1193 (s), 1028 (s), 995 (m), 862 
(m), 775 (m) 731 (m) cm-1; 1H-NMR (300 MHz, CDCl3) δ = 4.25 (q, J = 7.1 Hz, 2H), 
4.21 (q, J = 7.1 Hz, 2H), 2.45 (s, 3H), 2.10–1.70 (m, 1H), 1.33 (t, J = 6.3 Hz, 3H), 1.28 (t, 
J = 6.3 Hz, 3H) 1.26–1.05 (m, 4H); 13C{1H} NMR (75 MHz, CDCl3) δ = 176.1, 175.0, 
160.6, 159.3, 63.0, 62.7, 17.2, 13.9 (3C), 12.4 (2C); HRMS (ESI+ -TOF): Calcd for 
C12H19N2O4S, [M+H]+ 287.1066 Found m/z 287.1069. 
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5at 
Light yellow liquid; Yield: 76% (280 mg); IR (neat): 2981 (w), 2935 (w), 1716 (s), 1597 
(s), 1573 (w), 1446 (w), 1369 (w), 1330 (w), 1292 (w), 1211 (s), 1095 (w), 1026 (m), 898 
(w), 864 (w), 771 (w), 732 (w), 690 (m), 528 (w) cm-1; 1H-NMR (300 MHz, CDCl3) δ = 
7.88 (d, J = 7.4 Hz, 2H), 7.60-7.47 (m, 1H), 7.47-7.30 (m, 2H), 4.23 (q, J = 6.9 Hz, 2H), 
2.19 (s, 3H), 1.45 (m, 6H); 13C NMR (75 MHz, CDCl3) δ =179.9, 165.0, 160.8, 160.4, 
133.1, 132.3, 128.7, 128.5, 63.1, 62.8, 14.0, 13.9, 8.3;HRMS (ESI+): Calcd for 
C15H19N2O4Se, [M+H]+ 371.0510 Found m/z 371.0528. 
5au 
Light yellow liquid; Yield: 73% (361 mg); IR (neat): 2981 (w), 2931 (w), 1716 (s), 1689 
(m), 1627 (m), 1577 (w), 1554 (w), 1494 (m), 1448 (m) 1365 (m), 1207 (s), 1180 (s), 
1093 (m), 1024 (s), 970 (w), 904 (m), 732 (m), 694 (s) cm-1; 1H-NMR (300 MHz, 
CDCl3) δ = 7.96 (d, J = 6.6 Hz, 2H), 7.70-7.00 (m, 8H), 4.32 (q, J = 7.1 Hz, 2H), 4.27– 
4.15 (m, 4H), 1.33 (t, J = 7.1 Hz, 3H), 1.30 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (75 MHz, 
CDCl3) δ = 179.0, 165.3, 161.0, 160.2, 135.1, 133.1, 132.1, 129.0, 128.7, 128.6, 128.5, 
127.3, 63.2, 62.9, 32.3, 14.0, 13.8; HRMS (ESI+ -TOF): Calcd for C21H23N2O4Se, 








1H NMR and 13C NMR spectra for N,N-dicarbamoyl 2-iminothioimidates 
1H-NMR (300 MHz, CDCl3) 
















1H-NMR (300 MHz, CDCl3) 
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1H-NMR (300 MHz, CDCl3) 




























1H-NMR (300 MHz, CDCl3) 
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1H-NMR (300 MHz, CDCl3) 














13C-NMR (75 MHz, CDCl3) 
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